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Resumo
Este trabalho centra-se no estudo do mecanismo de acção dos péptidos
microbicidas (AMPs) omiganan (ILRWPWWPWRRK–NH2) e BP100
(KKLFKKILKYL–NH2). Estes péptidos catiónicos foram desenhados
com base na sequência de AMPs naturais, nomeadamente da indolicidina
— dos neutrófilos de bovino — no caso do omiganan e da cecropina e
melitina — da traça e do veneno de abelha, respectivamente — no caso
do BP100. Foram empregadas principalmente técnicas de espectrosco-
pia óptica em conjunto com sistemas modelo de membranas (vesículas
fosfolipídicas); estes foram preparados para mimetizar tanto membranas
celulares bacterianas — de natureza aniónica — como de mamíferos —
essencialmente zwitteriónicas. Na constituição destes modelos foram uti-
lizados principalmente fosfolípidos com o par de cadeias acilo palmitoíl e
oleoíl, ligados a uma fosfatidilcolina ou a um fosfatidilglicerol (formando
fosfolípidos zwitteriónicos ou aniónicos, respectivamente). O grau de
afinidade dos péptidos para os modelos de membrana foi interpretado
de acordo com um formalismo de partição de Nernst, onde bicamadas
fosfolipídicas num meio aquoso são vistas como uma fase líquida imiscível
para a qual a partição de um soluto é regida pela constante de partiçãoKp
(a razão das concentrações locais de soluto nas fases lipídica e aquosa, res-
pectivamente). A partição foi seguida experimentalmente por alterações
na emissão dos resíduos fluorescentes de cada péptido ao longo de titula-
ções com vesículas. Ambos os péptidos se particionaram para os modelos
bacterianos com valores deKp com uma magnitude de 104, uma ordem de
grandeza superior à da partição para modelos de mamíferos. Esta obser-
vação explica em parte a selectividade dos péptidos para bactérias e a sua
baixa taxa de hemólise. A afinidade do péptido omiganan para um mo-
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delo de parede bacteriana (extractos de parede celular de Staphylococcus
aureus) foi também testada, desta vez por quantificação no sobrenadante
após separação por centrifugação. Observou-se uma afinidade elevada do
omiganan para os extractos de parede celular — equivalente a um valor
de Kp na ordem de 103 — mas inferior à demonstrada para os modelos
de membrana celular bacteriana.
Observaram-se, para os dois péptidos, desvios ao comportamento de
partição esperado sempre que se atingiram altas concentrações locais de
péptido nos modelos de membranas aniónicos. Foi desenvolvido um mé-
todo para melhor caracterizar estes desvios, baseado numa titulação de
lípido com péptido na presença do quencher de fase aquosa acrilamida,
tendo-se determinado que correspondem a uma saturação das bicamadas
fosfolipídicas: a partir desse ponto de saturação as moléculas de péptido
adicionadas deixam de poder ligar-se à membrana e escapar ao efeito de
quenching da acrilamida. Conjugando a ocorrência de saturação da mem-
brana com o formalismo de partição pôde ser estabelecida uma relação
entre as concentrações globais de péptido e lípido nos pontos de saturação.
A partir desta relação pôde descrever-se quantitativamente o fenómeno
da saturação, nomeadamente a razão péptido-lípido (P:L) neste limite. Os
valores elevados obtidos para a razão P:L são consistentes com a ocorrên-
cia de saturação; tendo em conta a proporção de fosfolípidos aniónicos
e zwitteriónicos pôde prever-se a neutralização da carga superficial das
vesículas ao ser atingido este limite. Postulando-se uma alteração con-
formacional na saturação com impacto na fluorescência dos péptidos foi
ainda desenvolvido um modelo que explica os desvios no comportamento
de partição. A aplicação deste modelo permite determinar a partir de um
único ajuste a uma curva de partição os valores deKp e da razão P:L na
saturação.
Detectou-se na saturação, por metodologias de quenching diferencial
(onde quenchers de fluorescência a diferentes profundidades na membrana
são utilizados para inferir a posição do fluoróforo), uma internalização em
profundidade do péptido omiganan. Com o péptido BP100 foi observado
na saturação um aumento de acção permeabilizadora (usando vesículas
marcadas com fosfolípidos fluorescentes); foi ainda detectada neste limite
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a indução da agregação de vesículas e a neutralização da sua carga su-
perficial por metodologias de dispersão de luz, confirmando as previsões
anteriores; por dicroísmo circular observou-se ainda que estes fenómenos
são acompanhados de uma alteração da estrutura secundária do péptido
na membrana, de uma conformação essencialmente de hélice α antes da
saturação para uma outra com um conteúdo aparentemente elevado de
voltas β. Esta observação valida em parte os pressupostos do método
explicativo dos desvios no comportamento de partição.
A observação de vários comportamentos potencialmente disruptivos
ao ser atingida a saturação levou a que fosse proposta a hipótese da
correlação deste limite biofísico com a ocorrência de morte bacteriana.
A plausibilidade desta relação foi testada pela construção de um modelo
matemático que prevê a quantidade de um AMP genérico que se ligará
à membrana bacteriana sob condições fisiológicas. Este modelo aplica o
formalismo de partição descrito acima à quantidade de membrana dispo-
nível para a ligação do péptido numa situação como a encontrada nos
testes microbiológicos de actividade microbicida. Resultou da aplicação
deste modelo que, embora apenas uma fracção muito pequena do pép-
tido total se ligue às membranas bacterianas, a concentração local deste
pode atingir os valores necessários para a ocorrência de saturação. Esta
conclusão verifica-se especialmente para as concentrações globais micromo-
lares de péptido às quais os AMPs tipicamente se tornam activos contra
bactérias. Isto sugere que a saturação, mais do que possível, pode ser
necessária para a actividade destes péptidos. As conclusões da aplicação
deste modelo foram validadas usando dados publicados para as afinidades
e actividades de vários AMPs. O modelo foi ainda modificado para, ao
invés de prever a quantidade de péptido que se acumula na membrana,
passar a permitir a previsão da concentração de péptido necessária para
alcançar na membrana uma concentração que cause a morte bacteriana;
ou seja, uma previsão da potência de um AMP. A aplicação deste mé-
todo requer apenas o conhecimento do valor de Kp para a membrana
bacteriana e a razão péptido-lipido correspondente à saturação ou a outro
limite que espolete a actividade microbicida do péptido. São apresentadas
várias metodologias para obter estimativas biofísicas destes parâmetros,
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nomeadamente a partir da relação péptido-lípido na saturação ou a partir
do modelo integrado para ajustar os dados de fluorescência na saturação.
Conduziram-se também experiências in vivo com Escherichia coli para
testar a correlação entre a ocorrência de saturação da ligação do péptido
BP100 a bactérias e a perda de viabilidade destas. Tentou-se adaptar o
método de separação de fases por centrifugação, utilizado anteriormente
na medição da afinidade do omiganan para extractos de parede bacteriana,
para quantificar a quantidade de péptido ligado a bactérias. A aplicação
da metodologia não foi bem sucedida devido principalmente a um elevado
grau de contaminação fluorescente do sobrenadante por proteínas bac-
terianas, não tendo sido possível obter dados conclusivos. No entanto,
utilizando técnicas de dispersão de luz foi possível observar a ocorrência
da morte das bactérias e a neutralização do respectivo potencial ζ a partir
da mesma concentração de BP100, o que sugere que os dois fenómenos
podem estar relacionados entre si e, indirectamente, com a saturação.
Aperfeiçoaram-se ainda várias metodologias relacionadas com o estudo
da interacção péptido membrana. Foi desenvolvido um método para a
determinação de constantes de partição onde se infere a fracção de péptido
na membrana a partir dos valores do potencial ζ de vesículas aniónicas
a várias concentrações de péptido. Foi também adaptado para Visual
Basic e C++ um algoritmo de interpretação de dados de quenching di-
ferencial, e acoplado um processo de ajuste por mínimos quadrados. Por
último, foi desenvolvida uma metodologia capaz de detectar translocação
de péptidos para o interior de vesículas que aproveita o facto de uma frac-
ção significativa de lípido estar inacessível quando se utilizam lipossomas
multilamelares.
Palavras-chave:
Péptido; Microbicida; Membrana celular; Saturação; Concentração mí-
nima inibitória.
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Abstract
The antimicrobial peptides (AMPs) omiganan (ILRWPWWPWRRK–
NH2) and BP100 (KKLFKKILKYL–NH2) were biophysically studied
with bacterial and mammalian cell membrane models, essentially using
optical spectroscopy techniques. Peptide-membrane binding was inter-
preted under a Nernst partition formalism. Both peptides strongly prefer
the anionic bacterial membrane models over the zwitterionic mammalian
ones, justifying, at least in part, higher antibacterial than hemolytic ac-
tivities. Deviations to the expected binding behavior were observed at
high bound peptide-to-lipid (P:L) ratios in the membrane whenever an-
ionic models were used. These deviations could be ascribed to membrane
saturation and occurred with both peptides. The saturation threshold
could be identified for both peptides; the obtained critical P:L ratios were
also consistent with membrane surface charge neutralization. Disruptive
events were observed above the saturation threshold: internalization into
the membrane (omiganan), leakage, membrane aggregation, membrane
surface charge neutralization, and structural reorganization (BP100).
The plausibility of high membrane coverage was evaluated using a
mathematical model devised to estimate the extent of binding under
physiological conditions. Not only is saturation a possible phenomenon
but it was also shown to be a potential requirement for peptide activity.
This hypothesis could be verified using the model with published data
on several AMPs. The model could be further adapted to provide a
means to predict, from simple biophysical parameters (a binding constant
and a critical P:L ratio), the peptide concentration at which antibacterial
activity is triggered. Different methods to implement this prediction are
presented.
xii
In vivo measurements using BP100 with Escherichia coli were carried
out to further test the correlation between membrane saturation and bac-
terial death. A suitable method to determine the occurrence of binding
saturation with bacteria could not be devised. Nonetheless, bacterial
surface charge did become neutralized by the peptide at the same concen-
trations that caused loss of viability, supporting a connection between the
phenomena.
Keywords:
Peptide; Antimicrobial; Cell membrane; Saturation; Minimum inhibitory
concentration.
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Symbols &Abbreviations
and Usage Notes
In this book acronyms are expanded on first usage and whenever deemed necessary to
improve clarity, although not necessarily along a description as found here. For reasons
of text economy very common acronyms, scientific or not — such as DNA or US —, are
not expanded nor described. Amino acid sequences are indicated using one-letter codes.
16NS 16-doxylstearic acid. Stearic acid labeled
at C16 with a nitroxide doxyl quencher group.
5NS 5-doxylstearic acid. Stearic acid labeled at
C5 with a nitroxide doxyl quencher group.
ANTS 8-aminonaphthalene-1,3,6-trisulfonic
acid. A fluorescent dye.
AMP Antimicrobial peptide. Used in this book
with the same meaning as ‘RAMP’.
CD Circular dichroism.
cfu Colony-forming unit. A common unit of bac-
terial numbers which reminds one that only bac-
teria that are able to form a colony will be
counted when an inoculum is plated.
DPPC 1,2-dipalmitoyl-sn-glycero-3-phospho-
choline. A zwitterionic phospholipid that forms
gel-phase bilayers at room temperature.
DPPG 1,2-dipalmitoyl-sn-glycero-3-(phospho-
rac-(1-glycerol)). An anionic phospholipid that
forms gel-phase bilayers at room temperature.
Dv Concentration-ratio binding constant of a
solute relative to a solid phase, such as the pep-
tidoglycan mesh.
E. coli Escherichia coli.
FDA US Food and Drug Administration.
fPL− Fraction of anionic phospholipids in a
mixed system.
fPLc Fraction of charged phospholipids in a
mixed system.
γL Molar volume of phospholipids in a bilayer.
GUV Giant unilamellar vesicle. A vesicle large
enough to be observed in detail using optical
microscopy techniques.
I The global fluorescence intensity of a system.
IC50 50% inhibitory concentration. The drug
concentration leading to loss of viability of half of
the cells. Preferentially used to describe toxicity
against mammalian cells (see ‘MIC’).
IL The global fluorescence a system would dis-
play if all the peptide molecules were bound to
membranes.
IMM Institute of Molecular Medicine.
IS The global fluorescence a system would dis-
play if all the peptide molecules were bound to
membranes and in a saturation conformation.
IW The global fluorescence a system displays
when all the peptide molecules are in the aque-
ous phase.
Kp Partition constant of a solute among two
phases, defined as a concentration-ratio.
KSV Stern-Volmer constant for pure colli-
sional quenching.The product of the bimolecular
quenching kinetic constant and the fluorescence
lifetime of the unquenched fluorophore.
[L] Global concentration of phospholipid
molecules.
L:P ratio Proportion of lipid molecules to
membrane-bound peptide molecules. Inverse of
the P:L ratio.
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[L]sat Global concentration of phospholipid
molecules at a saturation point.
LUV Large unilamellar vesicle. A vesicle with
a diameter of the order of 102nm.
MLV Multilamellar vesicle. Vesicle containing
one or more smaller vesicles within. Sizes may
range from those of LUVs to those of GUVs.
MIC Minimum Inhibitory Concentration. The
antibiotic concentration required to achieve a
50% decrease in bacterial viability. More pre-
cisely designated MIC50.
nL Global amount of phospholipid molecules.
NMR Nuclear magnetic resonance.
npeptide,L Amount of peptide molecules in
the lipidic phase of a system.
n
PL
−
neutralized Amount of anionic phospho-
lipid molecules neutralized by the binding of a
cationic peptide.
n
PL
−
total Total amount of anionic phospho-
lipid molecules in a system.
OCD Oriented circular dichroism. CD spec-
troscopy of chromophores embedded in a semi-
solid oriented matrix, namely, oriented phospho-
lipid bilayers.
OD Optical density. Reduction of the intensity
of light transmitted through a sample due to ab-
sorption and/or scattering by particles in suspen-
sion, in absorbance units.
[P ] Global concentration of peptide molecules.
[P ]L Local concentration of peptide molecules
in the lipidic phase of a system.
[P ]L,MIC [P ]L when [P ] = MIC and at
lipid concentrations that parallel the low amount
of bacterial membrane available for binding un-
der MIC assay conditions.
P :LMIC The P:L ratio under the same condi-
tions as for [P ]L,MIC.
P:L ratio Proportion of membrane-bound pep-
tide molecules to lipid molecules. Inverse of the
L:P ratio.
POPC 1-palmitoyl-2-oleoyl-sn-glycero-3-phos-
phocholine. A zwitterionic phospholipid that
forms fluid-phase bilayers at room temperature.
POPG 1-palmitoyl-2-oleoyl-sn-glycero-3-(phos-
pho-rac-(1-glycerol)). A zwitterionic phospho-
lipid that forms fluid-phase bilayers at room
temperature.
[P ]sat Global concentration of peptide mole-
cules at a saturation point.
[P ]W Local concentration of peptide mole-
cules in the aqueous phase of a system (usually
assumed to occupy the whole volume of the sys-
tem).
[P ]W,MIC [P ]W for a system under the same
conditions as for [P ]L,MIC.
RAMP Ribosomal AMP. An AMP that is ei-
ther ribosomally assembled or a synthetic deriva-
tive of AMPs that are.
σ The P:L ratio at saturation.
S The bound concentration above which a sat-
uration conformation is gradually induced, in a
model that includes an intermediate state be-
tween non-saturation and saturation.
S. aureus Staphylococcus aureus.
SIMEXDA Acronym for ‘simulated experi-
mental data analysis’. An algorithm used to calcu-
late in-depth fluorophore distributions from dif-
ferential quenching data.
XL Fraction of peptide molecules that are in
the lipidic phase of a system.
XL,ns Fraction of peptide molecules in the li-
pidic phase of a system, in a non-saturated confor-
mation.Used inmodels that allow the coexistence
of saturated and unsaturated membrane-bound
conformations.
XL,s Fraction of peptide molecules in the li-
pidic phase of a system, in a saturated conforma-
tion. Used in models that allow the coexistence
of saturated and unsaturated membrane-bound
conformations.
XW Fraction of peptide molecules that are in
the aqueous phase of a system.
ζ The ζ-potential of particles in a solution or
suspension.
ζ0 The ζ-potential of a suspension of charged
vesicles in the absence of peptide.
zpeptide Global electric charge per peptide, in
absolute value.
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Preface
My PhD work, carried out under the supervision of Professor Miguel
Castanho,* was projected as the study of antimicrobial peptides using
mainly biophysical methodologies. However, I soon became aware that
my posture as a researcher led me into a duality: I was no longer sure
whether I was more interested in applying biophysical methodologies to
study antimicrobial peptides or rather in using these peptides to develop
and test new methodologies. The dichotomy in the perspective with
which I came to face my work persists even now, and the structure of
the text deliberately reflects that dual nature.
As it turned out, the work developed by me and the people with
whom I collaborated contributed to the state-of-the-art both at the level
of the particular peptides that were studied as well as at the level of
the development of new methods and models — hopefully applicable to
many other molecules. I, therefore, do not regret not having opted for
any of the approaches over the other. Yet, I must admit up-front that I
found the development of methods and models to be more intellectually
challenging and of greater impact: it was not innocently that most results
were placed in Part II, which is devoted to the developed methods, rather
than in Part I, which tells the same tale from the perspective of the studied
peptides. As it stands, however, neither part is completely independent
of the other for the full understanding of the work, which parallels nicely
the relationship between these two aspects of scientific research.
*To whom I will henceforth simply refer to as Miguel, to reflect the close professional and
personal friendship we developed along these years. The reader will find in these pages some
of the reasons behind this proximity.
xxiii
This project began in the final, practical year of my graduation in
Biochemistry, also carried out under Miguel’s supervision. While I could
focus this book exclusively on the work performed during the PhD proper,
leaving the first year out of this description would mean that key events
in my research and in my development as a scientist would have to be
skipped. I, therefore, chose to cover in this text the work of roughly five
years: from the beginning of my last undergraduate year to the end of my
PhD. To avoid unnecessary repetition of this description, throughout the
book I used simply the term ‘PhD’ to refer to the whole project.
This thesis is extensively based on published work, which is repro-
duced within: as less technical detail had to be described the writing
process was significantly simplified. The downside to this approach is that
theses written in this format risk becoming a collection of papers glued
together by space-filling text that simply rephrases the already published
introductions or repeats the theoretical bases of the used methodologies.
Rather than going in that direction myself, I found it more interesting,
to me as the writer and also to potential readers, to dedicate that text to
the description, from a scientific standpoint, of the path that has led me
through my PhD. Unlike introductions and theoretical backgrounds, this
account cannot be found in the bibliography.
Because the story of my PhD is not based exclusively on the published
work, and also for the sake of completeness, chapters were included to
describe data and methods that have not (yet) found their way into
scientific papers. Minding the above considerations I looked for a balance
between descriptiveness and readability. In the end, I have tried to write
a thesis as pleasant to read as my PhD work was to carry out.
xxiv


Part I
The Antimicrobial Peptides
Beginning
When I joined Miguel Castanho’s team — the Molecular Biophysics
group, then at the Faculty of Sciences of the University of Lisbon — the
choice of antimicrobial peptides (AMPs) as my subject matter fit nicely
with the ongoing work. Miguel had made a strong bet on the biophysical
study of novel peptide drugs and, besides the AMPs that I was going
to work with, projects included the study of cell-penetrating peptides
(by Sónia Henriques), peptidic HIV fusion inhibitors (by Salomé Veiga),
and peptide analgesics (by Sílvia Lopes). The fact that everyone at the
group was already working with peptides, but not AMPs, meant that I
could tap into the group’s experimental background in the field and still
be independent in the execution of my project.
Miguel’s invitation to studyAMPs attractedme because of the relative
novelty of the theme, the apparent simplicity of the peptides and model
systems — the methodologies I would be using revolved mostly around the
characterization of peptide-membrane interactions using liposomes — and,
above all, by the easewithwhich such simple systems lent themselves to be
mathematically modeled. I admit I may be projecting these considerations
a posteriori but the fact is I have frequently felt fortunate for having
accepted that invitation.
2
1. A brief introduction to AMPs
The establishment of the AMPs as a class dates back to the 80’s when
the discovery of the frog-skin AMP magainin spurred research in the
field,1 although other peptides with antibacterial properties were already
known by then.2, 3 Many more peptides from several other organisms —
including humans — have been characterized in subsequent years, with
the rather generic label ‘AMP’ providing a minimum of systematization
to their classification.*
While the name ‘antimicrobial peptides’ clearly indicates that the group-
ing of these peptides is dictated by their antibiotic properties, other com-
mon characteristics have emerged and have since become close synonyms
with the term ‘AMP’ itself. These characteristics, inevitably repeated in
any self-respecting review on AMPs (see references 4 and 5 for some of
the most comprehensive ones), relate mainly to peptide length, charge,
and hydrophobicity: most AMPs do not exceed 30 amino acids in length;
they frequently have a high cationic charge — 6+ is common, even for
peptide lengths under 20 amino acids; and they usually contain, alongside
with the basic residues, a high content of hydrophobic sidechains. A
corollary of the last two attributes is that AMPs tend to interact strongly
with phospholipid membranes, especially the anionic bacterial ones.
The observation of common traits among AMPs led to a somewhat
*Any peptide with antimicrobial properties may be classified as an AMP but the term is
commonly used to denote exclusively the peptides that are either ribosomally assembled or
the synthetic derivatives of these. This was the usage adopted throughout the book. The
term ‘RAMP’ (ribosomal AMP) is also used to designate, more appropriately but much less
frequently, the same subgroup; ‘ribosomal’ was kept in the title of this thesis, and ‘RAMP’
was used throughout Article ii.
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A brief introduction to AMPs
tacit conviction that other features, namely their mechanism of action,
could be equally generalized.6 If a complete understanding of such a
general mechanism were attained very accurate antimicrobial drug design
would be possible — an important advance considering the worrisome
worldwide drug resistance scenario. It was not long, however, before
it was realized that a unified mechanism could not even account for
the differences in AMP-mediated cell membrane disruption,7 much less
for the whole antimicrobial process. Presently, and for the membrane
disruptive AMPs alone, at least three distinct mechanisms of membrane
perturbation have been proposed8–11 (see Figure 1.1 for an illustration
of these mechanisms; incidentally, the figure was the one intended for
Article v but ended up being replaced by a much duller — if of greater
scientific accuracy — editorial version). Alternatively, AMPs have been
classified according to their structure when bound to membranes,4 content
of specific amino acids,12 percursor forms,13 or natural occurrence.14 But,
while trends in behavior have been found within such classes, an accurate
prediction of an AMP’s mechanism still cannot be made solely from these
general characteristics.
Therapeutically, some very attractive characteristics make up for the
often incomplete description of the action of the peptides: AMPs are
antibiotics to which widespread resistance has not yet developed and,
more importantly, AMPs are antibiotics against which bacterial resistance
seems to be costlier to acquire.15 This is presumed to be so because most
AMPs target the cell membrane, a vital structure that cannot be easily
modified without compromising other cellular functions.16 In addition, the
peptides often interact diffusely with the membrane without a specific
binding target (for an opposite example think of β-lactam binding to
their transpeptidase targets17); point mutations seem unlikely to prevent
that unspecific interaction. Ultimately, I believe bacteria fail to effectively
develop resistance to AMPs for the same reasons we find it hard to fully
describe their modes of action.
The apparent absence of specific binding targets for most AMPs has
earned them the nickname of “dirty drugs” in that relatively high con-
centrations are required for activity, which potentiates the occurrence of
4
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Figure 1.1 – Proposed models for AMP-mediated membrane disruption.
After a threshold concentration in the membrane is reached peptides may
induce: a) barrel-stave pores8; b) carpeting and bilayer disintegration9;
c) toroidal pores10; and d) disordered toroidal pores,11 which are a recent
modification to the toroidal pore model. See the legend of Figure 1 in
Article v for further details on each model.
side-effects. However, rather than just a source of undesired action, this
lack of specificity may also be one of the factors behind the broad range
of therapeutic applications of these peptides: besides antimicrobial activ-
ity some AMPs have been shown to possess antiviral,18, 19 antitumoral,20
immunomodulating,21 or cell-penetrating properties (see Article i ahead).
Because of this, and because membrane interaction seems ubiquitous to
these processes, Miguel is keen on seeing outside the antimicrobial box
and suggests that the more abstract label ‘membrane-active peptides’ may
better suit these drugs. Sónia, Miguel and I co-wrote a discussion paper,
included at the end of the section as Article i, on the features shared
by antimicrobial and cell-penetrating peptides. As argued in the review,
this is more than just a conceptual proximity: AMPs, for example, have
been used as templates to rationally design or improve cell-penetrating
peptides.
Returning to the action of AMPs, the requirement of relatively high
concentrations translates as MIC (the antimicrobial minimum inhibitory
concentration) values typically lying in the low micromolar range. This
5
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Figure 1.2 – Number of patents issued per year by the US Patent and
Trademark Office with the terms ‘antimicrobial peptides’, ‘antibiotic pep-
tides’, ‘antibacterial peptides’, or ‘antifungic peptides’. Search conducted on
the Free Patents Online database22 for patents where the two terms occur
within three words of each other.
stands somewhat midway between the nanomolar activities of target-
specific drugs such as the β-lactams, and the millimolar concentrations
at which many more substances can be expected to become toxic by
sheer ionic and osmotic imbalance. Still, peptides can be modified so that
toxicity to mammalian cells occurs only at concentrations at least one order
of magnitude above the MIC,23 which means there is a reasonably wide
therapeutic window. In addition, while seemingly just a consequence
of unspecific binding, the relatively high MICs will later be shown to
play an important role in the development of a model of the antimicrobial
mechanism of AMPs.
Twenty years of AMP research have yielded a handful of drug leads
that are currently crawling their way through the approval process. Two
peptides have made it as far as Phase III testing with the US Food
and Drug Administration (FDA) but, to date and rather disappointingly,
no one has resulted in a new drug application. This, it seems, has not
discouraged researchers: a coarse search on issued patents (Figure 1.2)
shows the AMPs’ to be a growing field.
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Cell-penetrating peptides and antimicrobial peptides:
how different are they?
So´nia Troeira HENRIQUES, Manuel Nuno MELO and Miguel A. R. B. CASTANHO1
Centro de Qu´ımica e Bioqu´ımica, Faculdade de Cieˆncias da Universidade de Lisboa, Ed. C8, Campo Grande, 1749-016 Lisbon, Portugal
Some cationic peptides, referred to as CPPs (cell-penetrating pep-
tides), have the ability to translocate across biological membranes
in a non-disruptive way and to overcome the impermeable nature
of the cell membrane. They have been successfully used for drug
delivery into mammalian cells; however, there is no consensus
about the mechanism of cellular uptake. Both endocytic and non-
endocytic pathways are supported by experimental evidence. The
observation that some AMPs (antimicrobial peptides) can enter
host cells without damaging their cytoplasmic membrane, as well
as kill pathogenic agents, has also attracted attention. The capacity
to translocate across the cell membrane has been reported for some
of these AMPs. Like CPPs, AMPs are short and cationic sequences
with a high affinity for membranes. Similarities between CPPs and
AMPs prompted us to question if these two classes of peptides
really belong to unrelated families. In this Review, a critical
comparison of the mechanisms that underlie cellular uptake is
undertaken. A reflection and a new perspective about CPPs and
AMPs are presented.
Key words: antimicrobial peptide, cell-penetrating peptide, drug
delivery, internalization, translocation mechanism.
INTRODUCTION
The hydrophobic nature of cellular membranes makes them im-
permeable for most peptides, proteins and oligonucleotides. Dif-
ferent strategies have been employed to penetrate the membrane
barrier and deliver hydrophilic molecules inside the cell for either
experimental or therapeutic purposes. So far, microinjection,
electroporation, liposomes and viral vectors have been used.
Most of these delivery strategies have serious drawbacks, such as
low efficiency, poor specificity, poor bioavailability and extensive
toxicity [1]. Moreover, they are time-consuming. The endocytic
route has been used as an alternative for the import of hydrophilic
macromolecules into living cells [2]. However, the proteins
engaging in this mechanism stay enclosed within endosomes,
and so fail to access the cytoplasm, thus missing their final target.
Peptides as vectors to introduce macromolecules into cells
An efficient strategy with which to penetrate the membrane barrier
was identified by the observation that some intracellular proteins,
when added to extracellular medium, were able to pass through the
membrane. Tat (HIV-1 transcriptional activator protein) [3] and
pAntp (Drosophila antennapedia transcription protein) [4] were
the first proteins to be identified with this characteristic. The abi-
lity to translocate is attributed to basic amino acid sequences
in these proteins, and the minimal peptide sequence necessary
for the translocation to occur within Tat [5] and pAntp [6] have
been elucidated. The observation that these basic peptides allow
cellular delivery of conjugated molecules such as peptides [7] or
proteins [8] made these molecules attractive, and a new class of
vectors, initially known as PTDs (protein transduction domains)
[9], but more recently re-baptized as CPPs (cell-penetrating
peptides) [10], emerged. This family now includes all the peptides
with the ability to translocate across membranes, regardless of
whether they are natural, synthetic or chimaeric peptides.
So far, these vectors have been used to translocate a wide range
of macromolecules into living cells, including proteins [8,9,11],
peptides [7,12], oligonucleotides [13,14], peptide nucleic acids
[15] and polysaccharides [16]. Nanoparticles [17] and liposomes
[18] have also been internalized by means of CPPs.
Can AMPs (antimicrobial peptides) also work as vectors?
Most organisms produce gene-encoded AMPs as innate defences
to prevent colonization and infection by several microbial
pathogens [19–22]. Despite their ubiquity, AMPs can have very
distinct sequences and modes of action [23,24]; nonetheless,
they usually share several characteristics, such as their short
length (a few tens of residues) and their cationicity, typically
of charge 4+ or 5+ [25]. Other features of these peptides include
their strong interaction with lipidic membranes, a usually broad
killing spectrum and their ability to preserve host-cell integrity
[23,24].
Clinically these peptides display antimicrobial activity at
micromolar concentrations or less, and target bacteria do not seem
to readily develop resistance. These properties make AMPs very
promising candidates for new generations of drugs to fight anti-
biotic-resistant strains of pathogens [23,26].
Although most AMPs seem to act mainly at the membrane level
[24,25], their translocation into the cytoplasm is not uncommon
[27,28]; because of this property, membrane-crossing AMPs have
also been used as templates for CPP development [29]. Thus
AMPs can have clinical applications both as antibiotics and as
precursors of drug transporters.
HOW DO CPPs TRANSLOCATE ACROSS THE CELL MEMBRANE?
There is no consensus regarding the mechanism of translocation of
CPPs; the information available in the literature is controversial.
First it was suggested that these peptides translocate by a
Abbreviations used: AMP, antimicrobial peptide; CF, carboxyfluorescein; CPP, cell-penetrating peptide; NLS, nuclear localization signal; pAntp,
Drosophila antennapedia transcription protein; SV40, simian virus 40; Tat, HIV-1 transcriptional activator protein.
1 To whom correspondence should be addressed (email castanho@fc.ul.pt).
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Table 1 Source, amino acid sequences and possible internalization mechanism for some examples of peptides that work as CPPs or as AMPs
Name (sequence) Source [reference] [internalization mechanism(s), reference(s)]
Penetratin (RQIKIWFQNRRMKWKK) pAntp homeodomain (amino acids 43–58) [6]
(mainly endocytosis [39], endosomal escape mediated by pH gradient or
transmembrane potential [36,53])
Tat (GRKKRRQRRRPPQ) HIV-1 transcriptional activator Tat protein (amino acids 48–60) [5]
(mainly endocytosis [40], endosomal escape mediated by pH gradient or
transmembrane potential [37])
Pep-1 (Ac-KETWWETWWTEWSQPKKKRKV-cysteamine) Amphipathic chimaeric peptide with a tryptophan-rich domain and an NLS [57]
(physical mechanism mediated by peptide–membrane interaction promoted by
pore formation [60] or by transmembrane potential without pores [35])
S413-PV (ALWKTLLKKVLKAPKKKRKV-cysteamine) Chimaeric peptide with AMP dermaseptin S4 and an NLS [61]
(mainly physical mechanism promoted by a transient membrane destabilization [62])
Magainin 2 (GIGKFLHSAKKFGKAFVGEIMNS) AMP from the skin of the South-African clawed frog Xenopus laevis [101]
(translocation mediated by toroidal pore formation; peptide molecules translocate
stochastically as the pore disintegrates [28])
Buforin 2 (TRSSRAGLQFPVGRVHRLLRK) AMP from the stomach of the Korean common toad Bufo bufo gargarizans [102]
(peptide molecules translocate stochastically after the formation and disintegration
of a non-permeabilizing pore-like structure [84])
Apidaecins (RP - - - - - PRPPHPR (conserved AMP from the lymph fluid of several insects [103]
sequence among class members) (receptor-dependent membrane docking and translocation into target cell [104])
mechanism independent of receptors [30] and independent of
the endosomal pathway [5,6]. A physically driven mechanism
was suggested, because the cellular uptake at 4 ◦C and 37 ◦C was
similar [5,6,30,31].
More recent observations led to controversial results, sug-
gesting that the cell localization observed for CPPs is an artefact
and results from cell fixation for immunochemistry and cell visu-
alization [32]. The high peptide affinity for membranes may allow
CPPs to remain attached to cells during washing. During the cell
fixation process, CPPs are released, and the apparent localization
inside the cell results therefrom. However, direct observation
of translocation in model membrane systems for some CPPs
[33–35] supports the existence of physically driven mechanisms
governed by spontaneous peptide–membrane interactions. The
translocation mechanism issue is thus complex and may differ for
different classes of CPPs (Table 1).
CPPs derived from natural proteins
The CPP derived from pAntp has 16 amino acids and is the
sequence necessary and sufficient for translocation to occur [6]
(Table 1) and is commonly called ‘penetratin’. The Tat fragment
corresponding to residues 48–60 [5] (Table 1), and a shorter
fragment (residues 47–57) [18,36,37], have frequently been used
in CPP research.
An endosomal pathway for internalization was initially ex-
cluded by comparison of the uptake at 4 ◦C and 37 ◦C under fixa-
tion conditions [5,6,30]. After re-evaluation for the interference of
artefacts during fixation, an internalization mediated by endo-
cytosis was concluded for both penetratin [38,39] and Tat peptide
[37,40–43]. The basic amino acids are essential for translocation
to occur, and membrane binding seems to be the first step
prior to endocytic uptake. Heparan sulfate proteoglycans at the
cell membrane were proposed to act as receptor for penetratin
[42,44–46] and Tat peptide [42,47].
Although it is accepted that these CPPs can enter the cells
by endocytosis, there is no consensus in the specific endocytic
pathway used for the import of these arginine-rich peptides. A raft-
dependent pathway involving macropinocytosis [48] or caveolae
[41,49,50], or a clathrin-dependent endocytosis [47,51,52], were
proposed. The dissimilarities among these results can arise from
the use of different cell lines, methodologies, labelled peptides,
protein-conjugated peptides and different conditions, which can
inhibit some pathways while favouring others.
Even in a picture where the endosomal pathway emerges as the
physiological uptake of CPPs, the escape from endosomes into
the cytoplasm through a physically driven mechanism persists.
An escape from endosomes due to acidification was proposed for
penetratin and Tat peptide [36,37]. This hypothesis is supported
by the results obtained by Gra¨slund and co-workers [53] with
penetratin encapsulated in large unilamellar vesicles. The escape
of penetratin occurred only in the presence of a pH gradient. The
role of intracellular pH in the internalization of CPPs was also
investigated using neutralization agents [38].
A dependence of translocation on a negative transmembrane
potential was identified in vitro for both penetratin and Tat peptide
[34] and in vivo for Tat peptide [54]. Terrone et al. [34] suggested
that a fraction of the peptide can transverse through the membrane
by a transmembrane potential-driven mechanism, whereas the
other fraction is internalized by an endosomal pathway. Once in-
side the endosomes, the transmembrane potential (luminal side
positive) drives translocation from the endosomal lumen to the
cytoplasm. By contrast, Drin et al. [38] did not find any internal-
ization of penetratin in liposomes, even in the presence of a trans-
membrane potential. Recently Ba´ra´ny-Wallje et al. [55], following
electrophysiological measurements in planar bilayers, failed to
detect translocation, even in the presence of applied voltages.
Chimaeric peptides
The usefulness of peptides as vehicles to introduce macromole-
cules into cells led to the development of many chimaeric peptides.
Pep-1 (acetyl-KETWWETWWTEWSQPKKKRKV-cysteamine)
is a CPP with primary amphipathicity (i.e amphipathicity resulting
from the amino acid sequence itself, not from the folding structure
[56]) that comprises a tryptophan-rich so-called ‘hydrophobic’
domain, a hydrophilic domain derived from an NLS (nuclear local-
ization signal) of SV40 (simian virus 40) large T-antigen, and a
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spacer between them [57]. A cysteamine group is present at the
C-terminus [57] (Table 1).
Pep-1 has been used to introduce large proteins inside cell lines
[57–59]. An endosomal pathway was rejected because (1) there
was no difference in translocation efficiency at 37 ◦C and 4 ◦C [57]
and (2) no co-localization of a delivered protein (β-galactosidase
from Escherichia coli) with different cellular organelles (early
endosomes, caveosomes and lysosomes) was detected [59]. By
contrast, Weller et al. [58] proposed an endosome-mediated mech-
anism based on the internalization of Pep-1–protein complexes in
the presence or absence of endocytic inhibitors.
Deshayes et al. [60] proposed a transient transmembrane-pore-
like structure promoted by α-helix conformation of the hydro-
phobic domain when it interacts with membranes. This conclusion
was not corroborated by other groups, because no membrane leak-
age was detected [35,58]. An alternative mechanism, mediated
by electrostatic peptide–lipid interactions, was proposed after
observation that Pep-1 translocation both in vitro [35] or in vivo
[59] only occurs in the presence of a transmembrane potential.
When Pep-1 was modified at the C-terminus [lack of cysteamine
group and grafting of a CF (carboxyfluorescein) group], the mem-
brane affinity and the translocation efficiency was truly impaired,
but a small uptake seems to occur by an endocytic mechanism
[16].
The chimaeric peptide S413-PV, which results from the combi-
nation of a 13-amino-acid sequence derived from the dermaseptin
S4 (S413 domain) with the NLS from SV40 large T-antigen (see
Table 1), was proposed as a potential vehicle to introduce macro-
molecules into cells [61]. The uptake of this peptide under non-
fixation conditions was not decreased in the presence of endocytic
inhibitors [62]. An endocytic uptake was only evident at low
peptide concentration [63]. The binding of the S413-PV peptide to
the cell membrane is promoted by electrostatic interactions with
negatively charged components at the cell surface, and a confor-
mation change in the S413 domain upon insertion into the bilayers
was detected [62]. The translocation of S413-PV across the cell
membrane is considered to be a consequence of a transient mem-
brane destabilization produced by peptide–membrane interactions
[62]. Endosomal internalization at low peptide concentration
suggests that higher peptide concentrations are necessary to
induce membrane destabilization.
Translocation mechanism or mechanisms?
Considering the abovementioned examples, it is clear that the
mechanism by which CPPs translocate across cell membrane and
deliver their cargoes in the cytosol is far from being totally under-
stood. Although some CPPs are able to translocate by an endocytic
pathway, the escape from endosomes demands a physically driven
mechanism.
The affinity of each CPP for lipid bilayers may be the key factor
for their main mechanism of uptake. Penetratin, for instance, does
not show a strong affinity for zwitterionic membranes [46,64,65]
and does not induce significant membrane destabilization [66].
Interaction with model membranes only occurs in negatively
charged lipid bilayers [46,65]. In studies of the interaction of this
peptide with eukaryotic cells, negatively charged proteoglycans
presented at the cell surface were regarded as essential for trans-
location to occur [42,44,45]. Cellular uptake of penetratin occurs
via endocytosis, but requires the expression of proteoglycans [42],
which demonstrates the importance of electrostatic interactions in
increasing the affinity of the peptide for cell membranes [45].
By contrast, Pep-1 has a high affinity for lipidic membranes,
even in the absence of negatively charged phospholipids or pro-
teoglycans [67], and it induces significant membrane destabi-
lization [35], which seems to favour internalization. Moreover,
the introduction of a CF dye into the hydrophilic domain of
Pep-1 and/or deletion of a cysteamine group decreased the
peptide’s affinity and, consequently, its uptake [16,58], and a
slight internalization by endosomal pathway occurs [16]. This
suggests that the membrane affinity and the capacity to destabilize
it dictate the extent to which a peptide enters the cell by a physical
mechanism (a fast process during which the endosomal pathway
may be considered stationary) to the detriment of the endosomal
pathway.
The hypothesis of the co-existence of endosomal and physically
mediated mechanisms was also proposed by Boisseau et al. [68]
in a study with maurocalcine, a CPP isolated from the Israeli gold
scorpion (Scorpio maurus palmatus). A contribution of both me-
chanisms was identified where the physically driven mechanism
results from a transmembrane potential. Moreover, Nakase et al.
[69] showed that greater amounts of oligo-arginine were found
in the cytoplasm when cells were incubated at 4 ◦C than at 37 ◦C.
They proposed that, when endosomal pathways are inhibited and
an alternative pathway can operate, the peptide is more efficiently
translocated to the cytosol. When incubation is at 37 ◦C, oligo-
arginine release in the cytoplasm is difficult, owing to endosome
entrapment.
Translocation by a physical mechanism demands not only the
existence of a high membrane affinity, but also a promoting force:
pH gradients [53] and transmembrane potentials [34] are two poss-
ible driving forces. The existence of such driving forces is well
understood in the cell context, where in/out media are char-
acterized by the preservation of gradients.
HOW DO AMPs GET INSIDE CELLS?
The mechanisms by which AMPs gain access to a cell’s interior
can be classified as pore-dependent and pore-independent, the
former being the most usual. In fact, there are relatively few AMPs
that do not exert their main function via cell lysis, membrane
permeabilization or other forms of bilayer disruption. Few AMPs
attack internal targets, and, of those, only a small number can do
so without membrane perturbation [70].
AMPs that induce membrane permeabilization
After the initial peptide–membrane interaction, mechanisms
diverge; besides lysis, usually by a mechanism known as the
‘carpet’ model [71,72], two other models have been proposed for
AMP pore formation: the barrel-stave pore and the toroidal pore
(for further detailed information, see references [73,74]).
Independently of the pore type, diffusion of free peptide through
the pore may not be the principal process of translocation; instead,
it has been proposed that it is the peptide molecules that are in-
volved in pore formation that stochastically translocate as the pore
disintegrates [28]. Several factors support this statement, the most
relevant being the fact that, for AMPs, the local concentration
of membrane-bound peptide molecules is usually several orders of
magnitude higher than in the aqueous phase (e.g. [75,76]); as
such, there will be many more peptide molecules available for
pore formation than for pore crossing. In addition, pore diameters
are relatively narrow and usually not longer than the length of the
peptides (alamethicin barrel stave pores have a diameter of 2–3 nm
[77] and those of toroidal mellitin have a diameter of 3–4 nm [74]),
preventing or hindering a free diffusion of the peptide; lastly, pore
lifetimes are in the microsecond-to-millisecond range (between
40 µs for magainin and 200 ms for dermaseptins [28,78]), which
is long compared with a single-molecule translocation time, but
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probably not long enough to quickly equilibrate inner and outer
peptide concentrations.
Given this hypothesis, pore formation can be regarded not only
as a membrane perturbation process, but also as an important
intermediate step towards cellular invasion by AMPs. This is
in agreement with recent findings that indicate that a synergic
effect of activity at both membrane and cytoplasm levels may be
required to fully explain the mechanisms of some pore-forming
AMPs [79–81].
Non-lytic AMPs
For AMPs that preferentially attack internal cellular targets,
similar translocation mechanisms have been reported: for buforin
2, which translocates efficiently, but with little membrane activity
[70,82,83], the structure and orientation in the bilayer have been
observed to be very similar to those of magainin 2 (Table 1)
[83,84]. From these results a model was proposed whereby buforin
2 molecules would form a toroidal pore, just as magainin 2 does,
but less stable; this would result in shorter pore lifetimes – with a
concomitant decrease in permeabilization – at the same time that
the translocation rate would increase because pore disintegration,
which is the actual translocation step, would become more
frequent [83,84]. This model is supported by results that show
that the presence of bilayer components that prevent the formation
of toroidal pores (such as dioleyl phosphatidylethanolamine [28])
inhibit buforin 2 translocation, whereas anionic phospholipids,
which decrease the charge repulsions between the cationic peptide
molecules, stabilize the pore to a point that significant leakage
and flip-flop is observed [84]. Buforin 2 translocation has also
been shown to withstand cargo addition, as demonstrated by the
attachment of green fluorescent protein [29,85], which makes this
peptide a promising candidate for its development into a CPP.
Other mechanisms of translocation
Apidaecins, which are another class of non-lytic AMPs that are
able to kill bacteria with undetectable membrane permeabili-
zation, act by binding to a cytoplasmic target (Table 1) [86]. In this
case, translocation has been proposed to occur by specific inter-
action with a putative membrane permease or transporter in the
target bacterial cell; this was suggested by the fact that the all-D
enantiomers of the peptides lose the ability to cross the membrane
[86]. This characteristic confers a high selectivity on these pep-
tides, which can even be modulated [87], but, on the other hand,
the need for a membrane transporter makes apidaecins unap-
pealing as templates for CPP design.
Despite their apparent simplicity, many AMPs have been shown
to possess activity-specific regions: through sequence manipula-
tion it has been possible to regulate translocating behaviour, target
specificity or antimicrobial efficiency [87–89]. By means of these
alterations, it has become possible to broaden the spectrum of CPP
template candidates beyond non-cytotoxic translocating AMPs.
This has been taken advantage of, for example, in the derivatives
of the membrane-active Bac7 peptide [29,88,90], which, unlike
their precursor, are not membrane-disruptive, but have retained
translocation capabilities.
CPPs AND AMPs OR JUST MEMBRANE-ACTIVE PEPTIDES?
Membrane translocation is a corollary for membrane permeabili-
zation. Although treated differently by people interested in CPPs
and AMPs, the ability to reach the inner leaflet of lipid bil-
ayers is of crucial importance to both. Potentially, all CPPs are
AMPs and all AMPs are CPPs. At high enough concentration, pep-
tides reported as CPP perturb membranes and become membrane
permeabilizers (see reference [91], in which antimicrobial activity
of different CPPs is evaluated), whereas AMPs may reach cyto-
plasmatic targets before membrane permeabilization. This is
not surprising, because both CPPs and AMPs are very similar
molecules: short cationic peptides. It should be stressed that both
classes cannot be differentiated on account of their structure
because there is a wide diversity of conformations within each
class of peptides [25,92]. The attention devoted to both CPPs
and AMPs is very application-oriented, which dictates why
these very similar classes of molecules are considered in such
a separate fashion. CPPs are mainly studied by people focusing
on gene therapy and drug delivery. AMPs are mainly regarded as
tools to fight bacterial infections. However, from the molecular
mechanistic point of view, the separation of these peptides into
two groups is really rather academic.
Cellular membranes of target cells where the activity of these
two peptides are evaluated are quite different. CPPs are generally
evaluated against mammalian cells, whereas the target of AMPs
is the bacterial cell. The major differences rely on anionic-lipidic
and cholesterol contents. The bacterial membrane has a higher
percentage of negatively charged lipids and does not contain
sterols [24]. Different effects reported with CPPs and AMPs
can arise from the differences in membrane composition, factors
which modulate peptide affinity and membrane destabilization.
Considering the overlap between the mode of action of CPPs
and AMPs, it does not seem reasonable to obstinately seek an
exclusive answer to the question whether CPPs enter cells through
endocytic or physical processes. As indicated above in the present
Review, depending on circumstances, the same peptide may
potentially use both [16,63,68]. Moreover, endocytic entrapment
has to be followed by physical membrane translocation if the
peptide is to reach the cytoplasm. The physical pathway can be
mechanistically described by the interaction equilibrium between
the peptides in the medium and the outer leaflet of membranes,
perturbation of bilayers, translocation among leaflets and a
second equilibrium of the peptides between the inner leaflet of
the membrane and the reducing conditions of the cell interior
[67,93–95] (Figure 1). A more effective or faster formation of a
membrane-disturbing structure, mediated by the AMP magainin,
was identified when a transmembrane potential was present [96].
Certain chimaera peptides, such as Pep-1, may even be con-
sidered a ‘blend’ between AMPs and CPPs. Although reported
as a CPP, Pep-1 is a strongly amphipathic cationic peptide,
rich in basic amino acids and tryptophan, having a proline residue
in its sequence. These are classical characteristics attributed to
AMPs. The ability to cysteine-bridge monomers, which greatly
improves translocation efficiency, further increases the similar-
ities to AMPs. Not surprisingly, Pep-1 uses mainly physical routes
to translocate membranes [35,57,59]. However, this route is not
always operative [16], and endocytic pathways are alternatives.
The results obtained with Pep-1 confirm the co-existence of
endocytic and physically mediated pathways. Such co-existence
was previously proposed by other authors [97] using other CPPs,
but this proposal was largely overlooked. The kinetic factor
is important, as progress through physically driven pathways is
rapid compared with that through endocytic pathways: when
both physical and endocytic pathways are operative, the physical
pathway is dominant, owing to faster kinetics [67,93].
These peptides are able to destabilize the membrane (fusion and
vesicle aggregation were detected) without evidence for pore
formation or flip-flop [35,66]. A ‘membrane-thinning’ effect was
proposed for the AMP magainin 2 [98], in which the peptide
aggregates on the surface of the membrane and the decreased local
surface tension allows the peptide to intercalate the membrane.
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Figure 1 CPP translocation by a physically driven process can be regarded
as a composite of three sequential steps
(A) The peptide (dark-grey cylinder) inserts in the bilayer outer interface (light-grey head-groups
with fatty acid tails) and causes local membrane perturbation. (B) Owing to a membrane gradient
(e.g. transmembrane potential, pH gradient) or concentration effects, the peptide overcomes
the hydrophobic core of the bilayer by an unknown mechanism. (C) The peptide is released
from the inner leaflet of the membrane (blue head-groups with fatty acid tails) to the cytoplasm.
In a model artificial system (e.g. a vesicle) the system would tend to an equilibrium that can
be accounted for by three different partition constants, one for each of the elementary steps
(A, B and C).
Flexible sealing between peptide side groups and lipid head-
groups minimize leakage during the peptide passage through the
membrane [29].
A pore-formation mechanism was proposed for MPG (a 27-
residue amphipathic peptide) and Pep-1 [60,99], which is also
a common mechanism used by antimicrobial peptides. In the
case of a transmembrane pore, a large pore would be necessary
to allow the passage of attached macromolecules, a situation
that compromises cell viability and all the significance of these
peptides as vehicles. In some cases pore formation can explain
the translocation of the peptides per se; however, these pores are
not large enough to explain the translocation of proteins [28].
The history of CPP research can be summarized from two dif-
ferent periods, with a sudden change of paradigm in 2001 [32],
later confirmed in 2003 [100]. First, the physical paradigm domi-
nated. CPPs were considered to cross bilayers by a physical
process. Since 2001–2003 there has been a tendency to think the
opposite. Reality may not be so black-and-white, and this rather
simplistic view of physically driven versus endocytic mechanisms
seems inadequate. The CPP research community should go back
to basics and redefine CPPs on the basis of their cargo trans-
location ability rather than their stand-alone peptide properties.
Most of the CPP research focuses on the peptides’ membrane-
translocation ability in the absence of cargoes. It is thus crucial to
develop new methodologies to detect and quantify translocation
of peptide-mediated cargo translocation in vesicles and cells.
As to the peptides themselves, and their interaction with lipid
bilayers, it may be that the frontiers between fusogenic peptides,
AMPs and CPPs become so undefined that, in the near future,
only the unified broad-scope title of ‘membrane-active peptides’
will make sense.
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2. Omiganan
The first AMP I studied was omiganan (more precisely, omiganan pen-
tahydrochloride), which happens to be one of the two AMPs mentioned
in Chapter 1 that has not continued past Phase III testing. Omiganan (se-
quence: ILRWPWWPWRRK–NH2, where NH2 indicates C-terminal
amidation) was designed having the naturally occurring AMP indolicidin
— itself known and studied24 since 1992 — as a template. Omiganan was
developed by MIGENIX Inc. as a topical antibiotic to prevent catheter-
related infections and I would be studying it following a not-for-profit
collaboration Miguel started with the company (then called Micrologix).
Background on omiganan and indolicidin is provided in Article ii. This
article, writtenwhen I began mywork with omiganan, is a reviewMiguel
was invited to author in which we and Dominique Dugourd, our contact
at MIGENIX, summarize what was then known about the two peptides.
In March 2009 the results of Phase III tests were released: the peptide
met several efficiency criteria but the main result — improved performance
relatively to the currently used standard —was not considered statistically
significant25 (a repetition of the less-than-optimal26 outcome of another
large-scale clinical trial in 2003). The development and commercialization
partner of MIGENIX’s has since quit the collaboration on the basis of
insufficient commercial interest due to little advantage of omiganan over
existing therapies.27 The drug is currently orphan as MIGENIX looks for
new partners. Other applications of omiganan as a treatment against acne
or rosacea erythema, already in Phase II testing, were also put on hold.
While it is sad to see the subject of my study be dismissed as commer-
cially unviable, the academic interest on omiganan and its contribution to
the advancement of knowledge on AMP action persist.
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also proved its efficiency against acne vulgaris. Omiganan is the most advanced molecule in the front line of clinical ap-
plications of antimicrobial peptides. The mode and site of action of omiganan are not yet settled although its interaction
with membranes is known to play a fundamental role. The biochemical and biophysical foundations for the action of in-
dolicidin and its analogues are reviewed in this paper, as well as the clinical application of omiganan. The in vitro  effi-
ciency tests and the outcome of clinical trials are addressed. Altogether, despite the very specific use of omiganan as a
topical antibiotic, it has the potential of being a pioneer of a new generation of antibiotics that carry the promise of ending
the multi-resistance problem.
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1- INTRODUCTION
Nearly 100 patents can be found in worldwide databases
having “antimicrobial” and “peptides” in their titles. In-
dolicidin derivatives raised particular interest and several
compositions and methods for treating infections have been
published (e.g.[1-3]).
Omiganan pentahydrochloride (omiganan – ILRWPWW-
PWRRK-amide), is a novel antimicrobial peptide (AMP)
developed by MIGENIX Inc. (Vancouver, Canada) that is in
development for use as a topical antimicrobial for the pre-
vention of catheter-related bloodstream infections [4]. Omi-
ganan is a synthetic peptide, an analogue of the naturally-
occurring AMP indolicidin (ILPWKWPWWPWRR-amide),
and, like indolicidin, also has a very high content of trypto-
phan (W) residues.
AMPs are part of non-specific host defence mechanisms
and have been found in specimens from all kingdoms
[5],[6],[7],[8]; in particular, indolicidin, which can be puri-
fied from the granules of bovine neutrophils [9], takes part in
the process of bacterial killing inside phagocytic vesicles.
Because they are used by the innate immune system,
these antibiotics often have very wide killing spectra: in-
dolicidin is active against Gram-negative and Gram-positive
bacteria [9], fungi [10], protozoa [11] and even HIV-1 (en-
veloped virus) [12]. Also, bacterial resistance to these pep-
tides seems to be a rare phenomenon, which makes AMPs
very interesting for the pharmaceutical industry. The studies
on the structure and mode of action of omiganan are ongoing
and the comparative analysis of the properties of omiganan,
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indolicidin, and indolicidin analogues allows for some ex-
trapolation towards a better characterization of omiganan.
1.1 - Challenges in the Therapeutic Use of AMPs
Indolicidin, a template for omiganan’s design, is included
in a sub-group of AMPs called ribosomally synthesized
AMPs (RAMPs or gene-encoded AMPs), which are pro-
duced by many organisms. The other group of AMPs are of
the exclusive production of bacteria and fungi and are syn-
thesized non-ribosomally (therefore termed non-RAMPs)
[13]. While some non-RAMPs or their synthetic derivatives
are already used as antibiotics [13,14], there is great concern
towards such use of RAMPs or RAMP-related synthetic
peptides, like omiganan, in case pathogen resistance devel-
ops: these peptides can be quite diverse in sequence and
structure however, should microbial cross-resistance arise
between them, their use as antibiotics could encourage the
growth of new strains resistant to human RAMPs. Such
strains would render an important part of the human innate
immune system ineffective and pose serious public health
threats [13].
On the other hand, the safe use of RAMPs as antibiotics
is favoured by the fact that bacterial resistance is argued to
be inherently hard to acquire [15,16]: these drugs usually
target the cell membrane integrity and make use of funda-
mental characteristics of bacteria such as the overall anionic
charge of the membrane phospholipids or the negative mem-
brane potential [16-18]. For resistance to develop, bacterial
membranes would have to undergo profound structural and
functional changes, thus implying prohibitive costs of resis-
tance [16]. Also, microorganisms have been subjected to
attacks by human RAMPs for at least as long as Homo
sapiens have existed; however, such a long exposure does
not seem to have strengthened human pathogens to the point
of making them resistant. This suggests that the mechanisms
by which microbes could resist RAMPs are already at their
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maximum efficacy and any added resistance also carries a
loss of viability [19].
2- THE BIOCHEMICAL AND BIOPHYSICAL FOUN-
DATIONS FOR THE ACTION OF INDOLICIDIN AND
ITS ANALOGUES
2.1 - Structural Characterization
The structure of indolicidin has been determined by
NMR and CD [20]. While it shows no distinctive structural
features in aqueous environments, indolicidin seems to adopt
an approximate poly-L-proline type II helix conformation,
together with β-turn behaviour, upon interaction with DOPC
[20]. This is a rather uncommon secondary structure for
RAMPs, the most usual being the α-helices, the β-sheets,
and the disulfide bond loops [15], ordered accordingly to
their relative frequencies. Extended structures, together with
the helix conformation, have also been observed in the
proline- and arginine- rich RAMPs bac5, bac7, and PR-39
[21-23]. Interestingly, despite the big differences in sequence
and size between indolicidin and these peptides, they are part
of the cathelicidin family, a mammalian subclass of RAMPs
in which the antibiotics are synthesized as large propeptides,
with highly conserved proregions [24]. Their common ori-
gin, together with their similar structural characteristics and
expression in closely related species [22], suggests that these
RAMPs could also share antimicrobial modes of action.
When interacting with micelles or liposomes, indolicidin
has a relatively stretched structure that nearly spans the
membrane (32 Å) despite having only 13 amino acids. This
is possible because poly-L-proline type II helices have very
high helical pitches (9.3 Å) when compared to α-helices (5.4
Å) [25]. The flexibility of the helix, the β-turn tendency, and
a lack of order of the N-terminal residues give indolicidin a
characteristic boat-shaped extended structure with positive
charges on both ends, which may be important when inter-
acting with membrane interfaces as it allows the central hy-
drophobic residues to be near the acyl chains of the mem-
brane phospholipids while the charged endings remain close
to the polar headgroups [6].
The secondary structure of omiganan has not yet been
determined but, upon interaction with phospholipids, it may
be closely related to that of indolicidin since other in-
dolicidin analogues also share structural similarities, as indi-
cated by CD spectra [26,27]. The differences in the primary
sequence between omiganan and indolicidin include the re-
moval of the Trp and Pro residues closest to the N-terminus,
the addition of a Lys residue at the C-terminus and the sub-
stitution of Lys-5 with an Arg residue which are changes that
appear to effectively centralize the hydrophobic core and
increase the C-terminal cationic charge.
Omiganan should still have a poly-L-proline type II
structure since its central hydrophobic segment, which is the
principal constituent of the helix, has been conserved from
indolicidin. Part of the peptide curvature has probably been
lost with the deletion of the Pro-3 and Trp-4 residues but the
peptide span might be similar to indolicidin since the deleted
pair contributed little to the molecule length and an extra
residue was added near the C-terminus.
Because poly-L-proline type II helices have three resi-
dues per turn, they will have a three-fold symmetry around
their axis, which has been observed to occur in indolicidin
[20] and should also be present in omiganan. This symmetry
will cause the alignment, in pairs, of the hydrophobic core
Trp and Pro residues. This leads to a segregation of Trp and
Pro side chains to opposite sides of the helix axis, effectively
creating a hydrophobic Trp face [28], which could be of im-
portance to the membrane partition and activity of these
peptides. A similar, yet more pronounced effect, occurs in α-
helical RAMPs, where charged residues are usually posi-
tioned opposite of hydrophobic ones in the helix. This prop-
erty has been shown to play a very important part in the
binding of α-helical peptides to the membrane surface [29].
2.2- Mechanisms of Action Against Bacteria
– General Properties
Membrane interaction is one of the most important and
most studied characteristics of RAMPs and, because most
RAMPs are both amphiphilic and cationic, it is tempting to
assume that a general mechanism based on these common
properties could describe their modes of action towards the
anionic bacterial membranes. The carpet mechanism [17],
[30,31] is one such model in which an antibiotic would inter-
act electrostatically and hydrophobically/hydro-philically
with a membrane and, above a critical concentration in the
bilayer, would destabilize it enough to the point that it would
lose its integrity. However, several killing processes have
been described besides straightforward lysis [18,32]; these
include membrane attacks that lead to permeabilization
through pore formation or cell depolarization and also cyto-
plasmic attacks such as DNA, RNA, or protein synthesis
inhibition. This diversity in behaviours suggests that al-
though the carpet model may explain the killing processes of
some RAMPs, membrane surface interaction is not the only
phenomenon involved in general RAMP action. It seems that
the only fact that can be safely generalized is that RAMP-
membrane interactions are always of great importance for
activity, whether the site of action is the membrane itself or
cytoplasmic targets [8].
Because such different mechanisms can potentially be
found in RAMP activity, recent studies have focused more
on the structural-functional relationship in these peptides and
thorough reviews exist on the subject [8,18,32,33]. Never-
theless, even within the same structural subclass, various
modes of action seem to coexist. New hypotheses propose
alternative points of view in which, for a single antibiotic,
cell death can occur through several of the aforementioned
processes acting synergistically [17,34]. In addition, micro-
environment changes may induce drastic behavioural
changes that may lead to different antimicrobial processes
from a single peptide towards different types of cells, as was
reported for the bee venom RAMP mellitin [35].
Having been discovered in the early 90’s [9], indolicidin
has been extensively studied and several possible modes of
action have been investigated. However, there is still lack of
consensus regarding which process actually leads to cell
death. At least three mechanisms have been proposed,
namely cell depolarization [36], membrane permeabilization
[37], and DNA/RNA/protein synthesis inhibition [38]. Re-
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gardless of the actual mode of action, the efficiency of in-
dolicidin, and probably of omiganan, seems to be correlated
with characteristics that they share with other antimicrobial
peptides [18]:
a. they are very small peptides, thus being hard to recog-
nize and mark for proteolysis;
b. they are amidated at their C-terminus, further resisting
proteolysis and eliminating the negative charge of the
carboxyl group;
c. they are amphipathic, being able to interact strongly
with cell membranes, which are expected to be one of
their primary targets;
d. they are polycationic, which favours their preferential
interaction with the negatively charged bacterial mem-
branes, lipopolysaccharide (LPS), and peptidoglycan,
rather than with the zwitterionic outer surface of mam-
malian membranes. Membrane potential is also more
negative in bacteria than in mammalian cells, which
could enhance antibiotic binding and translocation.
The last factor may be responsible for one difference
between omiganan and indolicidin. Indolicidin has the clini-
cal disadvantage of also being active against erythrocytes
[26-28] while omiganan seems to be much less haemolytic
[26,39]. As indicated above, the charged residues of omiga-
nan are located closer to each end and away from the central
hydrophobic segment of the peptide, and the overall positive
charge of the peptide is increased from 4+ to 5+, which
could account for the haemolysis reduction as these changes
would not favour the peptide analogue associating with the
zwitterionic mammalian membranes [31]. This is corrobo-
rated by the findings of Staubitz et al. [40] in which the cen-
tral segment of indolicidin, conserved in omiganan, is related
to activity whereas the terminal segments seem to regulate
target specificity.
– Outer Membrane Interaction
Although it is probably not a lethal event for itself, the
crossing of the Gram-negative outer membrane is also very
important for antibiotic activity. A widely accepted mecha-
nism of self-promoted uptake into the periplasmic space has
been proposed for indolicidin and some other antimicrobial
peptides [15,36]. In this model, the cationic peptide displaces
the ions that equilibrate the anionic charge on the outer leaf-
let LPS, disturbing the bilayer and allowing the antibiotic to
cross the outer membrane through transient pores or cracks.
Besides the electrostatic interactions needed for the self-
promoted uptake pathway, binding of indolicidin to LPS has
also been proposed to be favoured by structural comple-
mentarity [26,41]. Omiganan can also be expected to follow
the self-promoted uptake pathway as it is even more charged
than indolicidin. Furthermore, it has been shown by the ex-
posure of periplasmic β-lactamases that, like indolicidin
[36], omiganan permeabilizes the E. coli outer membrane
[42], which is in agreement with the destabilization required
for its crossing to the periplasmic space.
– Cell Wall Interaction in Gram-Positive Bacteria
One aspect of antibiotic interaction with Gram-positive
bacteria that has been neglected is the crossing of the thick
peptidoglycan wall. Peptidoglycan is a negatively charged
mesh that, in Gram-positives, also contains long polymers of
glycerophosphate or ribitol-phosphate (termed teichoic ac-
ids) which contribute extra anionic charge to the wall
[43,44]. Cationic peptides will certainly have a great affinity
for the Gram-positive cell wall which will work as another
target selection mechanism. However, despite being rela-
tively small, the size of omiganan and indolicidin, and also
of most RAMPs, is of the same order of magnitude as the
peptidoglycan tesserae’s (mesh “pores”) diameter [45]. This
means that the anionic charge, together with the intricate
peptidoglycan mesh, could act as a peptide trap, compro-
mising the antibiotic efficacy. Little or no study has been
done in order to determine whether certain characteristics of
RAMPs are required for them to cross the peptidoglycan
wall and reach the membrane and other targets. Neverthe-
less, it has been shown that S. aureus strains incorporate
positively charged D-alanyl-teichoic acid esters into the
teichoic acid polymers, effectively lowering the antibiotic
affinity, as a means of RAMP resistance [46].
– Membrane Interaction
After the interaction with the outer membrane or the
peptidoglycan wall, other processes must take place before
cell death occurs. Despite having been the focus of much
research, the interactions of indolicidin with the bacterial cell
membrane and the actual process of killing are not yet rec-
onciled. Indolicidin, but not omiganan, permeabilized the E.
coli inner membrane, as determined by cytoplasmic β-
galactosidase exposure assays [36,42]. This could indicate
that indolicidin and omiganan have different modes of action
regarding lipidic bilayers. Nevertheless, care must be taken
when analysing such data because β-galactosidase substrates
are bulky [47] and membrane permeabilization may be un-
derestimated if the formed pores have small diameters or are
very short-lived. Should that be the case, omiganan could
possibly permeabilize bacterial membranes, despite being
undetected by β-galactosidase assays. In another study, in-
dolicidin was shown to be able to induce vesicle contents
leakage, at a moderate rate, as long as the liposomes were
constituted by negatively charged phospholipids [37]. It
should be noted that because of the charged endings and the
hydrophobic core of indolicidin and omiganan, any hypo-
thetical pores formed by these peptides are expected to be of
the toroidal type rather than barrel-stave [48].
Even if omiganan does not permeabilize the inner mem-
brane, it is at least able to disrupt its electrical potential, de-
polarizing the cell, as was determined by fluorescence assays
with a membrane potential probe [42]. The difference in its
behaviour relative to indolicidin may simply be a question of
pore size or degree of membrane perturbation that does not
necessarily imply a different mode of action.
EM studies also show that although lysis due to bacterial
wall/membrane fragmentation does not occur upon treatment
with omiganan or indolicidin, very profound membrane
perturbations are induced, the most notable being the forma-
tion of multilayered membranes and membranar inclusion
bodies (mesosomes) both in Gram-positive and Gram-
negative bacteria, giving support for the membrane disrup-
tion hypotheses [49,50].
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While membrane depolarization is not incompatible with
permeabilization, little evidence for it as a killing mechanism
was found by EM since significant leakage of cell contents
was not observed. An exception is indolicidin analogue CP-
11 acting on S. epidermidis [49], possibly related to hypo-
thetically larger pores. Yet, we cannot conclude right away
that depolarization is the main killing mechanism of these
peptides as depolarization per se may be insufficient to cause
death [18]. In recent work, Hancock, one of the proponents
of a depolarization mechanism for the action of indolicidin
against Gram-negative bacteria, reported to have observed
very little correlation between cell depolarization/permeabili-
zation and death or antimicrobial activity in Gram-positive
bacteria [49]. With indolicidin for example, the majority of
the cells would have died before becoming fully depolarized;
there were also other antibiotics that could induce very
strong and fast depolarization but were not necessarily very
active or led to cell death some minutes later.
– Action on the Cytoplasm
Another mechanism proposed for the action of these
peptides is based on findings that nucleic acid and protein
synthesis were inhibited in bacteria treated with either in-
dolicidin [38] or omiganan [51]. This hypothesis is consis-
tent with the morphological effects that indolicidin or omi-
ganan have on bacteria: E. coli treated with these antibiotics
demonstrated filamentation, rather than lysis, as observed by
EM [38,50]; this phenomenon can be a consequence of DNA
damage or replication perturbation [52]. Moreover, DNA
condensation seemed to occur in S. epidermidis [49], further
suggesting that indolicidin and omiganan may attack the
DNA itself or related cytoplasmic targets, which is also in
agreement with predictions that poly-L-proline helices have
affinity for B-DNA major grooves and may recognize certain
nucleotide sequences [53].
In this last hypothesis, the peptides are required to cross
the membrane to reach their targets. Translocation is ex-
pected to occur due to a number of factors. Firstly, both in-
dolicidin and omiganan seem to have the size, when ex-
tended, to span both membrane leaflets, albeit with a small
negative mismatch. Since their structure is almost symmetri-
cal in relation to hydrophobic properties it can be assumed
that if the peptides were to reversibly insert themselves per-
pendicularly to the membrane they would then be able, by
the inverse reaction, to exit the membrane either to the exter-
nal side or to the luminal side of cells/vesicles, thus effec-
tively being able to translocate. Secondly, the negative
membrane potential that is present in most cells may lower
the free energy for the translocation and actively pull these
cationic peptides to the cytoplasm. Lastly, although these
peptides may prefer the membrane surface [20], they have a
very high affinity for lipid bilayers judging by the magnitude
of the water-lipid partition constant for indolicidin towards
POPC and POPG liposomes [37]. Such a large extent of par-
tition could induce the perpendicular insertion of some pep-
tides if the membrane surface became too crowded [54]. De-
spite all these factors, indolicidin translocated very poorly
across model membranes [55]. It should also be noted that
for the reasons stated above, translocation can be a side-
effect of reversible pore formation in the instances that the
peptides are positioned perpendicular to the membrane. This
also means that the event of translocation probably follows
membrane permeabilization through pore formation.
– Multi-Targeted Action
All the proposed effects of omiganan and indolicidin
have parallels in modes of action to other extended
cathelicidins [22]: bac5 and bac7 permeabilize, depolarize,
and inhibit the respiration of Gram-negative bacteria [23]
while PR-39 seems to interfere with DNA replication but not
with cell membranes [21]. This comparison corroborates the
plausibility of the mechanisms proposed but is inconclusive
as to which process is responsible for cell death. On the other
hand, regardless of which processes take place, they seem to
do so in a receptor-independent fashion, as shown by the
retained activity of indolicidin analogues with inverted se-
quences, all D-amino acids, and both [40]. This indicates that
any putative attacks on the DNA or other cytoplasmic targets
must not be based on specific chiral recognition.
All these seemingly incompatible hypotheses have led to the
proposition of an alternate mechanism, by Friedrich et al.
[49], that encompasses all the observed facts. Because cells
are not expected to die simply because they depolarize or
become permeabilized, it is reasonable to assume that an
intracellular target must be attacked; this putative target
would be related to DNA replication or cell division mecha-
nisms, as first proposed by Subbalakshmi and Sitaram [38]
and supported by the observed effects on E. coli and S. epi-
dermidis. The observed depolarization and permeabilization
may just be consequences of the membrane interactions
needed to promote the antibiotic entrance into the cell, but
they are more likely to play a direct part in cell perturbation
and death themselves.
3- CLINICAL APPLICATIONS OF OMIGANAN
3.1 - Omiganan is a Novel Cationic Peptide
Indolicidin was selected as the parent molecule for the
design of small antimicrobial peptides for topical and for
potentially systemic use because it is a relatively small pep-
tide, it has a broad spectrum of activity and targets Gram-
positive and Gram-negative bacteria, yeast, fungi, and even
enveloped viruses and parasites, and is lethal to a variety of
organisms [9,11,56,57]. Omiganan was initially selected for
clinical development from a large panel of peptides because
of its spectrum of activity, potency, killing activity, solubility
in aqueous solutions, and stability. Potential advantages of
omiganan over currently available prescription topical an-
timicrobial products include the following: its broad spec-
trum of activity, rapid killing action, mechanism of action,
lack of cross-resistance with other currently approved an-
timicrobials, lack of incidence of resistance, no evidence of
toxicity when applied topically at doses up to 5%, room tem-
perature stability of its formulations, and ease of use. Omi-
ganan’s mechanisms of action and killing activity makes it
an attractive candidate for the treatment or prevention of
topical infections or for infections that originate from skin
pathogens. In particular, omiganan’s antifungal activity is an
important feature given the documented risk of fungal over-
growth when conventional topical antibacterial drugs are
used for prophylaxis [58]. Furthermore, omiganan may be
used to protect patients from device-related infection by
coating devices with omiganan before implantation. In 2003,
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a Phase II clinical trial for the treatment of acne vulgaris with
Omiganan was completed, where efficacy was demonstrated
with statistically significant data confirming the anti-acne
properties of omiganan. Omiganan is currently being inves-
tigated in a Phase III study in the USA and Europe for the
prevention of local catheter infections Also in 2003, a com-
pleted Phase III study demonstrated a 49% reduction in local
catheter site infection and a 21% reduction in catheter colo-
nization.
3.2 - In vitro Antimicrobial Efficiency Tests
Antimicrobial potency of omiganan was investigated
using various susceptibility techniques: modified agar dilu-
tion and broth microdilution with both Mueller Hinton broth
(MHB) and cation-adjusted MHB (CAMHB) [4,59,60].
Omiganan’s spectrum of activity was investigated against
750 clinical isolates using modified agar dilution methodol-
ogy based on the NCCLS recommendation (NCCLS M7-A5)
[60]. Using broth microdilution methodology, 1,437 bacterial
and 214 Candida spp. clinical isolates [4], and 4,766 bacte-
rial isolates from a Phase III Omiganan 1% Gel trial [59]
were tested. Omiganan demonstrated a broad spectrum of
antibacterial and antifungal activity with superior activity
against most Gram-positive pathogens (such as S. epider-
midis, S. aureus, and Corynebacterium spp.), and moderate
activity against viridans streptococci and some Gram-
negative species [4,59,60]. It is interesting to note that in
general, the broth MICs of omiganan against Gram-positive
bacteria were 2 to 4 times higher than the solid-phase MICs
[4,59,60]. For example, the MIC90 of omiganan in the solid-
phase assay was 4 µg/mL against S. aureus  [60], compared
with 16 µg/mL in MHB or CAMHB [4,59]. No decrease in
susceptibility was observed in clinically relevant resistant
pathogens including vancomycin resistant Enterococci spp.
(VRE), methicillin resistant S. aureus (MRSA), or penicillin
resistant streptococci [4].
3.3 - Demonstrated Benefits of Omiganan in Clinical Tri-
als
– Acne
With the large, growing acne market, the increasing bac-
terial resistance seen with current acne therapies, and the
clear need for a novel, first-in-class, topical treatment, omi-
ganan represents an ideal product opportunity for further
development. Omiganan has completed 5 acne clinical trials
in the US: 3 Phase I studies and 2 Phase II studies. The three
Phase I acne clinical studies of omiganan, performed in a
total of 36 healthy volunteers and 35 acne patients, showed
that the drug was very well tolerated and non-irritating over
6 weeks of treatment. There were no serious adverse events
related to the study drug, and no systemic absorption of omi-
ganan was detected after topical application of an omiganan
formulation twice a day for five days.
A 6-week randomized, double-blind, multicentre Phase
IIa trial was performed in 75 subjects with facial acne vul-
garis to establish proof of concept for the anti-acne proper-
ties of an omiganan-containing acne solution. Omiganan
diminished the severity of acne in subjects with mild to
moderate disease, as shown by reduced counts of inflamma-
tory lesions (papules and pustules), non-inflammatory le-
sions (comedones), and improved physician’s Global Sever-
ity Assessment scores. This Phase IIa trial also confirmed the
safety and local tolerability findings from the Phase I studies.
A Phase IIb, randomized, double-blind, vehicle-contro-
lled, dose-finding study was conducted in 241 subjects with
mild to moderate acne vulgaris at nine US centers to evaluate
the efficacy and safety of omiganan solutions over a 12-week
treatment period. After only 6 weeks of treatment, omiganan
2.5% topical acne solution demonstrated statistical superior-
ity over the vehicle control in reducing inflammatory acne
lesions (p = 0.004), non-inflammatory lesions (p = 0.037),
and total lesions (p < 0.001) [61]. Physician’s Global Sever-
ity Assessment scores also showed that omiganan 2.5% so-
lution was clinically superior to the vehicle control [61].
– Catheter-Related Infections
At least two-thirds of the catheter-related infections are
due to Gram-positive bacteria and yeasts making omiganan
an attractive candidate for the prevention of these infections.
Omiganan was formulated as 1% weight-weight in a gel ve-
hicle (omiganan 1% gel). Systemic absorption and safety of
omiganan 1% gel was evaluated in three randomized double-
blind studies in approximately 270 healthy volunteers. No
serious adverse events related to omiganan and no systemic
absorption of omiganan was detected when applied on intact
or abraded skin [39]. Omiganan demonstrated sustained re-
ductions in skin colonization (> 3 log10 reduction for 3 days)
and reduction in colonization of peripheral intravenous
catheters (83% reduction versus placebo).
A Phase III, randomized, evaluation-committee-blinded
study was then performed to further evaluate the efficacy and
safety of omiganan 1% gel. The study enrolled over 1,400
subjects at 29 US centers. The primary objective of the Phase
III trial was to demonstrate that omiganan 1% gel, adminis-
tered at central venous catheter insertion sites, is superior to
povidone iodine in preventing central venous catheter-related
bloodstream infections. Omiganan achieved a clear, statisti-
cally significant reduction in the two secondary efficacy
endpoints of the study: catheter colonization (p=0.002) and
catheter-related local site infections (p=0.004) compared to
povidone iodine [62]. These two endpoints, documented
extensively in the published literature, correlate to the devel-
opment of catheter-related bloodstream infections. The pri-
mary endpoint, a reduction in catheter-related bloodstream
infections, resulted in a 15% improvement as compared to
povidone iodine but this effect was not statistically signifi-
cant. There were no serious drug-related adverse events re-
ported in this trial. The product was out-licensed to Cadence
Pharmaceuticals, Inc. (“Cadence”, formerly Strata Pharma-
ceuticals, Inc.) in 2004 [63]. Cadence has submitted its re-
quest for a Special Protocol Assessment to the US FDA and
plans to initiate a confirmatory pivotal Phase III trial by the
end of the calendar year 2005.
CONCLUSION
The studies on the killing processes of indolicidin are far
from concluded, not to mention those of the much more re-
cently developed omiganan [64]. Because these peptides,
like many RAMPs, do not have a specific binding target,
there are many challenges to the unravelling of their detailed
mechanism. The fact that a RAMP may, depending on the
circumstances, display many modes of action and have sev-
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eral cellular targets has also been a source for apparently
contradictory evidence; new models describing antibiotic-
pathogen interactions have been developed but the precise
killing mechanisms of many RAMPs, including indolicidin,
and analogues such as omiganan, still remain obscure. How-
ever, the characteristics that make RAMPs so elusive to our
studies also make them so efficient at killing pathogens: the
varied and complex mechanisms of RAMP action require
bacteria to undergo high-cost, multi-step adaptations to be-
come resistant; if we were able to easily pinpoint the site and
mode of RAMP action we could probably expect bacteria to
evolve into resistant forms just as easily.
CURRENT & FUTURE DEVELOPMENTS
Despite its very specific use as a topical antibiotic, omi-
ganan has the potential of being a pioneer of a new genera-
tion of antibiotics that carry the promise of ending the multi-
resistance problem. The difficulties in the determination of
its precise bactericidal mechanism are not likely to discour-
age its clinical use, especially given the therapeutic qualities
it has shown so far. Only time will tell whether omiganan
will live up to the expectations. For the time being, it can be
regarded as a successful case of rational drug design where
the activity and selectivity of the parent peptide indolicidin
were manipulated to best fit clinical needs.
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Omiganan
2.1 Early work
The initial part of my work consisted in obtaining partition constants of
omiganan towards phospholipid* vesicles of different compositions. The
partition constant, or Kp, is the ratio at equilibrium between the local,
membrane-bound peptide concentration — ‘local’ denoting that only the
membrane volume is considered — and the bulk aqueous phase peptide
concentration. The value ofKp reflects how extensively the peptide parti-
tions to the phospholipid membrane in question, higher values meaning a
higher affinity.**Vesicles, more precisely, large unilamellar vesicles (LUVs),
are spherical phospholipid bilayers made unilamellar and homogeneous in
size by a process detailed in Articles iii and iv, in turn adapted from
reference 28. Phospholipid vesicles provide a model of cell membranes
that allows a fine control over its constituents, and are extensively used
in biophysical studies29–31 as a substitute for real membranes, which are
harder to obtain and prone to containing contaminants.
The purpose behind the determination ofKp values was to find differ-
ences in the partition towards vesicles modeling either bacterial or mam-
malian membranes. Such differences would then be used to justify, at least
in part, the simultaneous activity and safety omiganan had displayed.32, 33
These were modest objectives: being highly cationic, a preference of omi-
ganan for bacterial membrane models over mammalian ones — the first
having a high content of anionic phospholipids, the latter being essentially
zwitterionic — was pretty much expected. Yet, in this initial work I was
able to get acquainted with the experimental protocols commonly carried
out in the lab, the optical spectroscopies used to extract data from peptides
and vesicles, and the mathematical formalisms that connected all that with
the abstract views of peptide-membrane interaction and partition. And
I did eventually find that the peptide interacted preferentially with the
bacterial membrane models, which constituted on its own a minimal set
of presentable results to fall back upon if later objectives failed to be met
*Throughout the book the terms ‘lipid’ and ‘phospholipid’ are interchangeably used.
**The reader is welcome to peek ahead into Section 4.1 for a more formal definition ofKp.
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(these results, together with most of our later research on omiganan, are
presented in Article iii, included at the end of this section).
However, almost at the beginning of these studies I made a quite
unexpected finding that was to deeply influence all my subsequent work.
* * *
The most common method to determine partition constants involves the
titration of peptide with a suspension of vesicles. The fluorescence inten-
sity of the peptide — in the case of omiganan due to its four tryptophans —
is then monitored: peptide binding to the membrane is likely to cause
an increase in the emitted fluorescence intensity due to a solvent effect
of the apolar bilayer environment on the peptide’s fluorescent residues.
Fluorescence intensity will increase along the titration until the amount
of lipid in the system is enough to have caused most peptide molecules to
become membrane-bound; at this point fluorescence intensity approaches
a plateau (see Figure 2.1 for a typical curve). As will be seen later, the
value ofKp can be extracted from this curve — the partition curve — in
the simplest case by fitting a two-parameter equation.
My first days, after an eventless characterization of the absorbance and
fluorescence properties of omiganan, were spent trying to generate those
hyperbolic-like curves. Eventually, such canonical curves were obtained
(Figure 2.1) for vesicles made of POPC (palmitoyl-oleoyl phosphatidyl-
choline — a zwitterionic phospholipid that forms fluid-phase bilayers
at room temperature). Following this success a clear deviation to a
hyperbolic-like curve was obtained for the partition of omiganan towards
DPPC (dipalmitoyl phosphatidylcholine — an also zwitterionic phospho-
lipid that forms gel-phase bilayers below 40 ◦C). A somewhat sigmoidal
curve was observed, with the fluorescence intensities at low lipid concen-
trations first decreasing, then increasing. Such a curve had already been
observed by Sónia34 when studying the cell penetrating peptide pep-1:
she and Miguel had ascribed the behavior to a preferential localization
of the peptide in the defects present in the gel phase phospholipid bi-
layer, and developed an extension to the partition model to account for
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Figure 2.1 – Partition curve of 7.7 µm omiganan titrated with POPC
vesicles — adapted from Article iii. The line is the fit by Equation 4.5
(from Part II) to the data, from which aKp value of (3.7±0.4)× 103 was
extracted.
the phenomenon. I gladly and successfully applied the extended model’s
equations to my curve, in the way learning that not only is the basic
Nernst partition formalism unable to account for more complex partition
behaviors, but also that its mathematical customization to suit particular
needs is not necessarily difficult.
Some weeks later I performed the same experiments with POPG
and DPPG (palmitoyl-oleoyl phosphatidylglycerol and dipalmitoyl phos-
phatidylglycerol: phospholipids with 1− charge and properties otherwise
similar to those of POPC and DPPC, respectively). As predicted, a
preference towards these anionic phospholipids could be seen even before
any curve-fitting: much less lipid — relative to the POPC experiment —
was required for the fluorescence intensity to reach a plateau. This meant
that less lipid was required to bind almost all of the peptide and, thus,
that the binding affinity was stronger. What was unexpected was the
observation of another deviation to the hyperbolic-like behavior, visible
in both POPG and DPPG curves. This deviation, unlike the one in the
partition to DPPC, consisted in two or three data points at low lipid
concentrations largely overshooting the expected curve, somewhat like a
systematic spike (see Figure 2.2 for an example). Such observation could
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be easily dismissed as casual outlying points, but the fact that both curves
behaved similarly was intriguing. Little did I know that these spikes in my
data, which I was not particularly happy about as they prevented a proper
curve fit, were to become an important source of information on peptide
action. Even more important, perhaps, than partition magnitudes.
2.2 Saturation
Analysis went on without a proper characterization of the spike phe-
nomenon. Kp values could be obtained by ignoring the affected data
points, and those were indeed higher than the ones obtained for the
neutral systems. Still, because the spikes spread over the would-be rising
portion of the curve, crucial for a good fit, the statistical validity of the
result was weak. As remarked earlier, however, a preference for these
anionic systems over zwitterionic ones could be qualitatively inferred,
which supported the magnitude of the obtained values.
The following studies involved mixtures of POPC and POPG, mimick-
ing the partly anionic, partly zwitterionic nature of the bacterial membrane.
These were the bacterial membrane models to directly compare against
the POPC-only mammalian model, whereas the POPG- or DPPG-only
systems represented unphysiological extremes of anionic charge. Even as
the results were being read already was it clear that also in these cases
there were spikes present at low lipid concentrations (Figure 2.2). These
turned out to be less sharp than those observed for the fully anionic
systems and were also spread over a broader lipid concentration range.
Furthermore, the lower the POPG content of the mixture, the flatter the
spikes would become, being no longer perceptible at a 1 : 4 POPG : POPC
proportion. Still, the spikes, now also dubbed humps, would prevent
a proper curve-fitting, and again the preference of omiganan for these
systems had to be inferred from the lower lipid concentrations required
to reach the plateau. Being more physiologically relevant systems it was
worth repeating the experiment several times to make sure about the
deviations, and indeed they proved to be reproducible.
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Figure 2.2 – Partition curves of 7.7 µm omiganan titrated with POPG (A)
and 4 : 1 POPG : POPC (B) vesicles — adapted from Article iii. The full
lines represent the expected hyperbolic-like curve, fitted using only the post-
deviation data points. In these cases Kp had values of (14.6±0.3)× 103
and (23.0±0.7)× 103, respectively, although their statistical validity is
questionable.
This time Miguel and I started putting more effort into understanding
the spikes. It had struck us that this phenomenon, which occurred only
in the anionic bacterial model systems, could play a role in the selective
activity of omiganan. Initial hypotheses to explain the observations in-
volved multiple partitions within the membrane or aggregation of the
bound peptides when in the presence of low lipid concentrations. These,
however, were not straightforward to verify. Instead, in an apparent sub-
version of the scientific method, I tested titrations of lipid with peptide
(the inverse setup of the partition curve determination) just to see if any
deviations showed up under such conditions. Indeed, some breaks were
faintly visible in what should be a straight line and, after some experi-
mental optimization, namely through the use of acrylamide to clarify the
breaking points (see Article iii and Section 5.1 for more details on the
method), a breakthrough was made: the breaking points did correspond
to the conditions at which the spikes appeared in partition curves and,
what was totally unexpected, they were the points above which no more
peptide seemed to be able to bind the lipid. We were dealing with spatial
membrane saturation!
30
2.2 Saturation
Several new questions were raised by this finding, most regarding
the validation of our interpretation of the results. But there was one
question central to our understanding of the peptide’s activity: could
such an extreme event as the complete coverage of the membrane have
physiological significance?
I addressed these questions in part of my subsequent work, along the
way adapting and developing different methods (discussed in Chapter 5).
In short, the correlation between the saturation points and the spikes
was strengthened by observations that the association between the two
held under different conditions. I was also able to further characterize
the saturation phenomenon by determining the bound peptide-to-lipid
proportion at saturation. To account for the overshoot of fluorescence
intensityMiguel and I hypothesized that a rearrangement of the peptide’s
conformation or position in the membrane took place at, or close to,
saturation; this rearrangement would cause an increase of the bound
peptide’s fluorescence quantum yield, leading to the observed spikes in
the partition curves. The rearrangement hypothesis at once explained
the increase of fluorescence intensity at saturation and associated the
phenomenon with a molecular level event with potential macroscopic
repercussions: we began thinking that saturation, a biophysically observed
threshold, could be related to the in vivo triggering antimicrobial action of
omiganan. Lastly, we were able to gradually demonstrate on theoretical
grounds — partly supported by experimental evidence — that saturation is
not only a physiologically plausible event but may be an actual requirement
for activity.
At the time of writing of Article iii some of these notions were in their
infancy, and only became fully developed when I no longer was focusing
my work on omiganan. In any case, even at that stage we could already
put forward one of the most important hypotheses that would stem from
my PhD work: antimicrobial activity of (some) AMPs is triggered at the
molecular level by events at, or close to, full membrane coverage.
From the point of view of my scientific development I feel very fortu-
nate for having stumbled upon an innovative idea hiding in outlying data,
even if at the time I saw it more as a curse than as a blessing! — Some of
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my friends may still recall my puzzled descriptions of early work, usually
accompanied by several drawings of humps, spikes and hyperbolas!
2.3 Later studies
Further work with omiganan involved the characterization of several
activity-related processes, such as membrane permeabilization or lysis, in-
depth positioning in the membrane, translocation, or interaction with the
bacterial cell wall. All of these measurements prompted, in one way or
another, for methodological adaptations, and were to me more challenging
in this aspect (more details in Part II) than in the interpretation of their
results.
It is noteworthy, however, that the in-depth positioning tests indicated
an inward movement of the peptide upon saturation, which supports the
rearrangement-at-saturation hypothesis. This was only found because we
specifically tested systems in and out of saturation. It is likely that if we
had not encountered saturation before only one set of conditions would
have been used, and an important insight missed.
Also interesting is the fact that omiganan did not induce permeabiliza-
tion but was later observed to be able to translocate across anionic mem-
branes (unpublished data; see Section ‘Translocation’ in the Appendix).
Paradoxical as it may seem, this is in agreement with preliminary biolog-
ical work carried out by the developers of the peptide, where bacterial
depolarization, but not leakage, had been observed.35
Most of these results, together with the partition and saturation data,
and tentative interaction models, compose Article iii. Although I did
address some loose ends on omiganan after the publication of this article
my work became mainly focused on another AMP. I haven’t since
produced enough data on omiganan to justify a second publication.
While there may have been many reasons to sideline omiganan, one
of the strongest was certainly the relative difficulty to optically study it:
its four tryptophans, which at first foreboded good fluorescence measure-
ments, were not only weakly emitting but also exquisitely sensitive to
photobleaching. Moreover, because these four residues were scattered
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across the sequence of omiganan, all information reported by fluorescence
was an average blurred by all the residues’ environments, which entailed
a loss of sensitivity of many of the used methods. I am very happy for
having had the chance to work with omiganan, but I did go through a few
moments of despair because of it. Anyway, those troubles mustn’t have
been that harsh — or at least I did not take them personally — because I
couldn’t avoid being a bit sad at the news of the pharmaceutical mishap
of the peptide.
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Abstract
Omiganan pentahydrochloride (ILRWPWWPWRRK-NH2·5Cl) is an antimicrobial peptide currently in phase III clinical trials. This study aims
to unravel the mechanism of action of this drug at the membrane level and address the eventual protective role of peptidoglycan in cell walls. The
interaction of omiganan pentahydrochloride with bacterial and mammalian membrane models – large unilamellar vesicles of different POPC:
POPG proportions – was characterized by UV-Vis fluorescence spectroscopy. The molar ratio partition constants obtained for the two anionic
bacterial membrane models were very high ((18.9±1.3)×103 and (43.5±8.7)×103) and about one order of magnitude greater than for the neutral
mammalian models ((3.7±0.4)×103 for 100% POPC bilayers). At low lipid:peptide ratios there were significant deviations from the usual
hyperbolic-like partition behavior of peptide vesicle titration curves, especially for the most anionic systems. Membrane saturation can account for
such observations and mathematical models were derived to further characterize the peptide–lipid interaction under those conditions; a possible
relation between saturation and MIC was deduced; this was supported by differential quenching studies of peptide internalization. Interaction with
the bacterial cell wall was assessed using Staphylococcus aureus peptidoglycan extracts as a model. A strong partition towards the peptidoglycan
mesh was observed, but not as large as for the membrane models.
© 2007 Elsevier B.V. All rights reserved.
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1. Introduction
Omiganan pentahydrochloride (omiganan, sequence:
ILRWPWWPWRRK-amide·5Cl; predicted peptide charge at
neutral pH: 5+) is a novel cationic antibiotic peptide,
currently in phase III clinical trials, designed for topical use
to prevent catheter-related bloodstream infections and to
reduce bacterially induced acne lesions. The sequence of
omiganan is related to that of indolicidin, a ribosomally-
synthesized antimicrobial peptide (RAMP) that can be
purified from the granules of bovine neutrophils [1].
Besides its clinical importance – especially regarding the
prevention of nosocomial infections – omiganan could
become one of the first RAMP-related antibiotics to obtain
market approval.
Omiganan demonstrated a broad spectrum of antimicro-
bial activity [2] and a favorable safety profile in clinical
trials for topical use [3,4]. However, the molecular bases
for these characteristics are still hypothetical and, like its
structural characterization, most information comes from
predictions based on studies of other RAMPs, namely the
related peptides indolicidin and CP-11 [4,5]. Moreover, as
with other RAMPs, bacteria exposed to omiganan seem to
be unable to evolve resistance even upon repeated expo-
sure [6,7]. This reflects the importance of the cellular
components that are targeted, which have been postulated
to either be the membrane or core metabolic pathways
such as protein or nucleic acid synthesis. Straightforward
membrane lysis, though, has been questioned as a
potential killing mechanism for both omiganan and indo-
licidin [4,8–10].
Bilayer and cell wall interactions might not be the only
microorganism killing processes of omiganan; nonetheless,
even if the peptide's main activity involves cytoplasmic
targets, such interactions with the membrane and cell wall
Biochimica et Biophysica Acta 1768 (2007) 1277–1290
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will always be of importance for antimicrobial action, as
these outer structures must necessarily be crossed. In
addition, because mammalian cells display profound differ-
ences relatively to prokaryotic ones [11,12], the interactions
of omiganan with membranes and cell walls of microorgan-
isms provide a potential step to improve target specificity.
Given this, the study of these interactions is essential to the
full rationalization of the macroscopic properties displayed
by omiganan.
While peptide–membrane interaction has been the subject
of many studies [13–17], the bacterial cell wall, especially
that of the Gram-positive bacteria, has been largely ignored
in what concerns the mechanisms of action of RAMPs or
RAMP-related antibiotics despite its likely role as a barrier
to their entry into the cell. The cell wall is mainly
constituted by an anionic peptidoglycan mesh with pore
sizes around 4 nm in diameter [18,19]; although the exact
topological disposition of the wall components is still under
debate [18–20] it is clear that larger peptides will not cross
it unchallenged [21,22]. Even for small peptides, such as
omiganan, the wall could potentially behave, if not as a
barrier, as an anionic trap.
Spectroscopic methodologies can yield detailed informa-
tion about several aspects of peptide interactions [23],
especially in the case of omiganan, which is intrinsically
fluorescent due to its four Trp residues; however, other
cellular constituents and processes often generate high
degrees of noise and interference. Resorting to model systems
is a workaround to these unwanted contributions: in this work
large unilamellar vesicles (LUVs), of varying anionic surface
charge, were used as models for both bacterial and
mammalian cell membranes. Because one of the main
differences between omiganan and indolicidin – which is
hemolytic – is the greater cationicity of the former, the
chosen models focus on the analysis of the charge effect,
rather than in specific interactions with membrane compo-
nents. In addition to the LUVs, a simple method was devised
using Staphylococcus aureus (S. aureus) peptidoglycan
extracts as a model system to clarify the omiganan–cell
wall interaction.
2. Materials and methods
2.1. Reagents and apparatus
Omiganan pentahydrochloride (purity >95%) was a kind gift from
MIGENIX, Inc. (Vancouver, Canada); 2-(4-(2-Hydroxyethyl)-1-piperazinyl)-
ethanesulfonic acid (HEPES), sodium chloride, chloroform, ethanol (spectro-
scopic grade) and acrylamide were from Merck (Darmstadt, Germany);
potassium iodide was from Riedel-de Haën (Seelze, Germany); 8-amino-
naphthalene-1,3,6-trisulfonic acid (ANTS) was from Invitrogen Corporation
(Carlsbad, California); 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
(POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))
(POPG), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-dipal-
mitoyl-sn-glycero-3-(phospho-rac-(1-glycerol)) (DPPG) were from Avanti
Polar-Lipids (Alabaster, Alabama); Cholesterol and Triton X-100 (TX-100)
were from Sigma (St. Louis, Missouri); S. aureus peptidoglycan extract was
from Fluka (Buchs, Switzerland) and the quenchers 5 and 16 NS (5- and 16-
doxylstearic acids, respectively) were from Aldrich Chem Co. (Milwaukee,
Wisconsin).
Absorbance assays were performed in a Jasco V-560 UV-vis or a
Genesys 10 UV spectrophotometer; steady-state fluorescence assays were
performed in a SLM Aminco 8100 spectrofluorometer (equipped with a
450WXe lamp and double monochromators) or, for the studies of
omiganan–peptidoglycan interaction, in a SpectraMax GeminiEM microplate
spectrofluorometer (equipped with a 1 J/flash pulsed Xenon lamp). Time
resolved fluorescence measurements were as described elsewhere [24]. Lipid
films were dried overnight with a vacuubrand vacuum pump and extruded
afterwards.
All experiments were performed at room temperature and, unless
otherwise stated, all solutions prepared in a 10 mM HEPES buffer, pH 7.4,
containing 150 mM NaCl, which is expected to mimic physiological
conditions. All steady-state omiganan fluorescence measurements were taken
at an excitation wavelength of 280 nm, except for the experiments
involving acrylamide where, to minimize inner filter effects due to its
absorption at 280 nm, the samples were excited at 295 nm. Emission
spectra were collected in the 300–450 nm wavelength range. When full
spectra were not taken, single wavelength measurements were read at
353 nm in the absence of lipids and at 343 nm otherwise. ANTS
fluorescence was taken by exciting at 360 nm and recording the emission at
500 nm.
2.2. Preparation of model systems
For the production of membrane model systems LUVs were prepared by
extrusion of hydrated phospholipids through 400 and 100 nm pore
membranes, as described elsewhere [25]; biological model systems include
100% POPC LUVs as well as 1:4, 2:1 and 4:1 POPG:POPC LUVs; the same
models, except for the 2:1 proportion, were also prepared with cholesterol in a
1:2 cholesterol:phospholipid ratio. Other studied LUVs were 100% POPG,
100% DPPC and 100% DPPG systems. To produce ANTS loaded vesicles
LUVs were prepared in the described buffer with the addition of 10 mM
ANTS; the resulting LUVs were then passed through a 10 mL Bio-Rad
Econo-Pac 10DG column (Bio-Gel P-6DG gel with 6 kDa molecular weight
exclusion).
To prepare the bacterial wall model systems, peptidoglycan extracts were
first softly mashed with a glass rod and then suspended in buffer. The
mashing was necessary to de-aggregate some larger particles of the
lyophilized extracts powder that would render the suspension inhomogeneous.
2.3. Photophysical characterization in bulk aqueous phase
The linear dependence of the absorbance and fluorescence intensity of
omiganan on its concentration was tested over the 0–14.5 μM range. To
check whether aggregation occurs in the aqueous phase aliquots of a 4 M
acrylamide solution were sequentially added to a peptide sample while
recording both the absorbance and fluorescence intensity. In this, and in
all subsequent studies where a constant peptide concentration was
required, 7.7 μM omiganan was used as a working concentration; this
concentration is both biologically relevant – it is within the range of the
MICs of omiganan against a number of strains [2] – and spectroscopically
adequate – it is high enough to provide a strong fluorescence signal while
having an absorbance under 0.1 at 280 nm, which ensures minimal inner
filter effects.
2.4. Membrane interaction studies
The extent of membrane partition to each modeled system was
determined by adding small aliquots of a LUV suspension to a peptide
sample and recording its fluorescence spectrum. Membrane saturation points
were determined by adding aliquots of a 205.3 μM stock peptide solution
to a suspension of LUVs, in the presence of 300 mM acrylamide, and
recording the fluorescence; to prevent acrylamide dilution the stock solution
was also prepared with 300 mM acrylamide.
Differential quenching studies were carried out by sequentially adding
aliquots of a lipophilic quencher – either 5-NS or 16-NS – to a LUV
suspension previously equilibrated with peptide; for each modeled system two
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different LUV concentrations were used so as to set either non-saturation or
saturation states and quencher concentration was increased or reduced
accordingly; both steady-state and time resolved measurements were taken
(the latter only on the first and last points). Because the 5- and 16-NS stock
solutions were prepared in ethanol, care was taken, while adding the quencher
aliquots, to keep final ethanol concentrations below 2% (v/v) in order to
prevent bilayer alterations [26].
For every addition in the described procedures, a minimum of 10 minutes
was allowed for incubation before measurement.
Peptide induced leakage of vesicle contents was tested by sequentially
adding 400 mM KI and 7.7 μM omiganan to ANTS containing vesicles; the
ANTS fluorescence quenching by iodide was monitored (excitation at 360 nm
and emission at 500 nm) and maximum leakage was assumed to be achieved by
addition of 0.2% (v/v) Triton-X100.
2.5. Peptidoglycan interaction study
Different volumes of a peptidoglycan suspension were added to separate
samples of omiganan at the working concentration and allowed to equilibrate for
10 minutes. The samples were then centrifuged at 4300 g for 5 minutes and the
supernatant was recovered for fluorescence recording. Blanks were prepared in
the same conditions but in the absence of peptide to correct for the fluorescence
interference from leftover peptidoglycan in suspension.
3. Results
3.1. Photophysical characterization in bulk aqueous phase
The spectroscopic behavior of omiganan in aqueous solution
resembled that of Trp, in respect to both absorbance and
fluorescence (data not shown); linearity between absorbance
and fluorescence intensity was observed up to 14.5 μM. The
calculated absorptivity coefficient (ε) of omiganan at 280 nm
was 1.72×104 M−1 cm−1, yielding a molar absorptivity per Trp
residue of 4.3×103 M−1 cm−1. The quenching of omiganan by
acrylamide also followed a linear Stern–Volmer relationship,
with a KSV of 15.5 M
−1. Static quenching by acrylamide
originated slight upward deviations from linearity above
300 mM of quencher.
3.2. Membrane incorporation studies
Upon the partitioning of omiganan to vesicles there was,
generally, an increase in fluorescence intensity as well as a
spectral shift of about 10 nm to lower wavelengths (not shown).
For the neutral, liquid-ordered POPC system, the increase in
intensity followed a hyperbolic-like relationship, whereas the
gel-phase DPPC system deviated from that behavior, inducing
an intensity decrease at low concentrations, followed by a
sigmoidal rise (Fig. 1A).
A deviation, or spike, in the fluorescence intensity vs. lipid
concentration relationships was observed at low lipid concen-
trations for the most anionic systems (100% POPG, 100%
DPPG, 4:1 POPG:POPC and 2:1 POPG:POPC systems) (Figs.
1B and C, and 3A; 2:1 POPG:POPC system not shown). This
was not observed in the less anionic 1:4 POPG:POPC system
(not shown).
Cholesterol enriched systems displayed sigmoidal curves
(Fig. 2), with a behavior similar to the one displayed by the
DPPC system (Fig. 1A).
Membrane saturation points were successfully obtained for
the 4:1 POPG:POPC system (Fig. 3B) and for the 2:1 POPG:
POPC system (not shown): in a titration of vesicles with
omiganan, at low peptide concentrations, a linear relationship
between fluorescence intensity and peptide concentration was
Fig. 1. Partition curves of 7.7 μM omiganan in several lipidic systems; fitted
parameters are summarized in Table 1. The solid lines represent the fitting of the
data to a partition model. Data points were connected to better evidence
deviations from a hyperbolic behavior. (A) 100% POPC (▵) and 100% DPPC
(○) systems; data were fitted to the simple partition model (Eq. (1)) or to the
self-quenching model (Eq. (2)), respectively. Due to possible bilayer saturation,
the second and third points of the POPC partition curve were left out of the
fitting. (B) 100% POPG (▵) and 100% DPPG (○) systems; data were fitted to
the simple partition model (Eq. (1)), but only the last four points of the POPG
curve and the last three of the DPPG curve were used in the fit. (C) POPG:POPC
4:1 system. Data were fitted to the simple partition model (Eq. (1)), but only the
rightmost 5 points were used for the fit. Partition towards POPG:POPC 2:1
LUVs (not shown) behaved similarly to the POPG:POPC 4:1 system, while for
the POPG:POPC 1:4 system fitting to any of the models was not possible.
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observed; however, after a critical point, which was dependent
on the used lipid concentration, a break occurred in the graph
and a second linear regime, with a lower slope, followed. These
breaks were assumed to represent membrane saturation, as
discussed below. For the other less anionic systems, saturation
points were impossible to determine since the curves did not
display a clear break, although their slopes did decrease with
increasing peptide concentration (data not shown).
In the membrane localization studies all biological model
systems performed similarly in that relative quenching efficien-
cies by 5-NS and 16-NS were the same regardless of the
membrane surface charge (Fig. 4). The time dependent
fluorescence data were in agreement with the steady state
measurements concerning 5- and 16-NS relative quenching
efficiencies. The greatest observed differences were not between
different systems, but between saturated and non-saturated states
within the same system: the quenching efficiency of both
quenchers was similar in non-saturated states whereas a clear
increase of 16-NS quenching efficiencywas observed in saturated
systems (Fig. 4).
3.3. Omiganan induced leakage of vesicle contents
Omiganan did not seem to induce any kind of bilayer
perturbation strong enough for membrane crossing by either
ANTS molecules or iodide that would result in a decrease in
the encapsulated ANTS fluorescence (not shown). The
methodology was tested using as a control a peptide that
induced leakage.
3.4. Peptidoglycan interaction study
After centrifugation of the peptidoglycan, a decrease in
supernatant fluorescence, with increasing peptidoglycan
concentrations, was observed (Fig. 5). This indicates that
part of the peptide was dragged along with the mesh and
that there is interaction between the two.
Fig. 3. (A) Partition curves of 4.1, 8.2, 12.8 and 25.7 μMomiganan in 4:1 POPG:
POPC. Saturation points were taken as the maximum of the deviation in each
curve and were used to determine the saturation ratio and the partition constant
(Fig. 6). There is an approximately common behavior of the curves after the
deviations, which is in agreement with the simulated partitions. A curve with
1.0 μM omiganan was also obtained (not shown), but a much higher IL/IW ratio
was observed; its Kp, however, was similar to the others'. Average Kp and IL/IW
ratio (Table 1) are in agreement with the already obtained constant and ratio for
the same system (Fig. 1C). (B) Titration of different phospholipid concentrations
with omiganan (4:1 POPG:POPC system) in the presence of 300mMacrylamide.
Saturation points were identified from the breaks in each curve. The dotted line
indicates the peptide concentration at which the partition curve in Fig. 1C has a
relative maximum (around 0.040 mM of phospholipid); this peptide concentra-
tion is very close to the saturation point in the 0.040 mM phospholipid curve.
Fig. 2. Partition curves of 7.7 μM omiganan for the cholesterol containing
systems; solid lines represent the fitting of the data to one of the described
models. (A) 100% POPC (▵) and 1:4 POPG:POPC (○) systems—because
there is a clear deviation of the partition behavior towards that of the DPPC
system (Fig. 1A) Eq. (2) had to be used to fit the 100% POPC system; Eq.
(1) was used for the 1:4 POPG:POPC fit. Obtained partition constants are
summarized in Table 1. (B) 4:1 POPG:POPC system—a distended and
sigmoidal behavior was induced by cholesterol, although a deviation still
occurred; because the remaining data points (two further phospholipid
concentrations were used) lie almost horizontally, no information on the
partition extent could be extracted.
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4. Discussion
4.1. Photophysical characterization in bulk aqueous phase
The observed behavior of omiganan in aqueous phase did
not reveal the presence of significant peptide–peptide interac-
tions at the used concentrations: the obtained molar absorptivity
is close to the one of free Trp+ (5.6×103 M−1·cm−1 [27]). The
linear Stern–Volmer plot is indicative of no Trp side chain
inaccessibility, the occurrence of which could be associated to
peptide aggregation [28], and is also in agreement with the
absence of Trp side chain protection since the KSV for
acrylamide quenching of free Trp+ is 15.8 M−1 [29].
4.2. Membrane incorporation studies
The procedures for the membrane incorporation quantifica-
tion were designed to allow the calculation of the Nernst
partition constant (Kp) from fluorescence intensity (I) vs.
phospholipid concentration ([L]) plots, at a constant peptide
concentration ([P]), by a simple partition model, described by
Santos et al. [30]. The partition constant is the ratio between
the equilibrium membrane-bound and aqueous phase peptide
concentrations1 [30], thus providing an easy assessment of the
extent of membrane interaction. The model used in this study
regards the membrane as a volume of a separate lipidic phase
within the bulk aqueous phase and treats the peptide–
membrane interaction as a Nernst equilibrium; the fluorescence
intensity of a peptide–lipid system, normalized by the
fluorescence intensity of the peptide in aqueous phase, is
then given by Eq. (1) (adapted from [30]):
I=IW ¼ 1þ KpgL½LIL=IW1þ KpgL½L
; ð1Þ
where [L] is the total phospholipid concentration available for
the peptide to interact with, Kp is the Nernst partition constant
and γL is the phospholipids molar volume, which is 0.763
M− 1 for liquid crystal phases [31] and 0.689 M− 1 for gel
phases [32]. IL and IW are the fluorescence intensities the
mixture would display if all the peptide was in the lipidic or
aqueous phase, respectively. IW can be readily obtained from
the measurement of I in the absence of lipid; IL, however, is a
limit value of fluorescence intensity as [L]→∞ and is
determined as a system parameter together with Kp.
2
Fig. 5. Normalized omiganan fluorescence after incubation with several
concentrations of peptidoglycan extracts, physically separated by centrifugation.
The data were fit (solid line) to a single parameter model (Eq. (9)) and aDg value
of 15.9±1.1 mL/mg (Dv= (3.1±0.2)×10
3) was obtained.
Fig. 4. Stern–Volmer representations (I0/I vs. quencher concentration) of the
quenching of 7.7 μM omiganan by the membrane quenchers 5- and 16-NS
(○ and● symbols, respectively), in the 4:1 POPG:POPC system (the quenching
behavior in this system is representative of what was obtained for 2:1 and
1:4 POPG:POPC and 100% POPC systems). (A) Membrane saturation was
induced by using 0.030 mM of phospholipid. (B) A phospholipid concentration
of 0.3 mM was used to avoid saturation. Effective quencher concentration in the
membrane was calculated using the partition constants provided by Wardlaw
et al. [49]. The increase in the difference of 16-NS and 5-NS quenching
efficiencies in A relatively to B is indicative of peptide burying in the bilayer,
although only an average localization can be inferred, as there are four Trp
residues in omiganan.
1 Note that, as remarked by Santos et al., care must be taken when
intercomparing Kp data from the literature since some authors define the
partition constant as the ratio between the lipid and aqueous phase solute
concentrations whereas others define it as the ratio between the molar fractions
of the solute in each phase. Approximate conversion can be obtained by using
Kp=Kp,x·γW/γL, where Kp and Kp,x are the concentration ratio and the molar
fraction ratio partition constants, and γW and γL stand for the aqueous and
lipidic phases molar volumes [30].
2 More accurately, IL should be attained when [L] reaches its maximum value
of 1/γL, which corresponds to a phospholipid only solution; for most practical
cases, however, this amounts to a negligible correction. Further considerations
on the subject can be found in [33].
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The I/IW vs. [L] representation, termed here ‘partition
curve’, is thus expected to be hyperbolic-like and independent
of the initial peptide concentration in an ideal partition. An
issue to bear in mind is that, because fluorescence emission
spectral shifts can also be a consequence of peptide–lipid
interaction, the integrated spectral intensity should be preferred
over single wavelength intensity. In this work, full spectra were
always used when possible, although the differences between
following that approach and using a single wavelength were
rarely significant.
In the present case, a difference between IW and IL was
expected to occur as a consequence of an alteration in the Trp
environment as the peptide enters the membrane [23,30].
4.2.1. Neutral systems
For the liquid-ordered phase POPC vesicles, which were
used to model the outer leaflet of the mammalian membrane
(the inner leaflet was modeled with a 1:4 POPG:POPC system),
there was a good agreement of the partition curve (Fig. 1A) with
the partition model, from which a Kp value of (3.7±0.4)×10
3
and a IL/IW ratio of 3.09±0.11 were obtained (partition
parameters obtained for all lipidic systems are summarized in
Table 1). For the gel phase neutral DPPC LUVs, which were
used for the sake of studying the influence of membrane
rigidity, initial deviations did not allow the fitting of the simple
partition model (Fig. 1A). However, the intensity drop,
followed by a somewhat sigmoidal behavior, was consistent
with the phenomenon of peptide self-quenching: this effect is
related to the accumulation of peptide molecules in membrane
line defects on the borderlines between different phospholipidic
crystalline organizations, favored by the rigidity of the gel
phase DPPC bilayers. Eq. 1 was adapted, as deduced by
Henriques et al. [34], becoming
I
IW
¼ KpgL½LIL=IW
1þ KpgL½L þ k2KpIL
þ 1
1þ KpgL½L
; ð2Þ
where k2 is proportional to the ratio between the bimolecular self-
quenching rate and the radiative decay rate. Note that the limit as
[L]→∞ is not altered by the occurrence of self-quenching or by
differences in the initial peptide concentration. The partition
constant determined by this method was of (4.9± 0.3)×103 and
the IL/IW ratio was of 1.80±0.03. While theKp is close to the one
obtained for the POPC system, the IL/IW ratio points towards a
slightly different peptide conformation/localization.
The partition of omiganan to the neutral lipidic systems was
very strong despite the absence of negative surface charge on the
vesicles. Although electrostatic interactions can be expected to
play a significant role in the activity of omiganan due to its 5+
charge, it was seen that the hydrophobic effect and van der Waals
forces that dominate the partition to the neutral systems can
account for an important part of the peptide's membrane
interaction. Hydrophobic residues such as Ile and Leu and an-
choring residues such as Trp may play an important role in par-
tition under these conditions.
4.2.2. Anionic systems
Accurate determination of the partition constant in systems
containing anionic phospholipid was difficult or impossible,
due to large deviations from either hyperbolic or sigmoidal
partition curves (Fig. 1B and C): at variance with the partition
to the neutral systems, the initial points of both liquid crystal
Table 1
Summary of the characteristics of each modeled system: constitution, partition parameters and initial behavior of the partition curve
Modeled system Constituent phospholipids a Kp/10
3 IL/IW Used model
b Initial deviation c
100% Neutral Membrane gel phase DPPC 4.9±0.3 1.80±0.03 SQ –
100% Anionic membrane gel phase DPPG 12.5±0.8 1.58±0.01 SP +
100% Anionic membrane liquid crystal phase POPG 14.6±1.3 1.76±0.01 SP +
Bacterial membrane models
Inner leaflet d 4:1 23.0±0.7 1.94±0.06 SP +
Inner leaflet+cholesterol e, f 4:1 n.o. n.o. n.a. +
Outer leaflet 2:1 43.5±8.7 1.84±0.04 SP +
Mammalian membrane models
Inner leafletf 1:4 n.o. n.o. n.a. −
Inner leaflet+cholesterol e 1:4 1.8±0.2 2.89±0.09 SP −
Outer leaflet POPC 3.7±0.4 3.09±0.11 SP +
Outer leaflet+cholesterol e POPC 8.2±1.2 2.08±0.14 SQ −
a POPG:POPC mixtures are indicated by the proportion between phospholipids. All other systems are constituted by a single type of phospholipid.
b Used model for the fitting of the experimental results—SP: ‘Simple Partition’, the formalism described by Santos et al. was used (Eq. 1); SQ: ‘Self-Quenching’, the
formalism described by Henriques and Castanho (Eq. 2) was used.
c Occurrence (+), or not (−), of an upward deviation in the partition curve, for low phospholipid concentrations.
d The parameters for this system are the average of the results of several partition curves at different peptide concentrations (Figs. 1C and 3A). The IL/IW ratio of the
1.0 mM curve (not shown) was not included.
e The system is also constituted by cholesterol in a 1:2 molar proportion relatively to the phospholipids.
f The extraction of partition parameters by curve-fitting was not possible for this system. Fields depending on this information are marked either ‘n.o.’ (not obtained)
or ‘n.a.’ (not applicable), according to each case.
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and gel phase partition curves seem to overshoot above a
hypothetical hyperbolic behavior, returning to it at higher lipid
concentrations, closer to the curve plateau. Nonetheless, the
partition of omiganan towards these vesicles seems to be greatly
enhanced relatively to their neutral counterparts, judging by the
very high initial slopes of the partition curves and the little
amount of lipid required to reach almost maximal interaction
(notice the difference in the x axis scale of Fig. 1B and C
relatively to Fig. 1A). Such an increase in the partition extent
was expected because electrostatic interactions are very likely to
affect the heavily charged peptide; in addition, it is possible that
this very strong partition is responsible for the observed
deviations from the partition model. Namely, membrane
saturation may occur at low lipid concentrations when the
bound peptide concentration hypothetically dictated by Kp is
higher than what the membrane can accommodate. Because it
considers the peptide as a volumeless entity, and thus incapable
of saturating the lipidic phase, the model of Santos et al. [30] is
not suited to the study of saturated systems and other models,
described below, were devised to better characterize these
situations. From the partition curves, Kp values could be
extracted by fitting only the non-saturated points to the simple
partition model (Fig. 1, Table 1). Statistical significance was, of
course, hurt by this approach both because the number of
available data points was reduced and because the initial rising
portion of the hyperbolic partition curve, which was absent, is
determinant in the calculation of Kp. Nevertheless, the obtained
partition constants (Table 1), which are greater than those of the
neutral systems, are consistent with the expected role of the
electrostatic interactions (the partition towards the 1:4 POPG:
POPC system – not shown – could not be fitted but was visibly
less intense than for the other anionic systems). The same charge
relationship was observed for the related peptide indolicidin
[35]. The occurrence of these deviations and the hypothesis that
they could represent a phenomenon not described by the simple
partition model led to the discarding of the second and third
points when fitting the POPC partition curve (Fig. 1A), which,
upon closer inspection, seem to also deviate from the hyperbole.
The different obtained Kp's are indicative of a strong
preference of omiganan towards negatively charged membranes
similar to the bacterial systems (2:1 and 4:1 POPG:POPC
systems, which are as anionic as the outer and inner bacterial
cell membrane leaflets [11,12]), which appear to induce the
highest extents of partition by providing an optimal negative
surface charge. This selectivity/affinity of omiganan for
prokaryotic bilayer membranes is thus one possible factor for
the favorable safety profile of omiganan as a topical drug [3]:
the peptide's concentration in a zwitterionic mammalian
membrane does not get as high as in an anionic bacterial
membrane. Partition constants of such magnitudes are com-
monly displayed by membrane-active peptides ([36,37] note
that intercomparison of different partition constants will require
an appropriate conversion), which supports the importance of
the membrane interaction in omiganan's mode of action.
An observed reduction in IL/IW ratios is in agreement with a
preferential interaction of the peptide with the membrane
surface, as this may reflect an exposure of the Trp residues to a
polar environment. For the models of biological membranes,
peptide localization was determined with more accuracy by
differential quenching methods, discussed below.
4.2.3. Cholesterol effect on the partition extent
To further assess the action of omiganan towards mammalian
cells, cholesterol was added to the 100% POPC and 1:4 POPG:
POPC model systems (phospholipid:cholesterol ratio of 2:1),
and the presence of specific peptide–sterol interactions were
investigated. These are undesirable interactions because their
occurrence may increase the peptide's partition extent towards
mammalian membranes (as opposed to bacterial ones, which are
sterol-free) and eventually represent an increased toxicity risk,
should the peptide disturb the structural properties that
cholesterol confers to the bilayer [38,39].
Both partition constants for the mammalian membrane
models (inner and outer leaflet) remained within the same order
of magnitude as the 100% POPC, sterol-free system, which is
unsupportive of the cholesterol having, per se, a very strong
interaction with the peptide. The most pronounced consequence
of cholesterol addition was the induction of a gel phase like
behavior (Fig. 2): the partition curves deviated from the
hyperbolic-like progression, indicating the occurrence of self-
quenching, as with the DPPC system. Since cholesterol
condenses liquid crystal bilayers, forming a liquid ordered
phase [40], this observation indicates that omiganan does not
have specific interactions with it, or at least not to a point where
its properties are significantly altered. This was further
demonstrated by testing the effect of cholesterol in the 4:1
POPG:POPC system, which has a higher charge and partition
constant: the same sigmoidal behavior was observed and an
apparently lower extent of partition was observed although it
was impossible to calculate a Kp value because the non-
hyperbolic regime dominated most of the curve (Fig. 2B).
These evidences predict a low cholesterol related toxicity of
omiganan towards human cells, in agreement with its clinical
safety profile [3].
4.3. Membrane saturation studies
The hypothesis of membrane saturation was tested by
titrating LUV suspensions with peptide while monitoring
omiganan's fluorescence intensity. Under the simple partition
model, for a given lipid concentration, the relative proportions
of peptide in and out of the membrane (XL and XW, respectively)
should be constant, independently of overall peptide concentra-
tion changes [23]. In this case, the total fluorescence intensity, I,
will be the sum of IL and IW, weighted, respectively, by XL and
XW [23]. Because IL and IW, are expected to be proportional to
the global peptide concentration, under these conditions I∝[P],
where [P] is the overall peptide concentration. The I vs. [P]
titrations were carried out in the presence of acrylamide, which
is an aqueous phase quencher, to increase the difference
between IL and IW, in order to better identify alterations in the
phase localization of omiganan.
The behavior displayed in the peptide titrations (Fig. 3B) is
consistent with the occurrence of saturation: for low membrane-
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bound peptide-to-lipid ratios (P:L), which correspond to the
rightmost part of the hyperbolic-like I vs. [L] partition curves,
the model of Santos et al. [30] is followed as I increases
proportionally to [P]; however, with the increase of P:L the
membrane will eventually run out of space and any further
added peptide beyond saturation will have to remain in the
aqueous phase; this is corroborated by the second slope being
similar to that of the I vs. [P] curve in the absence of lipid, i.e.,
after the saturation point the system behaves as if no lipid were
present for the peptide to partition to.
The I vs. [P] curve with [L]=0.040 mM has its saturation
point close to [P] ≈7.7 μM (Fig. 3B), which is precisely the
peptide concentration that yields an I vs. [L] curve with a
deviation maximum close to 0.040 mM (Fig. 1C). In other
words, the [P] and [L] values at the saturation point in Fig. 3B
are the same than those at the end of the deviation in Fig. 1C,
which is evidence for a correlation between deviations to
partition curves and saturation.
To further extract information from the saturation phenom-
enon, a relationship between the [P] and [L] values at the
saturation points was devised: at membrane-bound peptide
concentrations below the saturation point it can be assumed that
the partition is dictated by a Nernst formalism, like the one
described by Santos et al. [30]. On the other hand, above the
saturation threshold, the amount of peptide in the lipidic phase
can be expected to be directly proportional to the total volume
of the lipid phase, and thus proportional to the amount of the
lipid itself. The bound peptide fraction above the saturation
point (XL,s) will be given by:
XL;s ¼ rnLnp ¼
r½L
½P ð3Þ
where σ is the P:L proportion in a saturated membrane and nP
and nL are the total number of moles of peptide and
phospholipid, respectively. At the saturation point it can be
assumed that XL,ns=XL,s, XL,ns being the bound peptide fraction
below the saturation point, and consequently:
XL;ns ¼ KpgL½L1þ KpgL½L
¼ r½L½P ¼ XL;s ð4Þ
where XL,ns is defined as by Santos et al. [23]. This equation can
be rearranged to
P½  ¼ r
KpgL
þ r L½  ð5Þ
which defines the total amount of peptide at which a saturation
point occurs as a linear function of the amount of phospholipid in
the system. Besides providing information on the magnitude of
the partition constant, the non-zero intercept indicates that there
is a minimum peptide concentration for saturation to occur,
according to this model. A related equation has been used by Pott
et al. [41] to define the relationship between the global peptide
and phospholipid concentrations at several membrane-critical
proportions of the toxin mellitin. Despite having been deduced
from different starting points, Eq. (5) and the one used by Pott et
al. [41] turn out to be equivalent, with the exception that Eq. (5)
directly relates the intercept with the Nernst partition constant.
Fig. 6 represents the saturation point ([P],[L]) pairs for the
POPG:POPC 4:1 and 2:1 systems. Eq. (5) was followed by both
systems and the correlation between membrane saturation and
the deviations to the partition curves was further corroborated
because saturation pairs from partition curves taken at different
peptide concentrations (Fig. 3A) were in agreement with the
saturation pairs obtained from the I vs. [P] curves (Fig. 3B). The
obtained saturation P:L ratios were of 0.17 and 0.027 for the
POPG:POPC 4:1 and 2:1 systems, respectively; this corresponds
to 5.8 and 37.0 phospholipids per peptide at the saturation of
each system.
Although the obtained saturation P:L ratios seem plausible
and robust, the values for Kp have large associated errors since
they are calculated from the reciprocal of a relatively small
intercept, which makes this an unsuitable method for determi-
nation of very large partition constants.
4.4. Partition curve models
The initial deviations in the partition curves could be
successfully attributed to membrane saturation; however, that
explanation is not enough to account for the higher fluorescence
intensities displayed by the saturated systems. In fact, saturation
of the membrane implies that some peptide is being left out of
bilayer interaction; as such, the system fluorescence intensity
should decrease rather than increase. Simulated partition curves
were obtained by setting the system parameters Kp, IL/IW and σ
and taking XL as the minimum between XL,ns and XL,s (Eq. (4)),
i.e., during saturation, the amount of peptide in the membrane is
limited by the saturated conditions, and afterwards by the Nernst
equilibrium. The total fluorescence intensity was obtained by
Fig. 6. Total peptide and phospholipid concentrations at saturation points for the
4:1 (● or ○) and 2:1 POPG:POPC (▴) systems, together with the respective
fittings to Eq. (5) (solid lines). Saturation points were obtained from the partition
curves at different peptide concentrations (Fig. 3A) (○), or from fluorescence vs.
[omiganan] titrations (Fig. 3B) (●). The concordance between saturation points
from fluorescence intensity vs. [omiganan] plots and from partition curves
supports the relation between the deviations in the latter and membrane
saturation. Obtained saturation proportions (P:L) were 0.17 for the 4:1 POPG:
POPC system and 0.027 for the 2:1 POPG:POPC system; partition constants
were 1.87×105 (but varying between 1.14×105 and 3.98×105 with the
regression associated errors) and (5.2±0.9)×103, respectively.
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weighting IL and IW by XL and 1−XL, respectively. These
simulated curves show that the points of a partition curve that are
under saturation describe a straight line below the non-saturated
hyperbolic behavior (Fig. 7A). The straight initial regime is in
agreement with what was observed for all systems containing
anionic phospholipids, but the increase in fluorescence above
the hyperbole needs further reasoning. Here we explore the
simple hypothesis that, under saturation, omiganan undergoes
some conformation/localization change that leads to an increase
in its fluorescence quantum yield. A second set of simulated
curves (Fig. 7B) were obtained by adding a fourth parameter to
the system: the IS/IW ratio, where IS stands for the limit
fluorescence the system would display if all the peptide were in
the hypothetical saturation conformation/localization. The
fluorescence intensity of the system was calculated as in the
previous simulations, with the exception that IS was used in
place of IL whenever the system was saturated, i.e., XL,s<XL,ns.
Simulated results under this hypothesis predict the occurrence of
a discontinuity in the partition curve at the saturation point (Fig.
7B) and that increasing peptide concentrations will lead to
decreasing slopes of the initial part of the curve, but constant
hyperbolic portions. In addition, higher peptide concentrations
should generate higher maxima before the discontinuity. All
predicted characteristics were respected in partition curves taken
at several peptide concentrations (Fig. 3A) except for the
increase in the maxima and that sharp saturation/non-saturation
transitions were only observed for low peptide concentrations.
Constant post-deviation behaviors were observed, with similar
resulting partition constants (average: (2.38±0.78)×104) and
IL/IW ratios (average: 1.93±0.44), and, as mentioned earlier, the
maxima of the deviations were successfully fit by Eq. (5) (Fig.
6). Even though this model may be too simplistic to fully
describe the system behavior, it shows that saturation-related
conformation/localization changes could be occurring in the
membrane; these may include phenomena such as multi-
merization [42], which could be involved in triggering the
action of omiganan and thus represent the biophysical conditions
behind its MICs against prokaryotes.
Another model was developed to deal with some limitations
of the previous hypothesis, namely, the implicit, and unlikely,
all-at-once conformation/localization changes undergone by the
peptide at the saturation point, which lead to the discontinuity in
the partition curves. In the new approach, these changes were
modeled as a gradual solute saturation in the lipidic phase: for
an increasing peptide concentration in the system, the peptide
molecules will partition according to three different states,
depicted in Figs. 7C and 8. States 1 and 3 correspond to the
notions of, respectively, non-saturation and saturation. In state 2
an intermediate peptide concentration in the membrane is
assumed: after the membrane-bound peptide reaches a critical
concentration – correspondent to an apparent solubility product
of the peptide in the lipidic phase – further interaction with the
membrane requires that some peptide molecules adopt a
saturated, more packed, conformation/localization, with fluor-
escence intensity IS; the rest of the membrane-bound peptide
remains at the concentration corresponding to the apparent
solubility product. Only when all membrane-bound peptide
molecules are arranged in that packed conformation does the
membrane become fully saturated.
The parameters of the new model are all homologous to the
ones of the previous model, plus a fifth parameter, the apparent
solubility product of the peptide. The equations that define the
peptide proportions in each conformation (water dissolved,
Fig. 7. (A and B) Simulated partition curves with the occurrence of saturation;
the saturation points correspond to the end of the linear portions of each graph.
Simulation parameters were: σ =0.1; Kp=20000; IW=1; IL=2; in B IS=3 was
used while in A no fluorescence change in IL was associated with saturation (see
the text for the meaning of each parameter). For the three curves in A and B
4 μM, 15 μM and 20 μM peptide concentrations were used (dotted, dashed and
solid lines, respectively); the lowest of these concentrations was chosen to be
below the saturation threshold (6.6 μM, under these conditions). Thinner line
segments represent discontinuities. (C) Fitting of the three-state model to the
8.2 μM omiganan partition curve in 4:1 POPG:POPC; the dotted lines divide the
fitted curve into the three states that were assumed (see text and appendix for a
better description of each state and involved equations, respectively). It can be
seen that the model is able to account for a transition between saturated and non-
saturated states. Obtained system parameters were: Kp=2.23×10
4; σ=0.15;
solubility product=88.4 mM; IL/IW=1.95; IS/IW=2.00. Kp, σ and IL/IW values
are in agreement with the ones determined by other methods.
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unsaturated-membrane-bound and saturated-membrane-bound;
XW, XL, and XS, respectively) are developed in the appendix.
This model was able to predict a transition between saturated
and non-saturated membrane states (Fig. 7C), although the
fitting of state 2 to the experimental data was not very good,
namely due to the straight behavior of the modeled partition
curve. The resulting Kp, σ and IL/IW values (2.23×10
4, 0.15
and 1.95, respectively) are in very close agreement with the
values obtained by the other described method, which indicates
that this model can be used for direct analysis of whole partition
curves with saturation. The remaining two parameters, which
have not been determined by other methods, should be
interpreted with care since they depend largely on the few,
and poorly fit, data points of state 2.
4.5. Membrane localization studies
The membrane localization of omiganan in each of the four
biological model systems was probed using the lipophilic
quenchers 5- and 16-NS. Time resolved fluorescence quenching
data (not shown) were analyzed according to a method
described by Fernandes et al. [43] which yielded two
preferential peptide locations, depending on saturation: the
peptide was found to be preferentially shallow into the bilayer in
non-saturation conditions and very close to the membrane
centre upon saturation. Because four Trp residues contribute to
the global peptide fluorescence, the quenching data reflects an
average localization of the central segment of the peptide.
The results obtained by differential quenching techniques are
in agreement with a saturation-dependent peptide localization
change. In addition, the internalization of the peptide seems a
likely starting point for either membrane translocation or
perturbation. In effect, the coordination of these data with the
obtained different saturation proportions for the models of the
inner and outer leaflets of the bacterial membrane indicates that
there are membrane-bound peptide concentrations at which the
outer leaflet is saturated – the peptide being internalized from
the outer side of the membrane – while the inner leaflet is not –
the peptide being pulled to the inner membrane surface; the
saturation mediated internalization coupled to the different
saturation proportions could thus represent a peptide transloca-
tion mechanism. While speculative, this hypothesis is a
plausible illustration of the possible consequences of membrane
saturation on the antimicrobial action of omiganan.
The dependence of the occurrence and intensity of the
partition deviations on the anionic membrane charge can also be
explained by the saturation-driven peptide internalization: when
the system is not saturated, the peptide lies at the bilayer surface
and, as mentioned, is exposed to a charged environment,
resulting in a low IL. Upon internalization, the Trp residues will
be moved away from the charged phospholipid headgroups and
exhibit greater quantum yields, translated in the proposed
models as IS, larger than IL. Peptide internalization in neutral
systems will not lead to such an intense increase in fluorescence
because the shallow peptide was already exposed to a non-
charged environment and IL≈ IS. Thus, partition curves of
neutral systems behave like the modeled curves of Fig. 7A,
whereas increasing anionic surface charge will induce partition
curves like the ones modeled in Fig. 7B and C.
4.6. Partition, saturation and observed MICs
From a macroscopic point of view, the findings on
omiganan–membrane interaction can be correlated to the
MIC: at variance with [44], common MICs are not expected
to be much greater than what is needed for saturation to occur.
Indeed, under the hypothesized conditions by Tossi et al. [44]
(phospholipid area=0.7 nm2; bacterium area=107 nm2;
bacterial concentration=106 bacteria/mL; MIC=1 μM), one
would have an overall lipid concentration accessible to the
peptide of 47 nM (for the sake of simplicity, two phospholipid
monolayers were assumed instead of an outer membrane model
of one monolayer of lipopolysaccharide and another of
phospholipid). According to Eq. (4) (XL,ns member), and
assuming a typical partition constant of 2×104 [36,37], only
0.07% of the total peptide molecules are expected to be engaged
in membrane interaction under these conditions. The aqueous
phase peptide concentration will thus remain virtually unaltered
and approximately equal to the total concentration. If we use the
MIC as the total concentration, by the definition of Kp, the
membrane-bound peptide concentration ([P]L) will be given by
Kp·MIC. With the hypothesized MIC of 1 μM, [P]L will be
20 mM. Multiplication by γL yields a P:L ratio of about 0.015
peptide molecules per lipid, or 66 lipid molecules per peptide,
which is a far lower membrane concentration than the obtained
by the calculations of Tossi et al. [44] (40 peptide molecules per
phospholipid) where implicit infinitely high partition constants
were used. The local membrane concentration of a peptide
Fig. 8. Illustration of the three states of peptide–membrane interaction according to the three-state model. Notice that any depicted conformation or membrane
localization of the peptide in this figure is merely illustrative (see text and appendix for a better description of each state and involved equations, respectively).
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predicted by these calculations is probably insufficient for
saturation to occur, but by a narrow margin; this means that
peptides with slightly higher Kp's or MICs may indeed be in
saturation: in the previously hypothesized conditions, omiga-
nan, which has a typical MIC50 of about 8 to 16 μM against S.
aureus [2] and a Kp of 23.0×10
3 (Table 1), would have a local
concentration in the membrane of 184 mM, correspondent to
about 7 phospholipid molecules per peptide. This is clearly a
saturation situation and is in close agreement with the obtained
saturation proportions (Fig. 6). This relation between MIC and
saturation supports the existence of possible saturation-
triggered antimicrobial mechanisms not exclusive of omiganan
but potentially shared by many other peptides with high enough
Kp and MIC.
4.7. Omiganan induced leakage of vesicle contents
Lack of leakage is in agreement with previous studies [10]
where the maximum observed effect of membrane perturbation
was depolarization. Together with the high extents of partition
towards the bilayer, the absence of severe membrane perturba-
tion favors a translocation mediated peptide action, in agreement
with the hypothesis from membrane saturation studies.
4.8. Peptidoglycan interaction study
The extent of interaction between omiganan and the bacterial
cell wall was assessed by a method similar to the one used for the
partition curves, with the difference that physical separation by
centrifugation was used and the peptide was quantified in the
supernatant only. This was needed because the peptidoglycan
extracts exhibited intense, Trp characteristic, fluorescence– very
likely from wall proteins that were not washed away during the
extraction process – which prevented an integrated approach.
By comparing the fluorescence intensity of the peptide that
remained on the supernatant (I) with the initial peptide
fluorescence in the absence of added peptidoglycan (IW), the
aqueous phase fraction can be readily calculated:
I=IW ¼ XW ð6Þ
XW can be defined as (1−Xp), where Xp is the peptide fraction
that was held in the peptidoglycan. To relate Xp with the extent
of peptidoglycan partition, it was considered that this interaction
behaved similarly to a solute–resin interaction, like the ones
involved in ion chromatography; the following relationship was
then applicable, as described elsewhere [45]:
Dg ¼
nOmg;PG
mPG
½OmgW
ð7Þ
where Dg (in volume per mass units), also called the column
constant, is a system parameter that, like Kp, dictates the
peptide–peptidoglycan degree of interaction; nOmg,PG is the
number of peptide molecules in the peptidoglycan mesh, mPG is
the mass of the mesh and [Omg]W is the water dissolved peptide
concentration. Dg can be converted to a molar ratio (usually
represented Dv) after multiplication by the fully hydrated
peptidoglycan density (H2O mass excluded) [45]. Obviously,
the peptidoglycan is not a solvent; however, a spatial
concentration of the peptide in the mesh can be considered. A
reported value of 196.1 mg/mL for the S. aureus wall was used
in this conversion [46]. However, due to possible peptidoglycan
volume changes, Dv must be carefully used [46]; it is,
nonetheless, a much more useful parameter than Dg since it
has a more intuitive meaning and can be directly compared to
Kp values.
Because Xp is given by the ratio of the peptidoglycan-bound
peptide and the total amount of peptide, it can be defined as a
function of Dg:
XP ¼ nOmg;PGnOmg;PG þ nOmg;W ¼
DgdCPG
1þ DgdCPG ; ð8Þ
where CPG stands for the mass concentration of the peptidogly-
can and nOmg,W for the moles of aqueous peptide. The
fluorescence intensity is then given by:
I=IW ¼ XW ¼ 1 XPð Þ ¼ 11þ DgdCPG : ð9Þ
A good fit was obtained (Fig. 5) with Dg=15.9±1.1 mL/mg
(Dv= (3.1±0.2)×10
3); which suggests that the omiganan
molecules will be much more concentrated in the mesh than
in the water. Despite this large partition towards the peptido-
glycan, in a biological system the highest local peptide
concentration will still be in the membrane (Kp>Dv), never-
theless, because peptidoglycan occupies a much larger volume
than the bilayer does (typically, 20 to 80 nm thick in gram-
positive bacteria [47], about 5 to 20 times the width of a bilayer)
the relative difference of Kp over Dv (approximately 7 to 13
fold) is compensated for, and the absolute amount of peptide
can be expected to be similar in both locations and possibly
even greater in the cell wall. While these results could, at a first
glance, lead to the conclusion that the cell wall is able to
compete with the membrane for the antibiotic and possibly act
as reservoir/trap that would reduce the peptide's efficiency, it
must not be forgotten that, as mentioned earlier, both the
membrane and the cell wall exist in minute concentrations under
MIC assay conditions, which results in the wall and membrane-
bound peptide fractions being negligible. Under these circum-
stances, both predicted aqueous phase and membrane bound
peptide concentrations should remain the same in the presence or
absence of the cell wall, defeating its role as a peptide trap. The
observed thermodynamic impossibility for the wall to become
such an ionic peptide trap is in agreement with the report that S.
aureus adapt by incorporating D-alanine esters into the teichoic
acid to lower the overall anionic charge of the wall as a means of
repelling cationic antibiotics [48], rather than entrapping them.
This does not invalidate the hypothesis that other components of
the system, such as anionic species in solution, can be involved
in peptide association and consequent reduction of membrane
interaction [44], however, such components must be in a
relatively large concentration for their influence to be sig-
nificant; likewise, other membrane constituents, which are
1287M.N. Melo, M.A.R.B. Castanho / Biochimica et Biophysica Acta 1768 (2007) 1277–1290
Article iii 45
usually in high local concentrations, may affect omiganan's
partition.
It should also be noted that these findings refer to
thermodynamic properties of the peptide–wall interaction; the
ability, or lack thereof, of the peptidoglycan to restrict the
diffusion of the peptide cannot be inferred from the usedmethod.
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Appendix
The three-state model is defined by the equation sets
described below, where XL,ns, XL,s and XW represent the non-
saturated membrane-bound, the saturated membrane-bound and
the aqueous phase peptide fractions, respectively; [P] and [L]
are the total peptide and lipid concentrations and [L]f is the free
lipid concentration (not involved in saturation); The parameters
Kp, σ and S are the Nernst partition constant, the saturation P:L
ratio and the apparent solubility product of the peptide,
respectively. The total fluorescence intensity I of the system is
given by the weighted sum of the fluorescence contribution of
each peptide population (IW, IL and IS, for the aqueous phase,
non-saturated membrane-bound and saturated membrane-
bound populations, respectively): I=XWIW+XL,nsIL+XL,sIS.
State 1—Low overall peptide concentrations—Because the
membrane-bound peptide concentration is insufficient to cause
saturation, XL,s is zero and no lipid is occupied by saturated
peptide molecules. The peptide fraction in the membrane is
dictated by the partition constant, as in the XL,ns member of Eq.
(4). The set of equations for this state is:
XL;s ¼ 0 ðA1Þ
XW ¼ 1 XL;ns ðA2Þ
XL;ns ¼ KpgL½L1þ KpgL½L
ðA3Þ
½Lf ¼ ½L ðA4Þ
State 2—Intermediate peptide concentrations—The peptide
concentration in the membrane exceeds the threshold of the
solubility product and two populations now coexist in the
membrane: peptide in non-saturated and saturated conforma-
tions/localizations, the concentration of the former being
constant and equal to the solubility product. Assuming, for
simplicity that exchanges between membrane-bound and
aqueous phase peptide concern only the non-saturated form
and still follow the Nernst equilibrium it can be seen that that the
aqueous phase peptide concentration should also be constant
and equal to (S/Kp). Considering that the aqueous phase volume
is approximately equal to the total system volume, XW can be
obtained as:
XW ¼ SKpd½P ðA5Þ
XL,ns can be obtained in a similar manner, but prior to
division by [P], the concentration of non-saturated membrane-
bound peptide molecules over the total volume must be
calculated; this can be done by multiplying S by the membrane
volume and dividing by the total volume (note that the
membrane volume concerns only the portion of the bilayer
that is not saturated):
XL;ns ¼ SdVL;fVtotal½P ðA6Þ
where VL,f is the non-saturated membrane volume and Vtotal is
the total volume of the system. VL,f is given by [L]f·Vtotal·γL,
and thus
XL;ns ¼ Sd ½Lf dgL½P ðA7Þ
[L]f can be calculated from the difference between the global
phospholipid concentration and the concentration of saturation
involved phospholipids. The latter is equal to
XL;s½P
r
, and thus
½Lf ¼ L½  
XL;s½P
r
ðA8Þ
XL,s can be obtained by mass conservation:
XL;s ¼ 1 XW  XL;ns ðA9Þ
However, with only this set of equations, XL,ns is recursively
dependent on itself. Eqs. (A7), (A8) and (A9) can be combined
to yield an independent definition of XL,ns:
XL;ns ¼ Sd gLr Sd gL
½Ld r
½P þ XW  1
 
ðA10Þ
State 3—High overall peptide concentrations—The mem-
brane becomes fully saturated with peptide. Only the aqueous
phase and the saturated conformation/localization peptide
populations coexist; the fraction of peptide in the membrane
is given by the XL,s member of Eq. (4):
XL;s ¼ r½L½P ðA11Þ
XW ¼ 1 XL;s ðA12Þ
XL;ns ¼ 0 ðA13Þ
½Lf ¼ 0 ðA14Þ
The equations for each state were solved for a range of lipid
concentrations and the parameters were fit to experimental data
by a least squares method, based on the Solver add-in of
Microsoft Excel 2003 (Microsoft, Seattle, WA).
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3. BP100
Two years into my PhD project, and after having done most of the
work with omiganan that would be published as Article iii, I started
working with the peptide BP100. This addition to my project resulted
from a collaboration Miguel started with the group of Eduard Bardají,
from the University of Gerona. BP100 had been designed by Eduard’s
group shortly before the beginning of our collaboration and its primary
development was being targeted at fighting crop diseases caused by Gram-
negative bacteria. The partnership was profitable for both groups: the
people in Gerona were essentially dedicated to synthesis and benefitted
from the insights our methodologies could provide on peptide action,
in turn, we benefitted from what they did best, which was to design
and produce peptides. The symbiosis was extended beyond the mere
exchange of information or peptides: Rafael Ferre, the PhD student that
synthesized BP100, visited our lab to perform part of the work with
the peptide; shortly after, Marta Ribeiro, a biochemist that had by then
started her PhD in our group, would visit Gerona to receive training in
the synthesis of the analgesic peptide she is studying.
3.1 Genesis of BP100
BP100 can be thought of as a fourth generation AMP: it results from
the modification of a peptide, called Pep3, itself a shorter version of
another peptide, termed CA(1-7)M(2-9), in turn designed from naturally
occurring templates.
CA(1-7)M(2-9) was first synthesized in the early 90’s as the result of a
strategy to shorten naturally occurring peptides for use as drugs.36 Briefly,
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a segment of the bee-venom AMP mellitin was appended to a segment
of the moth AMP cecropin A in order to broaden the latter’s spectrum
while reducing the former’s cytotoxicity (the designation CA(1-7)M(2-9)
reflects the chimeric origin of the peptide: the first seven residues of ce-
cropin A followed by the second through the ninth residues of melittin;
its actual sequence is KWKLFKKIGAVLKVL–NH2, also C-terminally
amidated like most AMPs). The shortening of active peptides is an
important objective mainly because the synthesis of long sequences —
and the 38 amino-acid-long sequence of cecropin A can be considered
very long — is unfeasibly expensive in a pharmaceutical mass produc-
tion context.36, 37 Pep3 was designed some years after CA(1-7)M(2-9), its
sequence, WKLFKKILKVL–NH2, resulting from further shortening.38
Overall, the size reduction strategy can be considered to have been suc-
cessful as both CA(1-7)M(2-9) and Pep3 possess good activities against
fungi and Gram-negatives36, 38 (although only a slightly modified version
of CA(1-7)M(2-9) has been tested for fungicidal activity). There was,
nonetheless, a tradeoff in the process of obtaining manageable sequence
lengths: the two peptides are still outperformed by cecropin A — against
Gram-negatives — and melittin — against Gram-positives.
BP100 was synthesized as part of a library of Pep3 analogs. The ob-
jective behind the design of this library was no longer to obtain shorter
sequences, but to improve the activity of the parent peptide against Gram-
negatives. However, unlike a random combinatorial chemistry approach,
the elements of this library are not the result of just any changes to the
sequence of Pep3. Instead, a very elegant — and successful — process to
enhance Pep3’s activity by targeting specific amino acid positions was de-
vised. It had already been remarked that upon the adoption of an α-helix
structure the charged and the apolar residues of Pep3 segregated along
the helix’s diameter38; this is evident in the the Edmunson’s projection
of the Pep3’s α-helix (Figure 3.1). It is widely accepted that this feature,
common inα-helical AMPs, stabilizes the parallel adsorption and burying
of peptides into membranes by simultaneously allowing the charged and
apolar residues to interact with the phospholipids’ headgroups and acyl
chains, respectively.5, 39 Focus was put on modifying the residues that lie on
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Figure 3.1 – Edmunson wheel projection of the α-helical template for the
library of Pep3 analogs. Cationic residues are shown in a full circle and
apolar residues in an empty one; positions that were scanned are labeled
X1 and X2, in dashed circles; the N-terminal modification is denoted R
in a dashed square (for Pep3 X1=W and X2=V; for BP100 X1=K and
X2=Y; none of the peptides was N-terminally modified). When bound to
membranes, Pep3 is expected to adopt an α-helical conformation, parallel
to the bilayer, with approximately diametral separation of cationic and
hydrophobic residues. Adapted from Article iv
the interface between the charged and the apolar patches of the helix, as
these were more likely to influence its insertion properties. The relevant
residues can be clearly seen, from Figure 3.1, to be those at postitions 1
and 10. Rafael constructed the library by scanning these positions with
different amino acids. In addition, because the N-terminal residue was
one of the target positions, several types of N-terminal substitution were
also performed.40–42
BP100 was selected from the library for displaying the best compromise
between hemolysis and antibacterial activity against a panel of Gram-
negative plant pathogens. In its sequence, relatively to Pep3, W1 was
replaced by a lysine residue and V10 by a tyrosine one; the N-terminus
was not derivatized (final sequence: KKLFKKILKYL–NH2). BP100
improves significantly on the activity of Pep3 against these Gram-negatives
but it is still somewhat weaker than the full-length cecropin A.41 Yet, its
creation does demonstrate the possibility of successfully using naturally
occurring peptides to design new AMPs — in this particular case better
suited for mass production.
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3.2 First results
The study of BP100 began, much in the same way as with omiganan,
by the construction of partition curves towards several systems. This
time the observed fluorescence was emitted by the tyrosine residue in
position 10 as no tryptophans were present in the sequence. Fortunately,
BP100 was one of the peptides in the library in which such a fluorescence
residue had been substituted in; otherwise, work would have had to be
carried out using the much fainter phenylalanine fluorescence of position 4.
Also fortunately, the fact that tyrosine has a lower quantum yield than
tryptophan did not mean data acquisition was harder with BP100 than
with omiganan: in general, results were much less prone to artifacts with
the single tyrosine of BP100 than with the four tryptophans of omiganan,
and this is one of the reasons why I later focused almost exclusively on
BP100 for testing new methods.
Having observed saturation with omiganan I paid particular attention
to the occurrence of similar events with BP100. And occur they did!
As with omiganan, anionic membrane models caused partition curves
to spike at low lipid concentrations. This observation corresponded to
some of the predictions we had made about AMP action and saturation,
which was very exciting (findings on BP100 are presented in Article iv,
included at the end of the chapter). But at the same time I was a bit
apprehensive about the similarities with the case of omiganan, afraid that
such a coincidence could be the result of some kind of experimenter error.
Before any further characterization of the deviations in the BP100 par-
tition curves — even before an unequivocal assignment to saturation — I
travelled to Brazil for a six months’ collaboration at the Federal University
of Rio de Janeiro (briefly described in Chapter ‘Other work’). During
this meantime Rafael Ferre came to Lisbon to learn our methodologies
and picked up the studies on BP100 where I had left, having the previous
work done with omiganan as a reference. Across the ocean I was very
glad, and relieved, when I heard that he obtained partition curves with
deviations just like mine, and also that he was able to successfully apply
to BP100 the method I had developed to identify the saturation points of
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omiganan. To top it off, the results were consistent with our hypothesis
of an activity triggered at high peptide concentrations; and this with an
AMP with sequence and origin completely distinct from those of omi-
ganan. Our confidence on a model of interaction applicable to more than
a handful of AMPs was growing stronger.
3.3 More on saturation
As Rafael would only return to Gerona a couple of months after I came
back from Rio, I got the chance to team up with him for that part of
the work — it is thus in all fairness that we share the first authorship of
Article iv. In the process I made a good friend and got to learn Spanish!
Like I stated earlier this collaboration extended far past the mere exchange
of scientific knowledge, and I hope to have many such partnerships in the
future.
While I was in Brazil, Rafael carried out with BP100 most of the
methodologies that had been adapted to study saturation with omiganan.
Upon my return, with that batch of work out of the way, we were able to
focus on new approaches to understand the saturation phenomenon and
to try to verify its link to antibacterial activity. Rafael made an important
breakthrough when he remarked that vesicle suspensions seemed to get
more turbid under saturation conditions: following this lead we were able
to correlate the occurrence of saturation with a sudden increase of the
optical density (OD) of the suspensions, which I could later ascertain to
be due to vesicle aggregation (or disintegration followed by phospholipid
aggregation). And before Rafael left we were still able to correlate
saturation with an increase in BP100-induced vesicle leakage.
* * *
During the second year of my work with BP100 the whole team moved
to the Institute of Molecular Medicine (IMM) at the medical school of
the University of Lisbon — a mere half-mile from our lab at the Faculty
of Sciences. At the IMM we formed the Physical Biochemistry Unit.
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The move followed Miguel’s taking over the chair of Biochemistry at the
Faculty ofMedicine and allowed us to come in contact with a much larger
and more biology-oriented research environment. This would significantly
influence my work, especially in the later stages of the studies with BP100.
Immediate plans, however, were maintained.
This was a very productive period. I had become very motivated as
I was decidedly exploring uncharted territories of AMP science: mem-
brane saturation had been proposed before, but only for non-peptide
anti-inflammatory drugs43 (incidentally, by the group of Margarida Bas-
tos, a biophysicist that also studies AMPs and with whom I had very
enriching exchanges of ideas over these years). And I wasn’t just explor-
ing the possibility of the occurrence of saturation, I was actually finding
very convincing evidence that this would be the membrane-level threshold
corresponding to the MIC with bacteria.
More than supporting a mechanism ofAMP action these ideas bridged
the gap between biophysical concepts and macroscopic events at the cell
level. This is a very important aspect in a biophysical context, where one
is always in danger of losing contact with physiological meaning when
dealing with model versions of reality. At the same time, a quantitative
perspective is brought to the processes underlying the biological event of
bacterial killing byAMPs. Afull chapter in Part II is devoted to exploring
the consequences of the convergence in this point of the molecular- and
cellular-level interpretations of AMP action.
Although the concept I proposed was new to the field of AMPs, it
was not at all incompatible with existing views: most of the proposed
disruption models implicitly assumed, in one way or another, the crossing
of a threshold (see Figure 1.1 and references therein). The carpet model,
which postulates that a given degree of membrane coverage is required
for activity to be triggered, is particularly close to my hypothesis. This
would be remarked by the very proponent of the model, Yechiel Shai, as
he saw my results when we met at the 30th European Peptide Symposium
in Helsinki.
* * *
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Subsequent work with BP100 involved mostly the creation or the adap-
tation of methods to better characterize its interaction with membranes.
Dynamic light-scattering methods were very important at this stage and
I am indebted to Marco Domingues, from the Biomembranes Unit at
the IMM, for having assisted me with this technique in which I had
no practice. Using light-scattering I was able to confirm that the sudden
increase in OD at saturation corresponded to vesicle aggregation. The
same technique also allowed the determination of the surface charge of
vesicles (as the ζ-potential — technical details in Section 4.3) upon BP100
binding. Initial characterization had pointed to very high peptide-to-lipid
(P/L) ratios at saturation (1 : 5.9 for omiganan and 1 : 8.4 for BP100); in-
terestingly, those values were consistent with a balance in the membrane
between the peptides’ and the phospholipids’ charges. Indeed, ζ-potential
measurements indicated a neutralization of membrane charge at saturation
and were a very welcome confirmation of that prediction (see Article iv).
It was also at this stage that I managed to successfully create and
employ a method to detect peptide translocation into the vesicular lumen,
an objective that I had pursued since the study of omiganan (BP100 did
translocate, irrespectively of the membrane-bound concentration, which
was an expected behavior given the peptide’s leakage- and aggregation-
inducing properties). I also perfected the method used for measuring the
depth of peptide insertion in the membrane and even started outsourcing
it to other group members. Unlike omiganan, no movement of BP100
was observed upon saturation; rather, the peptide’s tyrosine residue —
the reporter in this method — seems to sit at a constant depth. In spite of
their significance regarding the action of the peptide, these weren’t exactly
thrilling results, but for me, as had happened with the advanced studies of
omiganan, the excitement was in the development of the methodologies.
3.4 Karlsruhe
In 2007, following the 2nd Workshop on the Biophysics of Membrane-
Active Peptides — which our group co-organized — Miguel started
a prospective collaboration with the group of Anne Ulrich, from the
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University of Karlsruhe, Germany. The collaboration would become
effective shortly after, when a joint application won a grant created to
promote scientific interchange between both countries.
The planned work consisted chiefly in applying nuclear magnetic res-
onance (NMR) and circular dichroism (CD) methodologies developed
in Karlsruhe to gain structural insight on the interaction of BP100 with
membranes. As one of the methods relied on the use of 19F-NMR, flu-
orinated analogs of BP100 had to be synthesized, which involved the
replacement of some residues with a fluorine-containing amino acid probe
developed in Karlsruhe.44 Synthesis was carried out by Christian Mink,
who was then a PhD student at the Ulrich group, and with whom I
would team up in this collaboration.
The first part of the work, important though not very informative on
BP100 action, was devoted to validating the use of the analogs: activity
tests were performed in Karlsruhe and in Gerona (all the analogs displayed
activities close to those of BP100, withMICswithin 5 µm), and Christian
came to Lisbon to test if the fluorinated peptides behaved similarly to
the native BP100 under our biophysical methodologies. Five analogs had
been synthesized, and these were simply too many to allow individual
in-depth partition and saturation studies: we settled on obtaining the
partition curves for each peptide in zwitterionic (POPC) and anionic
(2 : 1 POPG : POPC) vesicles and checking for similar partition behavior
and the occurrence of saturation-dependent deviations. Remarkably, all
the analogs displayed deviations at roughly the same conditions and the
partitions could be seen to lie in the same order of magnitude — although
only in some cases was there an almost perfect superposition of results
(see Figure 3.2). It was important that the analogs displayed saturation-
dependent effects, and Iwas hopeful thatwewould arrive at the structural
characterization of such phenomena. So far, studies of the fluorinated
analogs had green light.
My turn to travel to Karlsruhe would come a few months after Chris-
tian’s visit. There, I found that most of the group’s effort was focused
on the application of two powerful techniques to extract information
on peptide membrane interactions: solid-state 19F-NMR,45 and CD of
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Figure 3.2 – Partition curves of native BP100 (full symbols) and of the
analog fluorinated at position 11 (empty symbols) with 2 : 1 POPG : POPC
vesicles (unpublished). The fluorinated analog reproduces faithfully the be-
havior of the native BP100, including the saturation-dependent deviation.
oriented* phospholipid bilayers46 (this type of CD will be denoted OCD
— oriented circular dichroism). In my opinion however, it was the chance
to use the more common solution CD that yielded the most interesting
results of my stay. Before any description of results I must acknowledge
Christian’s contribution to the work: not only did he synthesize the pep-
tides, he also carried out practically all the NMR and a large part of
the OCD measurements — while in Karlsruhe I became able to perform
sample preparation and CD and OCD experiments independently, but
much more time is necessary before I would get properly acquainted with
NMR acquisition.
From NMR and OCD data the peptide was found to lie mostly
parallel to the membrane surface. However, none of these techniques
was able to see past the saturation threshold because, as could have been
predicted from previous results, the peptide got disruptive by then and
disintegrated our carefully crafted oriented bilayers. In turn, solution
CD — employed mainly to make sure the peptide indeed assumed an
*Oriented bilayers are obtained by allowing phospholipids to assemble in a flat surface, usually
by solvent (aqueous or organic) evaporation. Resulting bilayers stack parallel to the surface.
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α-helical structure when bound to membranes (knowledge of the bound
structure is a prerequisite of the NMR method) — is not affected by
loss of anisotropic membrane integrity. By using it to characterize the
BP100-vesicle interaction I was able to identify a second membrane-
bound peptide structure/aggregation state that showed up precisely along
saturation! (Figure 3.3) This was a very important observation: up to
that point the existence of an alternate structure or aggregation state had
been a postulate required to conciliate saturation with fluorescence data
but this assumption had only been supported, very indirectly, from the
observation of omiganan’s internalization (see Section 2.3, and Section
‘Differential quenching’ in the Appendix). I must here thank the precious
help I received from Jochen Bürck, the CD expert at Karlsruhe: he
spent quite some time teaching me the theoretical and practical bases of
CD spectroscopy, which allowed me to design my own procedures and
eventually make that important find.
The precise structural characteristics of the saturation conformer of
BP100 are still unknown: its CD spectrum always overlaps with either
the random coil features the peptide displays when in the aqueous phase,
or the α-helix spectrum when membrane-bound and out of saturation.
Tentative deconvolutions47, 48 indicate the presence of β-turns together
with β-strands; from these results I am inclined to imagine the formation
of some sort of aggregates, since it is not likely that an eleven-amino-acid
peptide has enough length to consistently fold into a β-strand. (Now
that the existence of this elusive intermediate has been ascertained, and
after my stay in Rio, I believe solution NMR would be the tool of choice
to accurately characterize it.) Still, irrespectively of the actual structure
of the intermediate, a major reorganization has been shown occur at, or
close to, saturation, and this is strong evidence supporting a link between
this molecular-level threshold and an activity-triggering mechanism.
3.5 Stepping into biological studies
While at the IMM, my work shifted from the lifeless in vitro models I
had used so far towards experiments closer to in vivo situations. Ana
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Figure 3.3 – CD spectra of 13.4 µm BP100 with increasing concentrations
of 2 : 1 POPG : POPC, indicated in micromolar units next to each trace
(unpublished). The spectra at zero and maximum lipid concentrations are
typical of random coil and α-helical, structures, respectively, but interme-
diate spectra (from 50 to 200 µm of lipid) display features that cannot be
ascribed to a linear combination of the first two, namely, a positive elipticity
in the 208 – 215 nm region.
Correia, the biologist that joined the group upon our arrival at the IMM,
partneredwithme in these studies, the first being to gauge the cytotoxicity
of the peptide against more complex eukaryotic models — hemolysis had
already been tested in Gerona as part of the peptide selection process.
The fact that the peptide was about five-fold more active against our cells
than erythrocytes raised some questions, and a corresponding number
of hypotheses. The description of our findings and of the mishaps that,
unfortunately, prevented a successful approach can be found in Chapter
‘Unfinished business’.
In subsequent studies focus was put on using live bacteria to verify our
hypotheses of AMP action: no matter howwell our models on membrane
saturation and possible subsequent neutralization fit available data, if the
predicted phenomena are not actually observed in vivo those will never
be more than interesting theoretical possibilities. This time, work with
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live cells would prove not to be as hard as the first attempt had led me to
believe.
Once again, being at the IMM facilitated the transition to biological
experiments: both Catarina Laborinho and Isa Serrano, a lab technician
and a post-doc that joined the group during my third PhD year, had an
extensive background in microbiology and provided important input on
the implementation of experiments with bacteria. But it has been Carla
Alves, the visiting PhD student from the University of Madeira, that
has contributed the most by carrying out a great part of the experimental
execution, especially since I started dedicating most of my time to writing
this book. Were it not for her, all the following description would have
had to be relegated to the ‘Unfinished business’ chapter.
Carla and I were able to successfully implement theMIC assay protocol
used in Gerona and gauged the MIC of BP100 against Escherichia coli
to be between 2 and 4 µm. This is not only in the same range that had
been obtained in Gerona against other Gram-negatives,41 but also in good
agreement with as of yet unpublished tests carried out by colleagues of
Christian’s in Karlsruhe also against E. coli. Staphylococcus aureus were
remarkably unsusceptible to the antibiotic — a likely consequence of a
significant overlap between the sequence of BP100with that of cecropinA,
itself inactive against Gram-positives36 (melittin does performwell against
Gram-positives36 but after all the shortening and optimization steps in the
design of BP100 the two sequences have only weak resemblances).
Having established a consistent system for working with E. coli, we
proceeded to testing the hypothesis of the co-occurrence of bacterial mem-
brane surface neutralization and death. Using an adaptation of the light
scattering method used to measure vesicles’ ζ-potential very exciting re-
sults were obtained: the ζ-potential of E. coli was observed to increase
from −20mV in the absence of peptide, to close to zero at a BP100 con-
centration equal to the MIC (Figure 3.4). While this does not imply the
existence of a neutralization-mediated killing mechanism it does confirm
our prediction that neutralization should occur close to the MIC. In turn,
this supports our hypothesis that bacterial surfaces are indeed saturated
at theMIC. And even if the ζ-potential reflects only the bacterial surface
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Figure 3.4 – Bacterial viability (full symbols) and ζ-potential (empty sym-
bols) of E. coli after exposure to different concentrations of BP100 (unpub-
lished). Bacteria lose viability over the same peptide concentration range
that causes the neutralization of their surface charge.
charge of E. coli — and not that of any inner structure such as the plasma
membrane — a neutralization of the also anionic outer membrane can still
be inferred, showing that peptide molecules do indeed reach very high
concentrations when bound to bacterial membranes.
Following the success of the ζ-potential measurements, the test of
the saturation hypothesis was the logical path to follow (actually, it was
even more logical to have started the in vivo experiments by testing this
hypothesis but the experimental setup for the ζ-potential determination
was much simpler to design and execute). However, though Carla and
I put a great effort into it, we could not get conclusive results due to
a number of methodological limitations (both the used method and its
shortcomings are described in Chapter ‘Unfinished business’). These
were the last experiments I performed with BP100, or with anything else
for that matter, before starting writing full-time.
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Synergistic Effects of the Membrane Actions of Cecropin-Melittin
Antimicrobial Hybrid Peptide BP100
Rafael Ferre,† Manuel N. Melo,‡ Ana D. Correia,‡ Lidia Feliu,† Eduard Bardajı´,† Marta Planas,†
and Miguel Castanho‡*
†Laboratori d’Innovacio´ en Processos i Productes de Sı´ntesi Orga`nica, Departament de Quı´mica, Universitat de Girona, Girona, Spain;
and ‡Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
ABSTRACT BP100 (KKLFKKILKYL-NH2) is a short cecropin A-melittin hybrid peptide, obtained through a combinatorial chem-
istry approach, which is highly effective in inhibiting both the in vitro and in vivo growth of economically important plant pathogenic
Gram-negatives. The intrinsic Tyr ﬂuorescence of BP100 was taken advantage of to study the peptide’s binding afﬁnity and
damaging effect on phospholipid bilayers modeling the bacterial and mammalian cytoplasmic membranes. In vitro cytotoxic
effects of this peptide were also studied on mammalian ﬁbroblast cells. Results show a stronger selectivity of BP100 toward
anionic bacterial membrane models as indicated by the high obtained partition constants, one order of magnitude greater
than for the neutral mammalian membrane models. For the anionic systems, membrane saturation was observed at high
peptide/lipid ratios and found to be related with BP100-induced vesicle permeabilization, membrane electroneutrality, and vesicle
aggregation. Occurrence of BP100 translocation was unequivocally detected at both high and low peptide/lipid ratios using
a novel and extremely simple method. Moreover, cytotoxicity against mammalian models was reached at a concentration consid-
erably higher than the minimum inhibitory concentration. Our ﬁndings unravel the relationships among the closely coupled
processes of charge neutralization, permeabilization, and translocation in the mechanism of action of antimicrobial peptides.
INTRODUCTION
Antimicrobial peptides (AMPs) form an essential part of the
innate immune system of virtually all forms of life (1–7).
During the last decades, AMPs have been widely studied,
as they may become an alternative to conventional antibi-
otics, especially for the treatment of drug-resistant infections
(8, 9). Hundreds of AMPs have been isolated (see a compre-
hensive list at http://www.bbcm.univ.trieste.it/~tossi/pag1.
htm) and several thousands have been de novo designed
and synthetically produced. They display a wide range of
biological activities against bacteria, fungi, protozoa, envel-
oped viruses, and even tumor cells (9–14). Interestingly, they
retain activity against antibiotic-resistant strains and do not
readily elicit resistance (15–17).
Despite displaying extensive sequence heterogeneity,
most AMPs share two functionally important features:
a net positive charge and the ability to assume an amphi-
pathic structure. These structural characteristics are essential
for the mode of action of most AMPs, which target the
microbial membrane. The net positive charge promotes their
binding to the anionic microbial surface, while the amphi-
pathic structure favors peptide insertion into the membrane
(10–12,15,16,18–20). Despite extensive studies, the precise
mechanism of peptide-membrane interaction and cell killing
has not been firmly established for many AMPs. Several
models have been proposed to account for the morphological
changes involved in AMPs-mediated membrane disruption,
such as pore formation (21), cell lysis (22), or peptide trans-
location into the cytoplasm (23). Recently, some studies
have shown that, apart from membrane damage, other mech-
anisms may be involved including intracellular targets
(9,15,16). However, in such mechanisms, peptides still
must traverse the cell membrane to reach their site of action,
which stresses the relevance of peptide-membrane interac-
tions for AMP activity.
Cecropins, first isolated from the hemolymph of the giant
silk moth Hyalophora cecropia, are some of the best studied
AMPs (24–26). They represent a family of peptides
composed of 31–39 amino acids with antibacterial activity
against both Gram-negative and Gram-positive bacteria. Ce-
cropins do not exhibit cytotoxic effects against human eryth-
rocytes and other eukaryotic cells, but are susceptible to
protease degradation (24,27,28). In an effort to overcome
the high production costs of such long peptides and to
improve their biological properties, short peptide analogs
have been designed and synthesized. These studies have
led to the identification of nontoxic and more stable peptide
sequences displaying a broader and higher activity than their
natural counterparts (29–36). In particular, the undecapep-
tide WKLFKKILKVL-NH2 (Pep3), derived from the well-
known cecropin A(1–7)-melittin(2–9) hybrid (30,33,34),
has been found to be sufficient for antifungal and antibacte-
rial activities, while displaying low cytotoxicity (32,37–40).
Recently, we have identified cecropin A-melittin hybrid
undecapeptides derived from Pep3 which inhibit in vitro
growth of economically important plant pathogenic bacteria
such as Erwinia amylovora, Pseudomonas syringae
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pv. syringae, and Xanthomonas axonopodis pv. vesicatoria
(38–40). In particular, KKLFKKILKYL-NH2 (BP100), ob-
tained through a combinatorial chemistry approach, displays
a bactericidal effect against these bacteria as well as mini-
mized cytotoxicity and low susceptibility to proteinase K
degradation (38). Moreover, BP100 is highly effective to
prevent infections of E. amylovora in pear and apple flowers,
being only slightly less potent than streptomycin, which is
the most active compound currently used in fire blight
control (38).
Although it has been proposed that the mode of action of
cecropins and melittin depends on the peptide concentration
and membrane composition (41–45), the mechanisms
involved in the action of cecropin-melittin hybrid peptides,
and especially that of short undecapeptides, are very far
from being completely understood. Insights into the mode
of action of BP100 are essential for the full rationalization
of the biological properties of this peptide as well as for their
further improvement. In this study, we investigated the inter-
action of BP100 with different model membranes using
spectroscopic methodologies, which can afford valuable
information about peptide-membrane interaction. A compre-
hensive study was carried out to ascertain the conditions
under which BP100 disrupts membranes or, alternatively,
translocates across them to reach the lumen of vesicles.
Moreover, the in vitro cytotoxic effects of this peptide
were also studied on mammalian fibroblast cells.
MATERIALS AND METHODS
Reagents and apparatus
The ultraviolet-visible absorption and steady-state fluorescence emission
assays were performed at room temperature in a model No. V-560 UV-
Vis spectrophotometer (JASCO, Hachioji, Japan) and in a model No. IBH
FL3-22-time-correlated single photon-counting (TCSPC) spectrofluorom-
eter (Horiba Jobin Yvon, Longjumeau, France), equipped with a 450 W
Xe lamp and double monochromators, or in a Cary Eclipse Thermo Spec-
tronic spectrofluorometer (Varian, Palo Alto, CA), equipped with a 75 kW
pulsed Xe lamp. Multiwell absorption measurements were performed in
a Multiskan RC plate reader (Labsystems, Helsinki, Finland). Time-resolved
fluorescence decays were collected in the FL3-22-TCSPC spectrofluorom-
eter using a time-correlated single photon counting (TCSPC) technique
with a 279-nm nanoLED source (IBH, Glasgow, UK); reduction of scattered
light contribution to the decays was achieved by horizontally polarizing the
excitation light with a Glan-Thompson polarizer; lifetimes were calculated
from time-resolved fluorescence intensity decays using at least 10 K counts
in the peak channel; fluorescence intensity decay curves were deconvoluted
with the software package DAS 6.1 from IBH.
Dynamic light scattering and z-potential measurements were taken in a Ze-
tasizer Nano-ZS (Malvern Instruments, Worcestershire, UK), equipped with
a 633-nm HeNe laser.
We used 2-(4-(2-hydroxyethyl)-1-piperazinyl)-ethanesulfonic acid
(HEPES), sodium chloride, chloroform, ethanol (spectroscopic grade),
acrylamide, dimethyl sulfoxide, and trypan blue (Merck, Darmstadt,
Germany). Phospholipids 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocho-
line (POPC) and 1-palmitoyl-2-oleoyl-sn-glycero-3-(phosphor-rac-(1-glyc-
erol)) (POPG) were from Avanti Polar Lipids (Alabaster, AL). Cholesterol,
cell culture media, serum, antimicrobials, trypsin/versine, 3-(4,5-dimethylth-
iazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), and crystal violet
stain were from Sigma (St. Louis, MO). Lipophilic quenchers 5- and
16-NS (5- and 16-doxylstearic acids, respectively) were from Aldrich Chem-
ical (Milwaukee, WI).
All the 9-fluorenylmethoxycarbonyl (Fmoc)-amino acid derivatives,
reagents, and solvents used in the peptide synthesis were obtained from
Senn Chemicals International (Gentilly, France). Fmoc-Rink-4-methylbenz-
hydrylamine resin (0.64 mmol/g) was purchased from Novabiochem (Darm-
stadt, Germany). Trifluoroacetic acid, N-methyl-2-pyrrolidinone, and
triisopropylsilane were from Sigma-Aldrich (Madrid, Spain). Piperidine
and N,N-diisopropylethylamine were purchased from Fluka (Buchs,
Switzerland). Solvents for high-performance liquid chromatography
(HPLC) were obtained from J.T. Baker (Deventer, Holland).
Solutions were prepared in a 10 mM HEPES buffer at pH 7.4, containing
150 mM NaCl (the so-called physiologic ionic strength). All BP100 fluores-
cence measurements were recorded at an excitation wavelength of 275 nm,
except for the experiments involving acrylamide in which the peptide was
excited at 285 nm to minimize the relative quencher/fluorophore light
absorption ratio.
Peptide synthesis
BP100 was synthesized as a C-terminal carboxamide on a Rink p-methyl-
benzhydrylamine resin by the solid-phase synthesis method using standard
9-fluorenylmethoxycarbonyl (Fmoc) chemistry (38). The peptide was puri-
fied by reverse-phase semipreparative HPLC on a 5 mm, 1.0  25 cm
C18 Tracer column (Teknokroma, Barcelona, Spain) using a linear gradient
from 10 to 60% acetonitrile in water with 0.1% trifluoroacetic acid over
50 min. The peptide was obtained with >95% HPLC purity. Electrospray
ionization mass spectrometry was used to confirm peptide identity.
Preparation of model membrane vesicles
Large unilamellar vesicles (LUVs) of 100-nm diameter and multilamellar
vesicles (MLVs) of different phospholipid composition were used as biolog-
ical membrane models. MLVs were obtained by hydration of dried phospho-
lipid films under vortex agitation; when required, multilamellarity was
enhanced by first hydrating the films in a fraction of the final volume.
LUVs were prepared by freezing-thawing and extruding MLVs, as described
elsewhere (46). Sonication of vesicles, when needed, was carried out in an
Ultrasound Technology UP200S power sonicator (Hielscher Ultrasonics,
Teltow, Germany). Mammalian model systems included 100% POPC
LUVs and 2:1 POPC/cholesterol LUVs. Bacterial model systems included
2:1 and 4:1 POPG/POPC LUVs.
Photophysical characterization of BP100
in aqueous solution
The linear dependence of the absorbance and fluorescence intensity of
BP100 on its concentration was tested over the 0–140 mM range. To check
whether peptide aggregation occurs in the aqueous phase, the Tyr fluores-
cence was quenched by sequentially adding aliquots of a 4 M acrylamide
solution to a 15 mM peptide sample, while recording both the absorbance
and fluorescence intensity. Quenching assays data were analyzed according
to the Stern-Volmer formalism (47) and were corrected for simultaneous
light absorption of fluorophore and quencher (48).
Peptide-membrane incorporation studies
The extent of the partition of BP100 to each model membrane was evaluated
by titrating a 15 mM peptide solution with the corresponding LUVs suspen-
sion and recording the fluorescence emission. Samples were incubated for
10 min after each addition of lipid suspension. The molar ratio partition
constants, Kp, were calculated by fitting the experimental data with Eq. 1,
as described elsewhere (49). The quantities IW and IL are the fluorescence
intensities the mixture would display if all the peptide is in the aqueous or
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the lipidic phase, respectively; gL is the phospholipid molar volume, which
is considered to be 0.763 M1, corresponding to the typical value for liquid
crystalline lipid bilayers (50); and [L] is the phospholipid concentration.
Fluorescence data were corrected both for dilution and scattered light (51),
I
IW
¼
1 þ KpgL
IL
IW
½L
1 þ KpgL½L
; (1)
Kp ¼ ½BP100L½BP100W
; (2)
where [BP100]L and [BP100]W are the peptide concentrations in the lipid
volume or in the aqueous phase, respectively. It should be noted that because
Kp implicitly includes electrostatic contributions that may be dependent
upon the global peptide concentration, it should be taken as an apparent
partition constant (52).
Membrane saturation studies were carried out with 2:1 POPG/POPC
LUVs. Saturation points were determined by adding small aliquots of
a 750 mM stock peptide solution to an LUV suspension (phospholipid
concentrations of 0, 40, 75, 125, 175, and 250 mM) containing 100 mM
acrylamide. The fluorescence emission was recorded after 10 min of each
peptide addition. To prevent dilution of acrylamide, the stock peptide solu-
tion also contained 100 mM of this aqueous phase quencher. The peptide/
lipid (P/L) ratio at saturation (s) and Kp were calculated by fitting the ob-
tained saturation points with Eq. 3, as described elsewhere (53):
½P ¼ s
KpgL
þ s½L: (3)
In-depth membrane localization studies
Differential quenching studies were carried out by sequentially adding
aliquots of a lipophilic quencher—either 5-NS or 16-NS—to a LUV
suspension previously equilibrated with 10 mM BP100; two different LUV
concentrations—125 and 250 mM—were used so as to set either saturation
or nonsaturation states and quencher concentration was increased or reduced
accordingly; time-resolved fluorescence measurements of the Tyr in BP100
were taken. To prevent bilayer alterations while adding the 5- and 16-NS
quencher aliquots, prepared in ethanol, care was taken to keep final ethanol
concentrations below 2% (v/v) (54). Results were analyzed with a method-
ology based on the knowledge of the quenchers’ in-depth distributions in
the membrane (55), modified to implement a least-squares fitting to the data.
Vesicle permeabilization studies
The kinetics of BP100-induced vesicle leakage was monitored by Co2þ
quenching of the fluorescence of 1% N-NBD-PE (56) incorporated into 125
mM 2:1 POPG/POPC vesicles, at BP100 concentrations ranging from 0 to
25 mM. Briefly, experiments were carried out by adding aliquots of BP100
to a suspension of vesicles in the presence of 20 mM CoCl2. The CoCl2, which
is unable to permeate phospholipid membranes, was added to the vesicles
shortly before the measurement, quenching the outer leaflet N-NBD-PE fluo-
rescence. The kinetics were started with the addition of BP100. Permeabiliza-
tion of the membrane to the Co2þ ions results in further quenching of the inner
leaflet N-NBD-PE population. The decrease of NBD fluorescence emission
intensity at 515 nm was monitored with excitation at 460 nm. The percentage
of leakage at time t after peptide addition was determined from Eqs. 4–6,
% leakage ðtÞ ¼ Co2þ 
in
ðtÞ=Co2þ 
out
ðtÞ
z½Co2þinðtÞ=½Co2þTOTAL; ð4Þ
where [Co2þ]TOTAL, [Co
2þ]in, and [Co
2þ]out correspond to the global,
luminal, and external quencher concentrations, respectively. The approxima-
tion of [Co2þ]out(t) as [Co
2þ]TOTAL can be made because no significant
decrease of external quencher concentration is expected upon leakage: at
these lipid concentrations, the total internal vesicle volume can be calculated
to be <0.005% of the sample volume (57). From the collisional quenching
Stern-Volmer formulation (58), quencher concentrations can be related with
fluorescence intensities,
% leakage ðtÞ ¼ DIinðtÞ
IinðtÞ  KSV 
DImax
Ic  KSV ¼
Ic  DIinðtÞ
IinðtÞ  DImax
(5)
where KSV is the Stern-Volmer quenching constant, Iin is the contribution of
inner leaflet fluorophores to the global fluorescence intensity, DIin is the
change in Iin after peptide addition, DImax is the maximum change in global
fluorescence from before quencher addition to complete leakage, and Ic
corresponds to the minimum fluorescence intensity at 100% leakage, ob-
tained by vesicle sonication. There are two populations contributing to the
global fluorescence: the inner and outer leaflet fluorophores; because the
external quencher concentration remains virtually constant, the fluorescence
intensity of the outer fluorophore fraction will also be approximately
constant and DI ¼ DIin, where DI is the change in global intensity upon
peptide addition. In addition, from the moment of quencher addition, the
external fraction decreases to its minimum possible fluorescence intensity
which, given the large size of a vesicle, is roughly one-half of Ic. This allows
the substitution of Iin(t) as I(t) – 0.5  Ic,
% leakage ðtÞ ¼ Ic  DIðtÞ
IðtÞ  0:5Ic
  Ic  Ipre
; (6)
where Ipre is the global fluorescence intensity before quencher addition.
Leakage kinetics were tentatively fitted with the system of ordinary differ-
ential equations described in Gregory et al. (59).
Membrane translocation studies
To determine the occurrence and extent of peptide translocation across the
membrane a novel method was devised: the increase of BP100 fluorescence
upon membrane interaction was followed after MLV addition. A control
experiment was performed in which the interaction kinetic was instead initi-
ated with LUVs produced from the same suspension of MLVs. In the occur-
rence of translocation, the interaction kinetic with the MLVs would be
slowed down with respect to LUV interaction due to the multiple membrane
crossing steps. In the absence of translocation, although the lipid concentra-
tion is the same in MLV and LUV suspensions, the peptide would sense an
apparently lower concentration of lipid in an MLV suspension, as only the
outer lipid shell is accessible; as such, fluorescence would never increase as
much with MLVs as with LUVs (see Fig. 1 for details). A quantity of 40 mM
2:1 POPG/POPC LUVs and MLVs were used. The sensitivity in the detec-
tion of peptide-lipid interaction was improved by adding aliquots of 200 mM
of acrylamide to increase the fluorescence change upon binding. Potential
artifactual increases of BP100 emission due to scattered light contribution
were controlled by monitoring the ratio of fluorescence intensities at 303
and 330 nm.
Vesicle aggregation and charge studies
Turbidity studies were carried out by monitoring the changes induced by
BP100 in the optical density (OD) of a vesicle suspension. Briefly, aliquots
of a 1 mM BP100 stock solution were added to 125 mM 2:1 POPG/POPC
vesicle suspensions. Peptide concentrations tested ranged from 0 to
21 mM. The OD was recorded at 450 nm every 2 s for 30 min after peptide
addition.
Dynamic light scattering measurements were carried out in similar condi-
tions as the OD measurements. BP100 concentrations ranged from 0 to
16.5 mM. The z-potential measurements were performed at 250 mM lipid
and at BP100 concentrations up to membrane saturation.
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Cytotoxicity assays
Cell culture
V79 Chinese hamster lung fibroblast cells (MZ subline (60)) were used for
the cytotoxicity assays (61). They were routinely cultured in 175 cm2 tissue
flasks in Ham’s F-10 medium, supplemented with 10% newborn calf serum
and 1% penicillin/streptomycin, in a humidified incubator at 37C with 5%
CO2. Cells were routinely subcultured in the semiconfluent state over
a maximum of eight passages and regularly tested negative for Mycoplasma.
The V79 cells used in this study were kindly obtained from Prof. H. Glatt
(German Institute of Human Nutrition, Germany) and were routinely main-
tained and kindly provided by Dr. Nuno Oliveira (University of Lisbon,
Portugal).
Exposure conditions in the assays
V79 cells were suspended in 180 mL culture medium in 96-well plates, at
a density of 5  103 cells/well, optimized to keep the cultures in optimal
growth during the whole experiment. After seeding, the plates were incu-
bated for 24 h before the experiment. BP100 was dissolved in HEPES and
added to 20 mL of the medium to obtain final concentrations of 90, 60,
40, 30, and 10 mM. Two replicates for each peptide concentration were
used. Each plate contained a negative control (culture medium þ 10%
HEPES) and a positive control (culture medium þ 10 mM H2O2). Cell
viability was measured after incubation for 24 h at 37C with 5% CO2.
Cell viability assays
Three assays were performed to test the cell viability. The MTT assay was
used to investigate the effect of BP100 on the mitochondrial dehydrogenase
activity, measured as the ability of viable cells to produce formazan crystals
(62). The cells were rinsed once with phosphate-buffered saline and then
200 mL MTT solution (5 mg/ml) were added to each well. After 2.5 h incuba-
tion at 37C, 200 mL dimethyl sulfoxide were added to each well to dissolve
the purple formazan crystals (63). The absorbance of the resulting dispersion
was determined at 595 nm in the multiwell scanning spectrophotometer.
Crystal violet is a dye that accumulates in the cell nucleus and was applied
in this study as an indicator for cell viability (62). The fixed dye correlates
directly with the nuclear DNA content, and thus also with the cell number.
After its application, nonviable, nonadherent cells were washed. The fixed
crystal violet was solubilized in 10% SDS for 20 min and the OD of the solu-
tion was measured at 595 nm.
The ability of cells to stain with trypan blue was used to investigate the
loss of plasma membrane integrity (64). The cells were washed with phos-
phate-buffered saline, dispersed with 40 mL trypsin EDTA and the resulting
cell suspension was diluted in 10 mL of culture medium. 20 mL of the mixed
cell suspension were added to 20 mL of 0.4% trypan blue fresh solution,
prepared in NaCl 0.9%, to stain nonviable cells. Cell viability was expressed
as the percentage of unstained cells (65).
Statistical analysis and regression modeling
To account for the interplate variability, the absolute values of the cell viable
parameters were normalized to the average of the negative controls (100%
viability) and the positive controls (0% viability, corresponding to 100%
cell death) (64). Statistical concentration-response analyses were performed
in the same way for all three in vitro tests by fitting a three-parameter
nonlinear regression Logit model to the data (66). Dunnett’s test (a ¼
5%) was employed to determine statistical significant differences between
the treated groups and the negative controls. IC50 values were determined
as the midpoint of the fitted curves.
RESULTS
Photophysical characterization in aqueous
solution
Both the absorbance and fluorescence intensities of BP100
depended linearly on concentrations up to 140 mM (data
not shown). The obtained photophysical parameters were
similar to those of free Tyr: the excitation maximum for
BP100 was at 275 nm (lem ¼ 306 nm), which is coincident
with the wavelength of maximal electronic absorption. The
calculated absorptivity coefficient (3) at this wavelength
was 1.40  103 M1 cm1. The quenching of BP100 by
acrylamide followed a linear Stern-Volmer relationship up
to 250 mM of quencher, with a KSV of 15.1 M
1 (not
shown).
Membrane insertion studies
For all the membrane models tested, an increase of fluores-
cence intensity was observed upon the partition of BP100
between the aqueous buffered phase and the lipidic
membrane studied (Fig. 2). Partition parameters are summa-
rized in Table 1.
For the neutral systems, liquid-crystal POPC and liquid-
ordered 2:1 POPC-cholesterol LUVs, the increase of fluores-
cence followed a hyperbolic-like relationship (Fig. 2 A). In
contrast, the anionic systems 2:1 POPG/POPC and 4:1
POPG/POPC deviated from this behavior (Fig. 2 B). At
low lipid concentrations, an overshoot of the fluorescence
intensity was detected. This result was assigned to reflect
membrane saturation. To confirm this hypothesis, membrane
saturation studies were carried out for the 2:1 POPG/POPC
system (Fig. 3). Saturation points were identified from the
A
B
C
FIGURE 1 Expected fluorescence increase kinetics of BP100 in interac-
tion with LUVs or MLVs. (A) LUVs with or without the occurrence of trans-
location: the entire lipid is accessible to the peptide at time 0 resulting in
a fast interaction kinetics. (B) MLVs, with peptide translocation: at time 0,
only a fraction of the lipid is accessible to the peptide, resulting in a fast,
but partial, increase in fluorescence; as the peptide translocates, more lipid
becomes accessible, and a full fluorescence increase is eventually reached
at a lower rate. (C) MLVs, without translocation: there is a fast interaction
with the accessible fraction of lipid, but no subsequent increase is expected,
as no more lipid becomes accessible. The hatched region indicates the
approximate relative measurement dead time for BP100 under our setup.
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breaks observed in the curves obtained from titration of vesi-
cles with BP100 and were fitted with Eq. 3 (Fig. 3, inset). A
Kp value of 8.41  104 was obtained and a s of 0.118 was
determined, which corresponds to 8.4 phospholipids per
peptide at the saturation of the vesicles.
The depth of membrane internalization was probed using
stearic acid molecules labeled at different carbon positions
(carbons 5 and 16 for 5- and 16-NS, respectively) with tyro-
sine quenching nitroxyl groups. With previous knowledge of
the in-depth distribution of each quencher, an integrated
approach was used to infer the distribution of the tyrosine
residue of the peptide from each quencher’s quenching
profile (based on (55)). These profiles did not change signif-
icantly upon saturation (not shown), indicating little change
in the in-depth localization of the peptide. This was
confirmed after analysis: in the absence of saturation, the
average in-depth localization from the bilayer center was
10.5 A˚ and the distribution half-width at half maximum
was 3.2 A˚ (a Lorentzian distribution was assumed); under
saturation, these parameters were 11.2 A˚ and 2.4 A˚, respec-
tively.
Vesicle permeabilization studies
Fig. 4 displays the leakage kinetics induced by increasing
BP100 concentrations. BP100 induced vesicle leakage in
a dose-dependent manner. It should be noticed that from
15 mM peptide the kinetics display a markedly sigmoidal
rise; this is evident in Fig. 4. A transition at 15 mM of
BP100 is also clearly observed in the leakage percentage at
390 s (Fig. 4, inset). Thus, for 125 mM lipid, 15 mM is a crit-
ical BP100 concentration dictating the transition between
two different regimes of peptide-lipid interactions.
A
B
FIGURE 2 Lipid titrations of 15 mM BP100 with different LUV systems.
Lines represent the fitting parameters of the data to the partition model in Eq.
1. (A) POPC (, solid line) and 2:1 POPC/cholesterol (6, dashed line)
LUVs. (B) 4:1 POPG/POPC (, solid line) and 2:1 POPG/POPC (:, dashed
line) LUVs; deviations occurred at low lipid concentrations and those data
points (empty) were removed from the fittings. The difference in the required
amounts of lipid for the titrations in panels A and B indicates a much higher
partition toward the anionic models; this is confirmed by the obtained parti-
tion constants. Fit parameters are summarized in Table 1.
TABLE 1 Summary of the characteristics of each studied
system: constitution and partition parameters determined
using Eq. 1
Modeled system
Constituent
phospholipids Kp/10
3 IL/IW
Bacterial membrane
models
Outer leaflet 2:1 POPG/POPC 30.8  6.2 3.59  0.06
Inner leaflet 4:1 POPG/POPC 87.6  9.8 3.58  0.02
Mammalian membrane
models
Outer leaflet 100% POPC 1.6  0.5 1.54  0.06
Outer leaflet þ
cholesterol
2:1 POPC/cholesterol 3.5  1.3 1.55  0.06
FIGURE 3 Titration of several concentrations of 2:1 POPG/POPC LUVs
with BP100 in the presence of 100 mM acrylamide (lipid concentration is
indicated in mM for each set of points). Saturation points were identified
from the breaks in each curve. (Inset) Linear dependence of the global
peptide and lipid concentrations at the saturation points, fitted according
to Eq. 3, yielding a saturation proportion of 8.4 phospholipids per peptide
and a partition constant of 8.41  104.
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The sigmoidal curves could be fitted with the model
described by Gregory et al. (59) (not shown), even though
in their work only hyperbolic-like kinetics were fit. Both
rate constants of pore formation/dissipation needed to be
two-to-three orders-of-magnitude lower than those observed
by Gregory et al. (59) to generate a sigmoidal behavior
comparable to the one observed in Fig. 4. Further quantita-
tive analysis of leakage parameters is, however, not reliable,
due to multiple minima in the solution space and some
degree of correlation.
Membrane translocation studies
There were marked differences between the peptide-MLV
and peptide-LUV interaction kinetics (Fig. 5). Whereas the
increase in peptide fluorescence intensity upon LUV addi-
tion was almost instantaneous, the MLV-induced increase
spanned several minutes. Fluorescence intensity for the
MLV additions started out lower than that induced by
LUV additions of the same lipid concentration, but rose to
approximately the same relative level, as expected for the
occurrence of translocation (Fig. 1). To better compare the
fluorescence change at both peptide concentrations, Fig. 5
depicts the relative increase in fluorescence upon lipid addi-
tion. As a consequence there are small differences in the
endpoint of the kinetics at low BP100 concentrations
(Fig. 5—MLV1 and LUV1), attributable to error introduced
by the low initial Tyr fluorescence signal and further aggra-
vated by the use of acrylamide.
Vesicle aggregation and surface charge studies
Apart from a transient initial increase in turbidity, no signif-
icant changes in vesicle OD were observed at peptide
concentrations <15 mM (Fig. 6). For peptide concentrations
at or >15 mM, however, there was a remarkable time-depen-
dent increase of the OD due to liposome aggregation induced
by BP100 (Fig. 6, inset).
A related change was also observed with light scattering
measurements where the average particle diameter of the
LUV suspension increased by ~10-fold (Fig. 7). Similarly
to permeabilization, the BP100-induced increase of vesicle
turbidity/aggregation displays a transition between two
regimes close to 15 mM, with 125 mM of lipid.
FIGURE 4 Time course of BP100-induced vesicle leakage to Co2þ with
125 mM 2:1 POPG/POPC LUVs doped with 1% N-NBD-PE; each curve
corresponds to a different BP100 concentration, indicated in the figure in
mM. Dashed lines correspond to subsaturation conditions. (Inset) Leakage
percentage at 390 s in which a transition in behavior with BP100 concentra-
tion is evident; this transition occurs close to the expected membrane satu-
ration point for the used lipid concentration, indicated by the dotted line.
FIGURE 5 Time course of BP100 interaction with 40 mM 2:1 POPG/
POPC LUVs and MLVs. LUV1 and MLV1: 4 mM BP100. LUV2 and
MLV2: 12 mM BP100. Chosen BP100 concentrations are below and above
membrane saturation, as per Eq. 3. Comparison with the expected kinetic
profiles (Fig. 1) indicates the occurrence of peptide translocation in both
cases.
FIGURE 6 Time course of BP100-induced OD change (l ¼ 450 nm) of
125 mM 2:1 POPG/POPC LUVs; each curve corresponds to a different
BP100 concentration, indicated in the figure in mM. Two different kinetic
behaviors are evident. Dashed lines correspond to subsaturation conditions.
(Inset) OD450 at 1500 s. The transition in behavior is evident above 15 mM;
as with vesicle leakage (Fig. 4), this transition occurs close to the expected
membrane saturation point for the used lipid concentration, indicated by the
dotted line.
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The particles’ z-potential was 38.3 mV in the absence of
peptide but was brought close to zero (0.1 mV) at satura-
tion (Fig. 8); aggregation and increase in turbidity prevented
z-potential measurement at higher peptide concentrations.
Effects of BP100 exposure on cell viability
Fig. 9 depicts the effects of BP100 on the mitochondrial
activity, cell monolayer adherence, and membrane integrity
of cultured hamster fibroblasts. All cell viability parameters
responded to the peptide (10–90 mM) in a clear dose-depen-
dent way. At the highest tested concentration (90 mM), low
cell viability (<10%) was observed. The peptide concentra-
tions, at which 50% inhibition was expected (IC50), were
interpolated from the regressions for each viability assay,
and ranged from 51.1 mM, for the crystal violet stain, to
64.3 mM for the trypan blue assay.
DISCUSSION
The biological activity of small, cationic antimicrobial
peptides has been largely associated with their interaction
with membranes. It is widely believed that for many of these
peptides, membrane disruption is the primary mechanism of
cell killing (10–12,15,16,18–20). However, their exact mode
of action is still poorly understood. Elucidating their mecha-
nism of action and their specific membrane damaging prop-
erties is crucial for the rational design of novel antibiotic
peptides with high antibacterial activity and low cytotox-
icity. With these observations in mind, and considering
that BP100 contains a Tyr residue, which makes it intrinsi-
cally fluorescent, we have exploited its photophysical prop-
erties to obtain information about its binding affinity and
damaging effect on bilayers having a lipid composition
FIGURE 7 Normalized intensity distribution determined by dynamic
light scattering of the particle sizes of a 125 mM 2:1 POPG/POPC LUV
suspension in the presence of increasing BP100 concentrations (error bars
represent SD). Above membrane saturation, which is expected at ~15 mM
BP100 at this lipid concentration, a significant increase in particle size
and heterogeneity is observed, in agreement with the occurrence of vesicle
aggregation. This result correlates with the observed distinct behavior of
BP100-induced OD change below and above saturation (Fig. 6).
FIGURE 8 The z-potential of 250 mM 2:1 POPG/POPC LUV in the pres-
ence of different BP100 concentrations (error bars represent SD). Peptide
concentrations are displayed either as bound peptide/lipid ratios (calculated
with the partition constant obtained from Eq. 3) or as the estimated global
charge per phospholipid assuming a 6þ charge on the peptide. A linear
regression of the points is displayed as a guide to the eye. The saturation
ratio is indicated by the dashed line. A neutralization of the LUV charge
at the saturation point was observed, in agreement with what was expected
from the saturation proportion (Fig. 3), the peptide charge, and the compo-
sition of the system.
A B C
FIGURE 9 Effects of BP100 on the viability of V79 Chinese hamster lung
fibroblast cells after 24 h exposure (error bars represent SE). (A) Mitochon-
drial activity determined by the MTT assay; IC50 ¼ 52.9 mM. (B) Loss of
monolayer adherence estimated by the crystal violet assay; IC50 ¼
51.1 mM. (C) Plasma membrane integrity estimated by the trypan blue assay;
IC50 ¼ 64.3 mM. Logit curves were fitted to the data and are shown as lines.
The IC50 values are proportionally greater-than the MIC, by approximately
the same factor as the partition constants toward the anionic bacterial models
are greater-than toward the neutral mammalian models, suggesting a concen-
tration-dependent disruption mechanism.
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similar to that of the bacterial and mammalian cytoplasmic
membranes.
Photophysical characterization of BP100
in aqueous solution
The photophysical characterization of peptides in aqueous
solution is a prerequisite to understand their interaction
with phospholipid model membranes. The observed
behavior of BP100 in aqueous solution reflects that peptide
aggregation does not occur at the studied peptide concentra-
tion range. This is supported by the linear dependencies of
fluorescence emission intensity and electronic absorption
on concentration and by the obtained lexc, lem, and 3-values
as they are similar to those of free Tyr (275, 303, and 1400,
respectively (47)), indicating that the Tyr in BP100 is
exposed to an aqueous environment (47). Moreover, a linear
Stern-Volmer plot for the fluorescence quenching of BP100
with acrylamide is observed up to 250 mM (not shown). In
addition, there are no significant differences between the ob-
tained KSV and the one for acrylamide quenching of free Tyr,
evidencing that Tyr is totally accessible to the aqueous
phase. The absence of aggregation observed for BP100,
together with its overall positive charge (þ6), could account
for its high solubility in aqueous solution and facilitates the
interpretation of the peptide-membrane interaction results.
Membrane insertion studies
The extent of the partition of BP100 into model membranes
was studied using a partition model described by Santos et al.
that allows the calculation of the Nernst partition constant
(Kp) from fluorescence intensity (I) versus phospholipid
concentration ([L]) plots at a constant peptide concentration
([P]) (49). The Kp, defined as the ratio between the equilib-
rium membrane-bound and aqueous phase peptide concen-
trations, provides an easy assessment of the extent of
peptide-membrane interaction (Eq. 2). For both neutral
systems POPC and 2:1 POPC/cholesterol LUVs, used as
models of the outer leaflet of mammalian membranes, the
fluorescence intensity increased following an hyperbolic-
like relationship (Fig. 2 A). The moderate Kp values obtained
for vesicles composed of 100% POPC and POPC/cholesterol
mixtures (Table 1) could be attributed to the hydrophobic
effect and the van der Waals forces that are likely to domi-
nate the interactions between the neutral lipids and the
hydrophobic residues of BP100. In this case, no specific
interaction with cholesterol was observed, which is an indi-
cator of low toxicity toward mammalian cells. Furthermore,
cholesterol seems to play an important role in preventing the
intercalation of AMPs into eukaryotic cell membranes (67);
its presence and the absence of acidic phospholipids in the
eukaryotic membranes could account for the low cytotox-
icity displayed by BP100 against erythrocytes (38).
For the anionic liquid-crystalline 2:1 and 4:1 POPG/POPC
vesicles, which served as models for bacterial cell
membranes, the partition curves deviated from the hyper-
bolic-like progression at low lipid concentrations (Fig. 2
B). A similar behavior has been recently reported for the anti-
microbial peptide omiganan and has been attributed to
a membrane saturation process: at low phospholipid concen-
trations, membrane saturation may occur when the bound
peptide concentration, hypothetically dictated by Kp, is
higher than what the membrane can accommodate (53);
under these conditions, interaction changes may occur, as
has also been described for other AMPs upon the crossing
of threshold P/L ratios (68,69). Since the model of Santos
et al. (49) is not well suited to study these saturated systems,
the Kp values were obtained by fitting only the nonsaturated
points to the partition model (Fig. 2 B and Table 1). This
approach is obviously subject to error because the initial
points of the curve, which are important for the accurate
calculation of Kp, cannot be used. However, even with great
associated errors, the obtained partition constants were one
or more orders-of-magnitude higher than those of the neutral
systems (Table 1). These results are consistent with the ex-
pected preference of cationic peptides for negatively charged
membranes as a consequence of the strong electrostatic inter-
action.
To ensure that the deviation observed in the partition
curves of the anionic vesicles was due to a saturation of
the system, membrane saturation studies were carried out
using 2:1 POPG/POPC LUVs. LUV suspensions were
titrated with peptide in the presence of acrylamide while
monitoring BP100’s fluorescence intensity. Acrylamide is
an aqueous quencher that facilitates the identification of
alterations in the phase localization of peptides. In a nonsatu-
ration regime, a linear increase of the fluorescence intensity
is expected: as per the formalism behind Eq. 1, the fractions
of the peptide in each phase are constant with constant [L];
therefore, any variation in peptide concentration will result
in a proportional increase in each of these fractions and,
also therefore, in a global proportional increase of the fluo-
rescence intensity (53). Conversely, if saturation occurs, the
membrane will not be able to accommodate any more
peptide, which will then remain in the aqueous phase.
Because acrylamide quenches preferentially the fluores-
cence of the aqueous phase peptide population, a weaker
progression of the fluorescence intensity, relatively to a non-
saturation state, should then be detected (53). This behavior
was indeed observed in the BP100 titrations (Fig. 3),
showing the occurrence of saturation: two different slopes
were obtained for each I versus [P] curve. The first slope
corresponds to a nonsaturated state while the second one,
which is similar to that of the curve in the absence of lipid,
can be ascribed to a saturation of the system. The saturation
points could be easily obtained from the breaks of the initial
slopes of each titration curve. It was observed that the I
versus [P] curve with [L] ¼ 125 mM had its saturation point
close to [P] ¼ 17 mM (Fig. 3), which is slightly higher than
the peptide concentration that yielded an I versus [L] curve
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with a deviation maximum close to [L] ¼ 125 mM
(Fig. 2 B). This result supports the hypothesis that the devi-
ations observed in the partition curves correspond to a satu-
ration of the membrane.
Further information from the saturation phenomenon was
obtained by representing the saturation point ([P],[L]) pairs
for the 2:1 POPG/POPC LUVs (Fig. 3, inset). This system
followed Eq. 3, which defines the total amount of peptide
at which a saturation point occurs as a linear function of
the amount of lipid in the system, and allows the calculation
of s—the P/L ratio at saturation—and the Nernst partition
constant Kp. However, it should be noticed that the values
for Kp have large associated errors because they are calcu-
lated from the reciprocal of a small intercept. Despite that,
the obtained Kp (8.41  104) had the same order of magni-
tude as that determined from the partition curve using the
model of Santos et al. (49) (3.08  104). In addition, the satu-
ration P/L ratio was 0.118, which corresponds to 8.4 phos-
pholipids per peptide directly in contact with the membrane
at the saturation. Because there are 2/3 anionic phospholipids
in the used system, there will be 5.6 negatively charged
phospholipids per peptide at saturation. Interestingly, this
number is very close to the expected charge of the peptide
(þ6) at pH 7.4, which suggests that electroneutrality is
reached at the saturation of the system.
There was no significant alteration in the tyrosine in-depth
location upon saturation, indicating that most of BP100
molecules maintain their positioning within the membrane.
The location of the tyrosine residue, approximately halfway
across the membrane leaflet, is coherent with a relatively
deep burying of the peptide if it adopts, as expected (40),
a horizontally oriented a-helical structure. The lysines have
the ability to snorkel and keep their charged amino groups
near the headgroup region (70,71) while the hydrophobic
side chains could go as far as the bilayer center. This local-
ization within the bilayer is likely responsible, at least in part,
for the membrane destabilizing capabilities of BP100.
Vesicle permeabilization studies
Investigations on the mode of action of AMPs, such as cecro-
pins and melittin, have shown that they exert their activity by
inducing the formation of transmembrane pores or by
causing cell lysis, depending on both the peptide concentra-
tion and the membrane composition (41–45). Moreover, it
has been reported that cecropin-melittin hybrids are also
able to cause membrane permeabilization (72,73). These
findings prompted us to test BP100-induced permeabiliza-
tion of model lipidic membranes.
Results showed that BP100 has an important permeabiliz-
ing effect dependant on peptide concentration. The increase
in the permeabilization rate with BP100 concentration is,
however, not linear (Fig. 4). The clear change of behavior
at ~15 mM peptide, toward faster, sigmoidal, and more
intense leakage kinetics—visible both in the permeabiliza-
tion kinetics (Fig. 4) and in the leakage percentage profile
at 390 s (Fig. 4, inset)—occurs very close to the peptide
concentration expected to cause membrane saturation for
the 125 mM lipid concentration (Fig. 3). These results
show that membrane saturation affects more than just the
amount of bound peptide: high P/L ratios at, or close to,
membrane saturation are able to induce a change in a func-
tional property of the peptide. The sigmoidal leakage kinetic
induced by BP100 is uncommon, as such profiles are usually
hyperbolic-like (74). Nevertheless, a similar kinetic was
recently observed for an unrelated AMP (74). In both these
cases, because the interaction with LUVs is not a limiting
step (Fig. 5, LUV traces), the lag involved in the sigmoidal
behavior may be related to postbinding events in the
membrane (74).
Further information was extracted by fitting the data with
the model used by Gregory et al. (59) to describe cecropin
A-induced leakage. This model was only used to fit hyper-
bolic-like kinetics, but, even in those cases (59), close
inspection of the model in the first seconds of each kinetics
does reveal a brief sigmoidal behavior. Upon fitting, the
magnitude of this behavior could only be manipulated to
match the timescale of BP100-induced leakage kinetics by
lowering the k1 and k2 constants of the model two-to-three
orders of magnitude, relative to the values obtained in Greg-
ory et al. (59). As these parameters are the rate constants of
pore forming/dissipation, this result suggests that, after
binding, BP100 becomes disruptive at a slower rate than ce-
cropin A.
The high degree of peptide-induced leakage after satura-
tion may reflect severe membrane damage or lysis, whereas
the lower permeabilization before saturation could reflect
a lesser destabilization of the membrane upon peptide
binding. High P/L ratios close to saturation would then act
as the trigger between these two states, and could be the
biophysical parallel to the in vivo onset of antibacterial
activity. This is supported by the fact that the threshold
dependence on peptide concentration (Fig. 4, inset) could
not be accounted for with data fitting without assuming
some kind of parameter change with increasing BP100
concentration—such as an increase in the mentioned k1
and k2 disruption rates. Although hypothetical, this scenario
is plausible, and stresses the importance of high local peptide
concentrations in the membrane.
Membrane translocation studies
The determination of the occurrence of membrane transloca-
tion is an important functional characterization: a nontranslo-
cating peptide can only exert its activity at the extracellular/
membrane level, whereas one crossing a membrane may also
have cytoplasmic targets. However, detection of transloca-
tion can be troublesome, and, although there are several
methods available, many require peptide derivatization or
have limited applicability (75).
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Despite there being other published methods where MLVs
are used to enhance an internalization effect (75,76), the
method developed in our work is extremely simple and
requires only that the peptide has intrinsic fluorescence and
that its interaction kinetics with LUVs are significantly faster
than its translocation kinetics; quencher enhancement is not
an absolute requirement. The results clearly showed a trans-
location behavior at both high and low P/L ratios (Fig. 5). As
predicted in Fig. 1 for a translocating peptide, the interaction
with MLVs was slower than with LUVs, but eventually
reached the same fluorescence increase. Occurrence of trans-
location is unequivocal and, together with the permeabiliza-
tion assays, constitutes a further proof of the membrane
activity of the peptide.
Vesicle aggregation and surface charge studies
Turbidity measurements have been described as an useful
tool to investigate the affinity of cationic peptides toward
charged vesicles (77). The stability of a dispersion of
charged vesicles is mainly governed by three types of forces:
electrostatic repulsion, van der Waals attraction, and hydra-
tion (77). Cationic peptides can alter the charge density of
the vesicle surface inducing vesicle aggregation, which can
be followed as an increase of the OD. Turbidity results
showed two different kinetic patterns depending on BP100
concentration (Fig. 6). For 125 mM lipid (2:1 POPG/POPC
LUV) and peptide concentrations <15 mM, which corre-
spond to a nonsaturated state, no significant changes in
turbidity were observed. However, when membrane satura-
tion occurs (R15 mM peptide), the optical density of the
solution increased until a plateau was reached, ~30 min after
the addition of BP100. This increase is likely due to vesicle
aggregation induced under membrane saturation conditions.
These results confirm the affinity of BP100 for acidic phos-
pholipids and reinforce the hypothesis that electroneutrality
is reached at the membrane saturation point.
These conclusions were confirmed using light scattering
methodologies: the change in the LUV suspension OD is
related to an increase in the average particle size from
100 nm—in the absence of peptide and up to saturation—
to >1 mm upon saturation (Fig. 7). In addition, z-potential
measurements in this range showed that BP100 brings the
LUV charge to approximate electroneutrality at saturation,
confirming the prediction based on the saturation proportion
(Fig. 8). This effect is certainly favoring vesicle aggregation
by canceling the electrostatic repulsion between them.
Partition, saturation, and prediction of MIC
During our recent investigations, we have found that minimum
inhibitory concentration, MIC, and saturation can be corre-
lated for peptides, such as omiganan (53). For this peptide,
MICs were found to be similar to the peptide concentration
needed to reach the saturation state, reflecting the existence
of possible saturation-triggered antimicrobial mechanisms.
Since findings from BP100-membrane interaction studies
also suggest that membrane saturation is important for the
activity of this peptide, we examined whether the results ob-
tained are in agreement with the experimental MIC values.
As previously reported (53), under typical bacterial titers
and using the MIC as the total peptide concentration, the
membrane-bound peptide concentration ([P]L) is given by
Kp  MIC. On the other hand, s can be determined as
[P]L  gL. Combining both expressions, the MIC can be
readily calculated as MIC ¼ s/(Kp  gL). Using the obtained
s (0.118) and Kp (3.08  104 or 8.41  104, from the parti-
tion and saturation studies, respectively) values, and consid-
ering gL as 0.763 M
1 (50), this equation leads to MIC
values of 2 or 5 mM, depending on the selected Kp. These
values are consistent with the antibacterial activity displayed
by BP100, which inhibited in vitro growth of the bacteria
E. amylovora, X. vesicatoria, and P. syringae at 2.5–7.5 mM
(38). In addition to validating the obtained values for Kp and
s, these results strongly support the correlation between these
constants and the MIC, evidencing the importance of the satu-
ration point in the mode of action of this peptide.
Physiological signiﬁcance of saturation-induced
activity
The obtained results clearly point toward the occurrence of
different membrane-disrupting events as saturation is
reached. Given the plausible correlation between saturation
and the onset of antibacterial activity of BP100, an extrapo-
lation of these events to an in vivo setting was sought.
Surface charge neutralization at saturation was found to
be an important occurrence, triggering the observed vesicle
aggregation, and probably being responsible for the destabili-
zation that led to an increase in membrane permeabilization,
as leakage enhancement correlates with vesicle aggregation.
The bacterial metabolism will certainly be sensitive to the
neutralization-induced loss of the membrane surface poten-
tial, as this will disturb the charge environment of the outer
leaflet proteins. The observed coupled permeabilization (if
not lysis) entails even further damage to the cell, namely the
dissipation of the transmembrane potential which, among
other effects, will halt ATP synthesis. Vesicle aggregation
may not have a parallel in vivo, as bacterial membranes
have additional layers of protection (LPS, peptidoglycan,
capsule) preventing direct membrane contact between
bacteria; its occurrence in vitro does, however, stress the
importance of the surface potential for membrane stability.
The observed translocation could be a consequence of the per-
meabilization or can be an independent event; either way,
direct interaction with cytoplasmic targets is yet another
possible cause of bacterial death.
Effects of BP100 exposure on cell viability
The experimental results from our studies show cytotoxic
effects in the cultured mammalian fibroblast cells at
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concentrations of BP100 above 50–60 mM (Fig. 9). This is in
good agreement with similar findings in human erythrocytes
(38), where an increased release of hemoglobin was
observed above 150 mM. Although the membrane integrity
in our V79 cells was affected at lower concentrations (IC50
¼ 51.1 mM), it probably just reflects the different cell lines:
different sensibilities to antibacterial peptides were also
found between human erythrocytes and mammalian COS-7
kidney cells (65), and might indicate a better resistance of
the human erythrocytes to this class of peptides (78). Results
from the MTT assay (Fig. 9) demonstrated changes in the
metabolic activity of mitochondria V79 cells, as the dehydro-
genase enzymes started to be less active to convert the
yellow water-soluble salt into insoluble formazan crystals
at increasing peptide concentrations. Whether this means
that there is a direct action on the mitochondria, or indirect
loss of mitochondrial activity, cannot be ascertained without
further investigation.
A successful application of this peptide as a bactericide
demands a high therapeutic index, i.e., a high antimicrobial
activity but low cytotoxicity. The high antimicrobial potency
(MIC ¼ 2.5–7.5 mM) and relatively low cytotoxicity in
human erythrocytes (38) reveals promising values for
BP100. Although cytotoxic effects were observed in V79
cells at peptide concentrations above 50–60 mM, this range
is still far above the anticipated antimicrobial application
levels.
Cytotoxicity against mammalian models is reached at
a concentration higher than the MIC by roughly the same
proportion that Kp values toward mammalian model bilayers
are lower than toward bacterial ones. This observation
suggests that cell killing may be dependent on a constant
local membrane-bound concentration, independently of the
considered lipid system.
CONCLUSION
This work clearly points out a correlation between high
membrane concentrations (possibly even saturation) of
BP100 and bacterial death. Three different potential causes
of activity of AMP, i.e., charge neutralization, permeabiliza-
tion, and translocation, were identified. In addition, a concen-
tration dependence of the killing phenomena, in bacteria and
in mammalian cells, was suggested. While the exact mecha-
nism of action of the peptide may remain elusive in vivo, and
depend on the peptide and bacteria species, our findings
unravel the bases of the closely coupled occurrence of those
causes, as experimentally observed by Friedrich et al. (79).
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My work and the AMPs
Work with omiganan and BP100 prompted the hypothesis that saturation,
or otherwise high membrane coverage, is somehow a requirement for
AMP activity in a general sense. But, from a functional perspective, why
should it be so? What is there that is intrinsically disruptive in the full
coverage of a bacterium? One can imagine several possible scenarios,
even ones in which bacteria become smothered by the peptide molecules,
which then clog any metabolite exchange routes in and out of the cell.
My view, however, after reading some of the work by Huey Huang
on threshold effects,49, 50 is that a high degree of membrane coverage is
needed to overcome the energy barrier involved in bringing together
the bound peptide molecules — this makes sense since the peptides are
heavily charged and likely to drift apart if there is room to. In turn, peptide
proximity increasingly destabilizes the bilayer: bound peptide molecules
can cause a local membrane thinning,* an effect that is amplified, potentially
to the point of disruption, when several molecules are forced together.50
This explanation has the advantage of not requiring the assumption of any
kind of specific peptide-peptide interactions in the membrane.
Under this perspective, the role of surface charge is that of the driv-
ing force that brings peptide molecules to the membrane even when the
already bound molecules have to lie close to each other. Charge neutraliza-
tion marks the limit upon which this force ceases to act. Rafael remarked
that the most charged peptides in the library he developed were not
*Membrane insertion of peptides, even if shallow, will cause separation of the phospholipid
molecules; as a consequence, either the involved acyl chains spread out and flatten to remain
in contact with each other, or the phospholipids from the opposing leaflet draw closer to fill
in the gap, or both.50 In any case, a local thinning of the bilayer is expected.
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necessarily the most active; that may be due to the fact that in those cases
the bacterial surface charge was neutralized before a high enough bound
concentration of peptide was reached. Interesting possibilities arise from
these considerations, namely that peptide action is ultimately dictated by
their charge, their membrane interaction properties, and their size.
In addition to this, the event of charge neutralization is also potentially
disruptive by itself: the complex environment of the membrane, where
important metabolic processes take place, will definitely be perturbed
by the loss of surface charge and the associated potentials, which will
certainly contribute to bacterial death.
* * *
A point I have not yet addressed is that of the model membrane composi-
tion. In myworkwith both peptides highly anionic phospholipid mixtures
have been used as models for bacterial membranes — 2 : 1 POPG : POPC
and even 4 : 1 POPG : POPC. Reported values51 for the in vivo mem-
brane content of anionic and phospholipids are lower than those I used,
lying between 30% and 40% — 3 : 7 is an anionic : zwitterionic phos-
pholipid ratio that seems to be growing in acceptance as a standard for
biophysical studies.52–54 The reason why I insisted on the use of highly
anionic models is of a practical nature: in less charged systems deviations
at high bound peptide concentrations simply become too faint for detec-
tion. In the end, some physiological significance was traded off for insight
into the threshold events of the peptides’ action. Of course, departure
from physiological conditions may invalidate this insight. However, if the
saturation-neutralization correlation holds for less charged models then
the effect of using highly anionic membranes amounts to having a pro-
portionally higher P:L ratio at saturation: for omiganan and BP100 the
expected saturation proportions at a 3 : 7 anionic : zwitterionic ratio are,
respectively, 1 : 16.7 and 1 : 20. These values still correspond to relatively
high concentrations and to high degrees of membrane coverage. The over-
all conclusions of the work can thus be shown to withstand the use of a
less-than-optimal membrane model system.
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Lastly, the possibility that the activity of many AMPs depends on
conditions at, or close to, saturation, is indeed corroborated by data
published on several peptides. Miguel, Rafael and I published a review
(Articlev, included ahead) on how our hypothesis successfully fits those
data. Ultimately, I hope that more than reporting a finished research our
work, reflected on that review, conveys the notion that there is now a
void in AMP characterization that must be filled.
End of Part I


Part II
Methods and Models
The other side
I have honored the commitment made in the thesis’ title and devoted
Part I entirely to my research on AMPs. Now, I will recount my PhD
work from an entirely distinct perspective. Much like some points in
the previous part, where omiganan and BP100 were regarded not as
the fulcrum of the research but as means to reach a more encompassing
knowledge on AMPs, the following text will describe how the two were
used to develop methods applicable beyond their immediate study.
The emergence of this side of my work was not specifically planned for
at the beginning of my PhD. Rather, I developed along the way — at first
unconsciously — a preference for the intellectual challenge in the devising
of new means to experimentally and mathematically wring information
from the studied systems.
The creation of new methods impacted more than just my work, as
I began assisting my colleagues in applying them to their peptides. This
was a very rewarding aspect because of both the recognition and the
opportunity to contribute to other people’s projects.
I am deeply thankful toMiguel for having let me foray into the method-
ological side of research, instead of limiting my work to the application
of established protocols. Throughout this process I always felt trusted by
him and this enabled me to become confident on the abilities I was acquir-
ing. I was extremely fortunate to begin my career under the supervision
of such a scientist and professor.
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4. Partition
Much of my work revolves around the notion of partition, which is
nothing more than the application of the concept of chemical equilibrium
to the distribution of a solute between immiscible phases. According to
the view we follow at the lab, the same principles can be used to interpret
the interaction of peptide molecules with the phospholipid bilayers of
vesicles. It does take a leap of faith to consider the thin bilayers to be
equivalent to spherical shells of an immiscible liquid phase but I believe
it to be a short leap compared with other approaches where specific
lipid-peptide binding stoichiometries are assumed.
4.1 The partition constant
The formalism of partition is rooted on thermodynamic grounds and
provides an equilibrium constant with which one can characterize a
system. This constant is termed ‘partition constant’ and the definition
that I will follow is based on the studies Marcelin Berthelot and Emile
Jungfleisch,55, 56 and later Walther Nernst,57 carried out in the 19th century.
According to their work, the ratio, at equilibrium, of the concentrations
of a solute in each of two immiscible phases is a constant; these phases are
here realized as a lipidic one — the vesicles’ membranes — and an aqueous
one — the bulk phase, the peptide being the solute:
Kp =
[P ]L
[P ]W
(4.1)
Kp is the partition constant of the peptide for themembrane-water system.
[P ]L and [P ]W are the concentration of peptide in the lipidic and aqueous
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phases, respectively. Note that these are local concentration in each phase,
not concentrations over the whole system volume.
The physical meaning of Kp is quite easy to understand from Equa-
tion 4.1. The partition constant reports how much more, or less, concen-
trated the membrane-bound peptide gets relative to the peptide in the
aqueous phase. AMPs haveKp values in the order of 104 to 105 towards
vesicles that mimic bacterial membranes (see Article v for some exam-
ples), which means the peptides get 104- to 105-fold more concentrated in
those bilayers than in the bulk aqueous phase.
By manipulation of Equation 4.1 we arrive at another important rela-
tionship:
XL =
KpγL[L]
1 +KpγL[L]
(4.2)
XL is themembrane-bound peptide fraction, or the ratio of the lipid-bound
peptide molecules over the total peptide; [L] is the global phospholipid
concentration, obtained after approximating the aqueous phase volume as
the total system volume — an acceptable shortcut even for the most con-
centrated vesicle suspensions used in studies with peptides. Equation 4.2
establishes a bridge between Kp, the bound peptide fraction, and the
lipid concentration, which is an independent variable of the system. As
such, Equation 4.2 is frequently at the core of methods to experimentally
determine Kp. The equation also emphasizes an important property of
peptide-membrane interaction: for a given lipid concentration the bound
and unbound fractions are constant and do not depend on the global
amount of peptide. The consequence is that if we increase the amount
of peptide (all other variables remaining constant) in a water-vesicle-
peptide system, the number of peptide molecules in both phases will rise
proportionally to the increase, and so will the local concentrations. These
implications will be explored later on.
Also of importance are the conditions for which Equation 4.1 holds.
Nernst pointed out that Equation 4.1 was only valid so long as the solute
under consideration does not establish significant secondary equilibria
in either phase — for example by ionization, oligomerization or even
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change of conformation.57 When such equilibria do take place each species
must be considered as having a Kp value of its own. For simplicity,
AMP-membrane binding studies do not usually take these aspects into
consideration, implicitly assuming that peptide molecules either exist in
a single ionization state or that all different states will partition with
the same affinity. Changes in peptide conformation or multimerization
— usually taking place in the membrane — are dealt with differently: in
my work the assumption that only one of the forms of the peptide is
able to partition in and out of the membrane yielded good results (see
Section 5.3), but in other cases that might not be valid. A last requirement
of Equation 4.1, not explicitly stated in the seminal works of Berthelot,
Jungfleisch and Nernst, is that both phases are ideally dilute solutions
(meaning that solute-solute interactions are negligible), and therefore that
the chemical potential of the solute changes linearly with the logarithm
of its molar fraction.58 It is only then that the partition constant really is
constant.* As will be seen later, violation of the precondition of ideally
dilute solutions led to very interesting results.
4.2 DeterminingKp
The methods for experimentally determining partition constants were,
like the formalism of partition, the basis of much of my work. It is thus
important that I describe the general approach for obtaining Kp even
though I had no actual role in its design.
At the lab we traditionally use fluorescence spectroscopy to measure
partition constants. This is well suited to study peptides, which are
frequently natively fluorescent due to the presence of tryptophan, tyrosine,
or phenylalanine residues. Fluorescence can be used to track the binding of
the peptides because the fluorescent moieties are sensitive to the polarity
*The thermodynamic basis of the partition equilibrium further states that it is the ratio of the
solute molar fractions in each phase that is constant, not the ratio of its molarities.58 Conversion
to a concentration ratio constant is also based on the assumption of ideally dilute solutions (see
the Supplementary Material of Article vi for an assessment of the error introduced when
that assumption is not valid); the two constants, however, are not equivalent.31
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of the environment the peptide is in: as the peptide binds the membrane
and comes into contact with the apolar portion of the bilayer there will be
a solvent effect that destabilizes the excited state, increasing its energy (the
slow-moving acyl chains cannot reorganize as fast as water in response to
the change in the molecule’s dipole moment upon excitation). Interaction
with the membrane also means the fluorescent groups are less likely to be
exposed to collisions by ions or the polar water molecules, which prolongs
their fluorescence lifetime and increases their quantum yield. Thus, the
fluorescence emitted by the peptide is expected, as a result of binding, to
increase in intensity and to shift to shorter wavelengths (the shift being
usually only observed with tryptophan). Other less common cases, such
as a reduction in the fluorescence intensity, are possible — imagine, for
example, a fluorescence residue that sits in a hydrophobic pocket of a
peptide or protein and that becomes exposed after a conformation change
that takes place in the membrane. To the determination ofKp, however,
all is needed is that there is a measurable difference in the fluorescence
emission of the peptide upon interaction with the membrane.
The fact that the populations of peptide in each phase have distinct
fluorescent behavior allows the whole ensemble to be observed simulta-
neously; there is no need to physically separate the phases to proceed
to the quantification of the peptide in each one. The global fluorescence
intensity* I is given by:
I = XLIL +XW IW (4.3)
IL and IW are the fluorescence intensities the peptide would display if
all its molecules were in either the lipidic or the aqueous phase; XW
is the water counterpart of XL (because only two phases are assumed
XW = 1−XL). Equation 4.3 simply states that the observed fluorescence
intensity is the sum of the maximum intensities from the two phases,
weighed by the fraction of peptide in each. Equation 4.2 can be combined
*It must be noted that the method involves fluorescence intensities but not wavelengths, which
means that the frequent spectral shifts are not accounted for. To avoid the introduction of an
error the area of the whole spectrum should be taken for the fluorescence intensity, instead of
the value at a single wavelength.
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with Equation 4.3 to link, through Kp, the observable (the fluorescence
intensity) to the independent variable (the lipid concentration):
I =
IW +KpγL[L]IL
1 +KpγL[L]
(4.4)
Equation 4.4 is appropriate for experimental determination ofKp. How-
ever, besides Kp, IL is also an unknown parameter. This means that at
least two data points at different values of [L] must be collected (IW
can be obtained experimentally and 0.76m-1 was taken from reference
59 as an approximation of γL for fluid membranes). The preferred setup
at the lab involves the titration of a peptide solution with vesicles. This
has several advantages, namely by saving peptide and by including the
measurement of IW , which is the point before any addition of lipid.
Still, the fact that Equation 4.4 depends on IW and IL makes the
data points also dependent on the amount of peptide. By representing
the normalization of Equation 4.4 to IW the points become robust to
the peptide concentration and the results of separate titrations will be
superimposable, even if the peptide concentrations differ:
I
IW
=
1 +KpγL[L]
IL
IW
1 +KpγL[L]
(4.5)
Normalization to IW also transforms IL — which has little meaning on
its own — in the IL/IW ratio. This is a much more informative value
that reflects the change of the fluorescence quantum yield of the peptide
upon binding the membrane. Although I haven’t frequently done so, the
IL/IW ratio can be used, alongKp, to characterize a peptide-membrane
interaction.
The extraction of Kp from titration data points can be done in many
ways, but the most common is to directly perform a non-linear fit of
Equation 4.5 to the data. According to Equation 4.5 the dependence of
I/IW on [L] is translated into a hyperbolic-like curve (see Figure 2.1),
unsurprisingly called a partition curve. The shape of this curve results
from the increase in fluorescence of the peptide as the adding of vesicles
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drives more and more molecules to the lipidic phase. An asymptotic
plateau (IL/IW ) is approached when most of the peptide is already
bound; there is no more peptide available to bind the membrane even if
much more lipid is added.
Another aspect of the titration process is that for every addition of lipid
(disregarding any changes in volume) and consequent binding of peptide
molecules, there will be a decrease in their bulk phase concentration. From
the definition of Kp in Equation 4.1 we can see that such a reduction of
[P ]W must be accompanied by a proportional drop in [P ]L. Thus, adding
lipid to a system will lower the peptide concentration of both phases. A
consequence of this fact is that the peptide will be most concentrated in
the lipidic phase when [L] → 0. This means that partition curves start
out with high local peptide concentrations in the membrane, which are
then gradually diluted as [L] increases.
* * *
Up to this point I have addressed the long established theoretical and
experimental bases of the partition formalism as it is adapted to the
characterization of peptide-membrane interactions. From here on I will
describe mostly those methods in whose development I was involved.
4.3 Alternative methods
Adifferentway to obtain the partition constant frompeptide-lipid systems
was devised by Miguel (I admit that my contribution here amounted to
the validation of Miguel’s conclusions using my data). It is a method
based on the light-scattering measurements of the ζ-potential of peptide-
vesicle mixtures. I include this description here for consistency with the
chapter’s contents, but rather anachronistically as the actual development
of the idea took place well into the last year of my PhD.
The ζ-potential can be understood as the susceptibility of a particle to
be electrophoretically displaced. It reflects the global surface charge of
that particle, taking into account the exchange of each counterion — the
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tighter a counterion binds the particle, the more effectively will it mask its
charges. Negative potentials correspond to anionic surfaces and positive
potentials to cationic ones.
ζ-potential measurements are frequently used to assess the importance
of electrostatic interactions in the binding of peptides to charged vesicles.
In this case, the particles in suspension whose ζ-potential is measured
are the vesicles as their size makes them much better scatterers than the
peptide molecules. Measurements are usually carried out for several con-
centrations of peptide, while the vesicles’ concentration is kept constant.
Vesicles containing anionic phospholipids typically display a markedly
negative ζ-potential that increases with the peptide concentration (this
description assumes the most common case of the interaction of a cationic
peptide with an anionic vesicle) until a plateau is reached close to 0mV.
Miguel set out to extract partition constants from this kind of data. I,
however, was skeptical: there is not enough information in a titration of
lipid with peptide to allowKp determination from fluorescence measure-
ments. This is so mainly because there is a second unknown in the system,
IL. I thought the same would apply to ζ-potential but Miguel proved
me wrong. In these experiments we know the charge of the peptide and
the charge and proportion of the anionic phospholipids; there is no IL or
analogous unknown parameter involved.
From the vesicles’ potential in the presence and absence of peptide
a relative reduction of the surface charge can be calculated. Miguel
pointed out that this reduction (in absolute value) reflects the proportion
of anionic phospholipid charges that is neutralized. This is translated by
Equation 4.6: ∣∣∣∣∆ζζ0
∣∣∣∣ = nPL−neutralizednPL−total (4.6)
where ∆ζ
ζ0
is the relative reduction in potential (as a function of the
global peptide concentration, [P ]), nPL−neutralized is the number of anionic
phospholipids whose charge has been masked, and nPL−total is the total
number of anionic phospholipids.
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If we make the (somewhat risky, but necessary) assumption that each
cationic charge of a bound peptide molecule completely masks one of
the phospholipids’ anionic charges, we can convert nPL−neutralized into the
number of bound peptide molecules (npeptide,L):
nPL−neutralized
= npeptide,L · zpeptide (4.7)
where zpeptide is the global charge per peptide, in absolute value. The
denominator of Equation 4.6 can be replaced by the total amount of phos-
pholipids (nL) multiplied by the proportion of anionic ones (fPL−); the
resulting expression can be readily transformed to include XL (dividing
numerator and denominator by [P ]):∣∣∣∣∆ζζ0
∣∣∣∣ = npeptide,L · zpeptidefPL− · nL = XL · zpeptidefPL− · [L] · [P ] (4.8)
The bridge between ζ-potential andKp is finally established by combining
Equation 4.8 with Equation 4.2:∣∣∣∣∆ζζ0
∣∣∣∣ = Kp · γL · zpeptidefPLc(1 +Kp · γL · [L]) · [P ] (4.9)
The symbol fPL− was replaced by fPLc , to mean ‘fraction of charged
phospholipids’, making the equation independent of the assumption of
an anionic vesicle. Equation 4.9 represents a straight line that crosses
the origin. Kp can be obtained from its slope. It should be noted that
the equation is only applicable to the rising portion of the ζ-potential vs
peptide curves: the reaching of a plateau usually signifies complete charge
neutralization, which is not contemplated in this model.
Equation 4.9 proved adequate to describe the data. Its application to
the ζ-potential data of BP100 returned a value ofKp of (56.4±0.9)× 103,
within less than 10% of my most thorough determination by fluorescence.
It is a shame that this method was only developed after the publication of
Article iv, which does include the ζ-potential data.
The successful application of the method leads us to suspect that the
assumption ‘one peptide charge – one neutralized phospholipid’ is actually
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valid. The obtained value of Kp, with a magnitude of 104, represents a
strong binding, and this too contributes to the validity of the assumption:
tightly-bound counterions mask the particles’ charges more completely.
This, however, raises the possibility that the approach may not be as
successful when applied to weakly-binding peptides.
* * *
At the end of my work with omiganan Miguel and I set out to better
characterize the influence of the bacterial peptidoglycan on the inter-
actions of the peptide. This was particularly important for omiganan’s
action because, unlike BP100, it can also target Gram-positives. These
bacteria have the thickest cell walls,60 in some cases with peptidoglycan
widths up to 80 nm. We wanted to know if this huge anionic structure
(I can now say I have worked with the largest naturally-occurring cova-
lent molecule!) could in any way sequester the peptide and prevent its
interaction with the membrane. To answer this question I tried to obtain
something akin to a Kp to quantify the affinity of omiganan towards
the peptidoglycan. I learned that if the peptidoglycan is considered a
solid phase, similar to a chromatography resin, the binding equilibrium is
subject to pretty much the same rules as the partition to vesicles.61 After
finding a value for the peptidoglycan mesh density62 I was even able to
arrive at a concentration-ratio binding constant (termedDv) comparable
toKp (see Article iii).
I soon discovered that an approach to obtainDv based on the titration
of the peptide with peptidoglycan would not work: the interior of the
peptidoglycan mesh, being flooded with water, is not a very different
environment from the outer bulk phase. The behavior of the peptide’s flu-
orescence was little affected by binding, which prevented the application
of the method. In addition, I faced a practical problem: I was working
with S. aureus peptidoglycan extracts that, judging from their intense
tryptophan-like fluorescence, had a lot of residual protein. Even if the
peptide fluorescence changed upon binding, this would most likely be
masked by the intense background.
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The solution was to separate the solid and liquid phases by centrifu-
gation and proceed to the quantification of the peptide in one of them.
When needed, the application of this approach to vesicles is quite trou-
blesome because their density is too close to that of the water to allow
a successful centrifugation. Peptidoglycan, however, readily sinks to the
bottom of a vessel, even at room g’s.
Before I could put the method into practice I had to find a way to
make the peptidoglycan suspension more homogeneous. The size differ-
ences in the particles were clearly visible to the naked eye, with actual
chunks floating about. Both bath- and power sonications did not work;
besides, I was afraid this technique would promote the release of protein
contaminants from the mesh. Crushing of the powder between glass
plates yielded better results. Still, much of the powder would stick to
the glass, interfering with quantification, and other portions would form
planar chunks, defeating the purpose of the process. After a few weeks,
the solution was provided by Margarida Rodrigues — my good friend
and scientific neighbor, then at the Free Radicals, Health, and Nutrition
Group, in the Faculty of Sciences, and now at the Biomembranes Unit, in
the IMM — who spent some hours helping me mold glass rods into the
appropriate shape to softly mash the peptidoglycan powder at the bottom
of a conical plastic tube.
After a homogeneous suspension was obtained, it was just a matter of
incubating different volumes of it with aliquots of omiganan and centrifug-
ing. The peptide could be successfully detected in the supernatant, even
though some contaminant fluorescence did creep up (the use of controls
without peptide was enough to correct it). The results could be well fit
by a simplified version of Equation 4.3 where only the aqueous phase
is considered. The mathematical link between Dv and XW is deduced
in Article iii. The fitting equation is significantly simplified relative to
Equation 4.5 because, the phases having been separated, there is no IL
parameter — or Ipeptidoglycan, if you prefer. The non-linear, least squares
fit of the equation to the data is not perfect, but still remarkably good for
a one-parameter regression.
The fit returned a Dv about one order of magnitude lower than the
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Kp of the peptide binding to anionic vesicles. As the peptidoglycan
in a Gram-positive has a proportionally larger volume than that of the
membrane, a similar overall amount of peptide can be expected to bind
the two bacterial constituents — this is a conclusion that will be important
later on.
To me, however, the successful determination ofDv was rewarding in
itself. It represented the design of a complete method — one of my first —
from the theoretical conception to the practical implementation.
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The partition model accounts for fairly ideal systems where the peptide
does not get close to saturation in the membrane. But a model is only
as strong as its assumptions. As described in Part I, deviations were
observed almost as soon as I started measuring partition curves.
The partition curves of omiganan with anionic vesicles, and later those
of BP100, were “plagued” by spikes or humps (see Sections 2.1 and
3.2). Initially, Miguel and I put forward many explanatory hypotheses
but most, like multiple partitions within the membrane or some sort of
self-quenching occurring only at intermediate concentrations, were a bit
far-fetched and difficult to test.
We then turned to what we were most certain of: the deviations oc-
curred early in the partition curve— inmost cases therewere even enough
remaining points to describe a hyperbolic-like variation (see Figure 2.2).
This indicated the deviations occurred as high bound concentrations were
reached (remember one of the implications from the definition of Kp:
peptide concentrations in the membrane increase as the concentration of
lipid decreases). Something was causing the peptides to either fluoresce
more or bind more above a given concentration.
This way of visualizing the process of binding prompted for an experi-
mental setup inverse of that of the partition curves, in which peptide is
added to vesicles. Under normal partition circumstances such a titration
should yield a linear increase of the fluorescence intensity: from Equa-
tion 4.3 we can see that I depends on the bound and unbound peptide
fractions and on the magnitudes of IL and IW . Equation 4.2 tell us
that, since [L] is being kept constant,XL (and, by definition,XW ) must
remain constant. Because IL and IW , the fluorescence intensities of the
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fully bound and unbound peptide, are proportional* to the total peptide
concentration, I will also be so. I expected to see an upward deviation to
linearity after a certain point in that line, corresponding to the hypothe-
sized increase in binding or in fluorescence output — such an observation
could be a starting point for the characterization of the phenomenon. It
turned out that the titrations with peptide did put me on the right track
but not at all with the results** I expected.
5.1 Saturation curves
Titration of vesicles with peptide (the one in question at the time of these
experiments being omiganan) produced almost perfect straight lines. At
best, a slight downward deflection could be observed after the midpoint
of titration. It was ironic that the moment I wanted to observe a system
misbehave it neatly yielded canonical results. But I did not give up.
The system I was using (4 : 1 POPG : POPC — see Figure 2.2) induced
relatively low humps: it could just be that the increase I was expecting to
see was too inconspicuous to be detected using that experimental setup.
I insisted on the method, this time after soaking the whole system in
acrylamide. Acrylamide is a good quencher of either tryptophan or tyro-
sine fluorescence, but interacts very poorly with membranes, quenching
only exposed fluorophores — it is actually frequently used to gauge in-
depth insertion of peptides. I expected that acrylamide might enhance the
deviations to linearity by selectively affecting either the pre- or the post-
deviation state of the peptide. At the time, inspired by interaction models
in which peptide molecules internalize to form pores, I imagined omiganan
would be driven inward, and away of acrylamide, at that post-deviation
state. This should lead to an upward deviation to linearity, as illustrated
in Figure 5.1a. I obtained the exact opposite result — Figure 5.1b.
*A linear relationship between emission intensity and fluorophore concentration is assumed.
Loss of linearity may occur because of inner filter (the fluorophore absorption significantly
dims the excitation light within the sample) or self-quenching effects, none of which occurs at
the micromolar peptide concentrations that were used.
**Almost all the results mentioned in this chapter can be found in Articles iii and iv.
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Figure 5.1 –A: Predicted results of a titration of anionic vesicles with omi-
ganan in the presence of acrylamide. The peptide was assumed to burrow
into the membrane above a threshold concentration. B: Results obtained
with the setup described for A; vesicles composed of 4 : 1 POPG : POPC,
at a concentration of 75 µm; acrylamide at 300mm.
I was extremely surprised by the outcome, but at once realized what
it meant: there is a point when the membrane becomes saturated and
further added peptide remains in the aqueous phase, fully exposed to
acrylamide. I would have never imagined, however, that this point could
be reached with micromolar peptide concentrations.
Evoking saturation raised more questions than it solved. Was it really
saturation that had occurred? Was there a correlation between saturation
and the deviations? And if the membrane was saturated and some peptide
molecules were being left out of the interaction, how come there was
an overshoot above the partition curve instead of a depression? Also
disguising as a question was the important hypothesis we would later
stand by: could such an extreme event as the complete coverage of the
membrane have physiological significance?
First things first, I needed to make sure the phenomenon was indeed
saturation. It was possible, though unlikely, that we were simply looking
at a different organization of the peptide in the membrane; one that
completely exposed it to acrylamide, resulting in a flat post-break segment
in the curve. This hypothesis was dismissed by a partition curve also taken
in the presence of acrylamide: the hump persisted; were it to represent an
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exposed state it should have been abolished by the quencher. (But why no
increase correspondent to such hump had been observed in the titration
of lipid with peptide I did not know). Measurement of more of these
titrations provided further evidence of saturation. The phenomenon was
shown to be related to a concentration-dependent threshold: titrations in
the presence of little lipid arrived at a break sooner (in peptide amounts)
than those with a large amount of it. Miguel and I decided it was
legitimate to start calling the titrations ‘saturation curves’.
5.2 Further characterization
Saturation invalidates the partition formalism: Equation 4.1 makes no
allowance for a saturated phase because if only ideally dilute solutions are
considered solute molecules are always free to enter any of them. Because
of this, theKp value that dictates binding at lower peptide concentrations
is no longer valid at saturation — it made sense that this phenomenon was
behind the deviations to hyperbolic partition curves. Indeed, I was able
to neatly correlate the breaks in the saturation curves with the deviations
in the partition curves. As stated earlier, the shape of partition curves
that are normalized to IW should not depend on the overall peptide
concentration because the fraction of bound peptide (XL) only depends
on the lipid concentration. Yet, if the deviations resulted from membrane
saturation they had to depend on the bound peptide concentration ([P ]L).
Having a constant XL implies that [P ]L will change proportionally to
the total peptide concentration, and this meant that I should be able
to influence the occurrence of the deviations in partition curves simply
by varying the initial peptide concentration. This time, as shown in
Article iii, the results did come out as I had predicted: the lower the
peptide concentration in a partition curve, the sooner, in terms of lipid
concentrations, were the spikes observed — and vice-versa.
At this point I had an important insight: given the linearity of the
saturation curve up to the saturation point it seemed that the partition
formalism was valid in that region. Above the saturation point peptide
distribution between the two phases was taken over by whatever order
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ruled that state. It was reasonable to assume that these two distinct
partition behaviors were equivalent at the saturation point.
Finding the binding distribution under saturation was straightforward.
It is easy to see that when the membrane is saturated the amount of bound
peptide must be proportional to the total amount of lipid — double the
lipid available for interaction and the amount of bound peptide will also
double (with the consequence that the local peptide concentration in the
membrane will remain constant, which makes sense since the phase is at
maximum capacity). From npeptide,L ∝ nL we can easily get to the value
of the bound peptide fraction under saturation (XL,s):
XL,s =
σ[L]
[P ]
(5.1)
where σ is the proportionality constant between the lipid and the bound
peptide molecules (we called it saturation proportion, hence the sigma).
Following the assumption that both distributions would be equivalent
at the saturation point I equated XL,s from the equation above to XL
from Equation 4.2. As a result I obtained a relationship between lipid
and peptide at the saturation point.
[P ]sat =
σ
KpγL
+ σ[L]sat (5.2)
The sat subscripts were added to [P ] and [L] because this equation is
only applicable at the saturation point.
According to Equation 5.2 there is a linear relationship between the
global amounts of lipid and peptide at the saturation point. Furthermore,
the relationship allows the extraction of the values of bothKp and σ from
saturation data. And data would not be a problem because by the time I
arrived at this equation I had already taken several saturation curves. I
immediately attempted to fit Equation 5.2 to the saturation points of those
curves and the results were very exciting: the points aligned very well
and the extracted parameters were in good agreement with saturation (a
lipid-to-peptide-ratio of 5.9). The value ofKp, however, was one order of
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magnitude higher than previous estimates. I could blame the very small
intercept for the inaccuracy, as its inverse was required for calculating
Kp; still, I was a bit skeptical. Miguel, on the other hand, was optimistic.
I recall he remarked something like: “You designed a model, almost from
scratch, that could returnKp and σ values anywhere from minus infinity
to plus infinity. The fact that they landed on reasonable numbers, very
much so in the case of σ, is more than could be asked for”.
Indeed, in spite of early skepticism I became very proud of Equation 5.2,
a successful attempt at model customization. However I soon found out
this was not a pioneering achievement. A few months after I derived
Equation 5.2, I came across a paper,63 published years earlier by Tanja Pott
and coworkers, where a similar relationship was used with the peptide
melittin. Therewas nomention to saturation in that paper: the used points
were critical disruptive thresholds that occurred at given concentrations
of melittin in the membrane. Also,Kp was not explicitly included in the
equation — but the authors did describe how to obtain it. Lastly, the
authors had derived their equation from assumptions distinct from mine.
Still, it was basically the same equation. I was a bit upset but managed
to find some value in having been able to arrive at my own equation and
from a different starting point. And I did learn that such linear equations
are valid for any event that occurs at a specific local concentration of
peptide; one just has to replace sat with the appropriate subscript.
To compensate for the mild disappointment, Equation 5.2 provided the
ultimate evidence linking the deviations in partition curves to saturation.
As mentioned before, I had taken several partition curves at different
concentrations of peptide. I plotted the ([P ], [L]) pairs corresponding to
the deviation maxima of those curves, and compared the result with the
plot of the saturation points (Article iii – Figure 6). There was an almost
perfect alignment: both events corresponded to the same phenomenon.
5.3 Extended models
My next challenge would be to devise a way to fit whole partition curves,
including the deviations. Up until then I had only been able to extract
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information by fitting the non-saturated segment of the curve or by using
the deviation maxima.
My first attempt involved the description ofXL by a piecewisefunction.
One of the pieces would be given the definition in Equation 5.1 and the
other by the definition in Equation 4.2. Both should be equivalent at
the saturation point (for the remainder of this chapter the fraction of
bound peptide under and outside of saturation conditions will be denoted
XL,s and XL,ns, respectively; XL will be used to generally denote the
bound fraction irrespectively of its saturation state). The implementation
of the idea amounted to take XL as the minimum of XL,s and XL,ns.
Application of Equation 4.3 to obtain the global fluorescence intensity
as a function of [L] resulted in a curve equation determined by three
parameters: Kp, σ and IL (Article iii – Figure 7a). This approach,
however, emphasized a so far unaddressed issue: because saturation
limits the amount of peptide that can bind, an overshoot can never be
accounted for without additional assumptions. The following step was to
hypothesize some sort of reorganization of the peptide upon saturation
that led to an increase in the bound fluorescence. This required the
introduction of a second fluorescence contribution to the model, which
was termed IS (for the fluorescence intensity all the peptide would display
if it was bound and in the saturated state). The bound peptide would
emit with an intensity proportional to IS when under saturation, and
to IL otherwise. By using a value for IS greater than IL I was able to
generate partition curves with an overshoot at saturation (Article iii –
Figure 7b). Still, this was not a satisfactory solution: there would be a
discontinuity at the saturation point that, besides being unnatural, did
not fit the observed data. I had to make the model more complex so that
it would account for some sort of transition between the saturated and
non-saturated states.
So far I had assumed in the curve models that the humps occurred due
to saturation and that they represented an alternative conformation with
higher quantum yield (and by alternative conformation I meant anything
from a structural rearrangement to movement within the bilayer — I did
not want to commit to a particular view). It then came to me that it was
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unlikely that the transition of the bound peptide to that conformation
happened all at once. Rather, a gradual progression to the saturated
state was more plausible and could explain the softness of the deviations
in the partition curves, as opposed to the sharp transition of the two-
piece model. Because we were dealing with saturation I hypothesized
that the conformation change that took place involved a reduction of the
bilayer space occupied by each peptide. This meant that there would be
a point above which the two conformations of bound peptide coexisted;
any added peptide would push more of the bound molecules into the
saturated conformation. The membrane would be able to take up peptide
as long as the available space wasn’t completely occupied by molecules
in the saturation conformation. The mathematical description of this
intermediate situation between excess lipid and full saturation — a bit
more complex than the previous cases — is carried out in the appendix of
Article iii. In the end I arrived at a three-piece, five-parameter equation
that could do a relatively good job at fitting whole partition curves
(Article iii – Figure 7c). In addition to the already introducedKp, σ, IL,
and IS I had also to include the parameter S: the bound concentration
above which the saturation conformation was induced.
The fit results were in very good agreement with previous determina-
tions of either Kp and of σ. Furthermore, σ could now be determined
from a single titration, no longer requiring multiple saturation curves. I,
however, felt that a five-parameter equation was a somewhat dirty way
to fit just about anything and was not confident in its application. I had
looked at the whole enterprise mainly as a challenge to find a plausible
model for the data and just because in the end the model did fit it did
not mean it was valid. Manuel Prieto, Miguel’s PhD supervisor (which
makes him akin to a scientific grandfather) and a close collaborator of
our group, disagreed of my position — I must thank Manuel for having
always been enthusiastic about my work, in these and in other occasions.
He pointed out the fit-worthiness of the equation: the saturated and
the non-saturated segments of the curve were only dependent on two
parameters each; only the very short intermediate state and its boundaries
depended on all five parameters. This realization gave me confidence to
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Figure 5.2 – Fitting of the three-state model to the entire partition curve
of 10 µm BP100 with 2 : 1 POPG : POPC vesicles (unpublished). Ex-
tracted parameters were: Kp = (46±14)× 103, IL/IW = 3.80±0.09,
IL,s/IW = 4.55±0.29 σ = 0.11±0.01, and S = 88±11mm.
describe the model in Article iii but not enough to later apply it to BP100.*
I now regret not having used it to fit the partition curves of BP100 before
Article iv was published — the results also agreed with measured Kp
and σ (Figure 5.2) and their inclusion would have added value to both the
article and the model. It serves me well for my skepticism. To compensate
for this less positive note I may add that recent developments, described
ahead, have presented the opportunity to put this method to a use far
more interesting than mere parameter determination. The ‘three-state
model’ will certainly be mentioned in upcoming publications.
5.4 Unpublished results
Recent observations have shed more light on the events surrounding the
occurrence of saturation. One of those was made when Rafael, who
*Back then I was fitting this model using a makeshift least-squares approach coupled to
Microsoft Excel’s solver — I was not totally confident on the output. I have since adapted the
model to be non-linearly fitted as a piecewise function by Systat’s SigmaPlot; despite its more
advanced solution-searching algorithms the results are practically the same.
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re-visited Lisbon for a short spell, and I were looking for alternative
ways to measure saturation curves — the reason why will be given in
Section 6.2. Of the biophysical parameters that changed upon saturation
the one most closely linked to the phenomenon was the optical density
of the vesicle suspensions. Indeed, saturation curves of BP100 could
be obtained from the optical density of the sample, and Equation 5.2
successfully applied (Figure 5.3). The data presented in Figure 5.3 result
from fluorescence intensity and OD measurements of the same sample,
which means that acrylamide had to be used. OD-only saturation curves
have also been obtained; in this case not only is acrylamide unnecessary,
but the measurement can also be carried out in an absorbance plate reader,
which significantly simplifies data acquisition.
Intriguingly, two breaking points are visible in the OD saturation
curves. At first we assumed the saturation point to lie midway between
the two; after comparisonwith the fluorescence intensity curves, however,
it became clear that it is the second breaking point that corresponds to
saturation. What, then, was the meaning of the first point? I now
believe it is the equivalent, in the OD curves, of the beginning of the
intermediate state hypothesized in the previous section. Corroborating
this interpretation is the fact that an ever-so-slight upward deviation in
the fluorescence curves occurs alongside the first breaks in the OD curves.
In fact, this is the very deviation I was expecting to see the first time
I measured a saturation curve! Such faint breaks are likely caused by a
small increase in quantum yield upon saturation. From the results of the
application of the three-state model to BP100 (Figure 5.2) that increase
is indeed expected to be only of ~20%. It is interesting that titrations of
peptide with lipid (partition curves) allow the observation of deviations
by fluorescence while the inverse setup (saturation curves) does not. On
the other hand, saturation is only clearly visible in the latter. The bottom
line is that in this kind of binding studies it matters which variable —
lipid or peptide — is scanned, and that complementary information can
be obtained from both approaches.
Another unpublished advance to a better understanding of saturation
explores that same concept. It involves the results of CD experiments
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Figure 5.3 –Saturation curves of BP100 with 2 : 1 POPG : POPC vesicles, obtained from
fluorescence intensity and optical density measurements (full and empty symbols, respectively;
unpublished). The lipid concentration at the beginning of the titration is indicated in each
panel. The breaking points of each curve are plotted in the lower-right panel and fit by
Equation 5.2; empty squares: first breaking point of the OD curves; empty circles: second
breaking point of the OD curves; full circles: breaking point of the fluorescence curves. The
extracted fit parameters are, respectively, σ = 0.110±0.005, Kp not determined (too large
associated error); σ = 0.136±0.007, Kp = (39.4±9.2)× 103; and σ = 0.175±0.009,
Kp = (166±100)× 103. In some of the fluorescence saturation curves an upward deviation
is visible alongside the first breaking point of the OD curves. It can also be seen that this
method is not well suited to the determination ofKp values.
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carried out in Karlsruhe, which have been partly described in Section 3.4.
Most of the NMR and CD protocols implemented in Karlsruhe relied on
varying only the peptide concentration. CD has a narrow dynamic range
and data quality heavily depends on peptide concentration*; titrations
with peptide, frequently covering more than one order of magnitude
of concentrations, meant that some of the spectra had to be taken at
suboptimal conditions. A second problem arose from the fact that high
lipid concentrations would be used, within the limits imposed by the
technique; the objective of such high concentrations was to promote
maximum peptide interaction in order for the bound structure to be easily
detected; however, under such circumstances crossing the saturation
threshold would require very high peptide concentrations. This was often
unfeasible both because of the inability of the technique to withstand the
resulting high absorptions and of the sheer amount of required peptide.
Still, some of the measurements under that setup did hint at the possibility
of a structural change at high bound concentrations. Such observations
weremostly inconclusive: usually only at the highest peptide concentration
would a structural change be visible, and, given the above technique
limitations, the spectrum would inevitably be of poor quality.
After becoming acquainted with the practical details of CD spec-
troscopy I was able to adapt the partition curve protocol (peptide titration
with lipid) to that technique. The differences relative to the conditions
used with fluorescence amounted to the use of KF instead of NaCl to
maintain the system’s ionic strength (chloride ions absorb at low wave-
lengths, preventing a proper CD measurement) and the use of an optical
pathlength suited to the overall sample absorption (for the data presented
in Figure 3.3, taken with 20 µm BP100, a 2 mm pathlength was used;
lower peptide concentrations could require up to 10mm pathlengths to
generate acceptable signal-to-noise ratios). With this setup all the bound
*CD spectroscopy relies on the measurement of the difference in sample absorption of right-
and left circularly polarized light. Some practical limitations arise from that difference usually
being minute compared to total sample absorption. When a sample is intensely absorptive
there are very few transmitted photons to accurately measure an absorbance. When the
chromophore is too diluted, there will not be a detectable difference in the transmitted light.
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states of the peptide could be clearly observed — from the initial random-
coil structure in water, through saturation, to the α-helical structure
when in excess lipid. Furthermore, the spectra obtained by this type of
titration had the advantage over the reverse setup that the chromophore
concentration was kept approximately constant along the titration. Signal-
to-noise ratios were therefore also fairly constant, decreasing only slightly
due to light scattering at saturation and at the highest lipid concentrations.
I was able to identify, from the CD measurements, a transition upon
saturation to a second bound structure or organization of BP100. The
relevance of such a concentration-dependent event to the mechanism of
the peptide has been discussed in Part I. In this part, that transition
is an important observation that supports two assumptions central to
the proposed interaction models: it justifies an increase in fluorescence
quantum yield at saturation and supports the existence of the intermediate
state postulated in the formulation of the three-state model. Curiously,
however, no significant change upon saturation was observed in the
measured fluorescence lifetime of BP100. As with the faint breaks in
the fluorescence saturation curves in Figure 5.3, I believe this to be a
consequence of the actual increase in lifetime also being relatively small.
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Ever since we suspected that the spikes, or humps, could reflect some sort
of threshold we have wondered at the possibility of a link to the macro-
scopic event of bacterial death (the observant reader will have noticed
that of all questions/hypotheses raised by saturation in Section 5.1 this is
the only one that has not yet been addressed). The notion that saturation
brought more than just a high membrane-bound peptide concentration
grew stronger with the observation that many biophysical parameters
changed when that threshold was crossed. With omiganan, saturation
was shown to induce a deepening of the peptide position. As for BP100,
vesicle aggregation and turbidity, ζ-potential, leakage, and CD measure-
ments all indicated a distinct and potentially disruptive behavior upon
saturation.
The ideas described ahead were first included inArticles iii and iv and
then fully developed in Articlesv andvi at the end of this chapter. They
represent theoretical research carried out in parallel with experimental
work along practically all my PhD. Most importantly, the following
notions inspired hypotheses that aim at being applicable to the generality
of AMPs, and not exclusively to our peptides.
6.1 Theoretical correlation
My first approach to test the physiological possibility of high membrane
bound peptide concentrations was a theoretical one. It was initially
spurred by a review64 byAlessandro Tossi, who is most famous for having
compiled a database of AMP sequences.65 In his review Tossi makes an
estimation of the bacterial membrane lipid concentration available under
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MIC assay conditions and remarks that it is about forty times lower than
a typical AMPMIC. If all the peptide would bind the membrane there
would be a very large oversaturation. Tossi concludes that the only way
to make sense of this is to admit that other elements besides the membrane
are able to significantly bind and sequester the peptide. What first drew
my attention in this estimate was that no notion of water-membrane
partition was included. Conversely, it was assumed that in absence of
sequestering elements all the peptide would bind the membrane. Having
been raised to the concept of partition (scientifically speaking) I redid the
estimate, this time introducing aKp of 50× 103, a typical magnitude for
AMPs. The result was quite different from the estimate in the review:
I obtained about 26 lipid molecules per bound peptide and no need to
evoke peptide sequestering. (I later found a paper by Jack Blazyk and
coworkers66 where essentially the same approximation as Tossi’s is carried
out, but less dire conclusions are made. The authors even allow for the
possibility that the peptide remains in solution and recognize that binding
will depend on an affinity constant.) Butwhatwas exciting about the result
I had obtained was not the dismissal of the hypothesis in Tossi’s review.
I found it much more interesting that the resulting lipid-to-peptide (L:P)
ratio represented a relatively high concentration of the peptide in the
membrane. A concentration which, depending on the peptide size, could
be very close to saturation.
Those were very stimulating results: at once I had established a the-
oretical basis that predicted that saturation was physiologically possible
and also that it might correspond to the MIC (recall that in the estimate
a typical AMP MIC was taken for the global peptide concentration).
This became even more exciting when I used in the model theKp values I
had obtained for omiganan and BP100, and the respective MICs: the ex-
pected bound peptide-to-lipid (P:L) ratio was very close to the saturation
proportion (σ) I had determined for the peptides! (Articles iii and iv.)
Therewas another important conclusion to be taken from the calculation
I made: Tossi estimated the overall lipid concentration to be of 25 nm,
which is a very low concentration. Applying a Kp value of 50× 103
Equation 4.2 returns an expected fraction of bound peptide of merely
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0.09%. There is so little lipid that practically all the peptide remains in
the aqueous phase, though still being able to reach a high concentration
in the membrane. This setup is the in vivo equivalent of the [L] → 0
limit discussed earlier: the concentration in each phase is maximal. Such
conditions allow an important approximation to be made: because the
peptide concentration in the bulk phase is virtually unchanged by the
presence of the lipid, one can assume that [P ]W ≈ [P ]total. At the MIC
[P ]W becomes theMIC itself. Combination with Equation 4.1 allows the
membrane-bound peptide concentration to be calculated from the MIC
and the partition constant:
[P ]L,MIC = Kp · [P ]W,MIC ≈ Kp ·MIC (6.1)
where theMIC subscripts were added to denoteMIC conditions. Multi-
plication of [P ]L,MIC by the lipid molar volume yields the bound peptide-
to-lipid ratio at the MIC:
P :LMIC = Kp · γL ·MIC (6.2)
With Equation 6.2 I could now easily estimate how concentrated an
AMP would get in a membrane at its MIC, provided aKp or a related
constant were available. Furthermore, as remarked earlier, the saturation
proportion, σ, is also a P:L ratio. This means that if saturation is assumed
to occur at the MIC Equation 6.2 can be used to calculate σ.
Equation 6.2was arrived at following some severe approximations, the
validity of which I have to address: in Tossi’s and Blazyk’s papers the
amount of available lipid was geometrically estimated from the bacterial
surface area and the area per phospholipid. In my published results I have
adapted that approach (essentially, by assuming a different bacterial shape)
with only slightly different results. The reduction of the bacterial shape
to a geometric surface representing an average bacterium will certainly
introduce an error into the estimate of available lipid concentration in
a MIC assay. However, that level of precision in this estimate is not
important for the above conclusions: the lipid concentration needs only
be low enough to maintain valid the approximation [P ]W ≈ [P ]total. I
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show in the Supplementary Material of Article vi that, for typical Kp
values of AMPs, that approximation holds if the lipid concentration is
lower or equal to the MIC. Because AMPMICs are in the micromolar
range there is wide margin for error in the nanomolar estimates of the lipid
concentration. Still, to make sure, I estimated the lipid concentration by
another approach. I took published results on the fraction of phospholipids
per bacterial dry weight67 and on the weight of a single bacterium68
(Articlevi) and obtained a value of 58 nm. The value is very close to the
geometrical estimates, which is quite remarkable given the coarseness of
the geometrical calculation and the drastically different approaches to the
two estimations.
Other system components that may be able to sequester the peptide are
the anionic peptidoglycan and the nucleic acids. Should significant binding
occur the approximation [P ]W ≈ [P ]total could be invalidated. It is here
that the peptidoglycan interaction studies from Section 4.3 come in handy:
the amount of peptide that binds the peptidoglycan is, at most, of the same
order of magnitude of that which binds the membrane. It would be as
if twice the lipid were present, which is well within the allowable error.
The same consideration stands for Gram negatives, which have twice as
much membrane (but only a very small peptidoglycan layer). As to the
nucleic acids a quick estimate (see Article vi) tells us that under the
aforementioned MIC assay conditions, about 8 nm of a peptide with 6+
charge would be enough to neutralize all the anionic DNA, mRNA and
tRNA bases in an E. coli suspension. As theMICs are in the micromolar
range, most of the peptide (~99% of it) would still remain unbound.
* * *
With the issue of the validity of the approximation out of the way I started
looking for AMPs for which threshold events at the molecular level had
been observed. I was trying to validate the use of Equation 6.2 by showing
that from the MIC and the partition constant one would be able to infer
the conditions at which such thresholds occurred. I looked especially
for peptides that underwent behavior changes at, or close to, saturation.
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Many authors, however, refrain from using high bound concentrations,
under claims that it is not physiologically relevant. This was the posture
of Robert Hancock, a central figure in AMP studies, when we met at the
Workshop ofMembrane-Active Peptides and I told him I had convincing
evidence that pointed otherwise — I admit that much of my resolve to
tell the world about my findings was spurred by the challenge to contest
such preconceptions.
Despite the taboo on using high bound concentrations I did find such
reports on some AMPs; it was not easy, though: to validate Equation 6.2
I needed to find peptides whose MICs were known (trivial), for which
Kp values with relevant systems had been measured (not so trivial but
still easy to find), and with reported molecular-level threshold events at
high P:L ratios (very rare!). For many of the AMPs for which all that
information was available, the critical molecular-level P:L ratio — always
measured in model membranes — could be reasonably well predicted
by Equation 6.2. And I could still make use of the cases for which
only the MIC and Kp were available: using those two elements with
Equation 6.2 I estimated for each peptide what would be its critical ratio
in the membrane at the MIC. In agreement with our predictions, most
P:L ratios were high enough to be considered saturation. It all comes
together in Article v, which describes this theoretical approach to the
action of AMPs (unfortunately, tacit editorial rules prevented most of
the mathematics to be formally included, hence the need for Articlevi). I
hoped that publication of this work would contribute to the recognition of
the relevance of high membrane-bound concentrations of AMPs; indeed,
I have since received very positive informal feedback from several AMP
researchers who had used our article to justify their replies to overly
conservative referees.
6.2 Prediction
Equation 6.2 plays an important role in the mathematical validation of
the occurrence of saturation. Still that is not all there is to that simple
expression. Some months after I had arrived at Equation 6.2 Rafael, then
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working at our lab, pointed out a trivial algebraic manipulation (I was
ashamed for not having thought of it myself!) that gave the equation a
whole new meaning:
MIC =
P :LMIC
Kp · γL (6.3)
This formulation emphasizes the possibility to estimate the activity of a
peptide from two biophysical parameters of the interaction with model
membranes, the Kp and the critical P:L ratio. It is a simple relation-
ship, but one that is able to bridge the far-apart fields of Biophysics and
Microbiology.
We applied the equation to omiganan and BP100, using the saturation
proportion as the critical P:L ratio. Because of that we knew that the
results of MIC prediction had to be good: Equation 6.2 had predicted
from the MIC a P:L ratio close to the observed values of σ; the opposite
process should be coherent. Indeed, the yielded MICs are very close to
the actual values (actually, right on target in the case of omiganan — see
Article vi).
One of the weaknesses of Equation 6.3 is that it is seldom known a
priori which is the threshold event that is related to the MIC. Given
that a peptide can display many such thresholds63 this can be a limitation
to the application of the equation. Still, Miguel, Rafael and I put efforts
into devising a simple and robust method for the biophysical estimation of
MIC values (we also aimed at patenting such methods, but because their
innovativeness relied mostly on an equation, which is not a patentable
find in Europe or Japan, we let go of that idea). It was then that we
started looking into alternative methods to measure saturation curves —
that one experiment at once yielded aKp and a P:L ratio (σ), enough to
calculate a MIC.
The use of optical density proved to be a very good substitute for
fluorescence: it was readily adaptable to microplate measurements and
it obviated the need of acrylamide and of a more complex fluorescence
measuring apparatus. As mentioned in Section 5.4 the use of OD was
powerful enough to reveal a second breaking point, and thus expose the
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limitation stated above. One other method that is able to provide the
elements necessary to estimate a MIC is the fitting of whole partition
curves using the three-state model: it allows the extraction of a value of
Kp and of two thresholds (S and σ) from a single titration. The involved
analysis, however, is definitely more complex than that of saturation
curves and we ended up focusing mainly on the simpler methodology.
The next breakthrough would be made by Miguel. He remarked
another obvious property of the prediction model and of saturation curves:
if we assume saturation to be the critical P:L ratio, then the MIC, as
defined by Equation 6.3, is the intercept of the linear fit of the saturation
points (see Section 5.2). Again, an extremely simple observation! And
one that significantly simplifies the analysis of saturation curves: if all that
is wanted is the MIC, taking the value of the intercept will be sufficient;
there is no need to specifically calculate Kp and σ values. It is also a
parameter of the linear fit subject to a much smaller error thanKp.
The ease-of-use of the MIC estimation method can be seen by looking
at any [P ]sat vs [L]sat plot of saturation points (in Articles iii, iv andvi,
or in Figure 5.3). The predicted MIC can simply be read from the y-axis.
Again, this is so because the low amount of lipid available under in vivo
conditionsmimics the biophysical limit of [L]→ 0. Furthermore, as stated
in Section 5.2, the linear [P ] vs [L] relationship is not restricted to the
representation of saturation points — it is applicable to any concentration-
dependent critical point in the membrane. A broader range of AMP-
induced membrane disruptions can thus be used for MIC prediction.
A last improvement to the method was made when I noticed that the
estimated MIC, being the intercept of the curve, did not change with
the slope. In other words, if the lipid concentration scale were to be
stretched or compressed, the same MIC would be calculated; all that is
needed is that the relative lipid concentrations among the data points are
correct. Independence of lipid concentration confers a great robustness
to this method, as only the peptide must be accurately quantified, but
it also allows a significant experimental simplification to be made: when
using model membranes vesicle unilamellarity is needed to ensure a proper
control over the lipid concentration available for interaction; this is so
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because when vesicles are multilamellar an undetermined portion of the
lipid becomes inaccessible. For MIC estimation, however, unilamellarity
is an irrelevant issue as long as all the saturation points are determined
using the same batch of multilamellar vesicles (MLVs) — obviating the
need for time-consuming procedures required to obtain unilamellarity.
This proved to be a successful strategy as results with MLVs, though
noisier, produce a MIC estimate very close to observed values.
The estimate with MLVs was also very close to the one obtained
with LUVs (Figures 1 and 2 of Article vi), both only slightly below
the observed MICs. The fact that both procedures agree in an underes-
timation of the MIC possibly reflects the use of an excessively anionic
membrane model, as discussed in Chapter ‘My work and the AMPs’. I
must, however, point out that the method is robust even in this aspect: a
more anionic system leads to a higher neutralization P:L ratio; at the same
time, the Kp of the peptide towards this system will be larger because
of a greater electrostatic contribution. It can be seen in Equation 6.3 that
a simultaneous increase of these two parameters will partly cancel out,
allowing a good MIC estimate even with a suboptimal membrane model.
On a practical aspect, what started out as a theoretical exploration
evolved into an idea with potential to be implemented as a kit for MIC
estimation without the need for bacteria: microplates covered by films of
phospholipid to which the user need only add water and peptide, and
that could be measured in any OD plate reader. But perhaps a more
valuable use of our conclusions would be the integration of the critical-
ratio–Kp–MIC relationship into drug design algorithms: Kp-predicting
models exist69; if methods are devised to also estimate critical ratios in
the membrane then a powerful in silico approach to AMP design can be
envisioned.
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o p i n i o n
Antimicrobial peptides: linking 
partition, activity and high 
membrane-bound concentrations
Manuel N. Melo, Rafael Ferre and Miguel A. R. B. Castanho
Abstract | An increasing amount of information on the action of antimicrobial 
peptides (AMPs) at the molecular level has not yet been translated into a 
comprehensive understanding of effects in bacteria. Although some biophysical 
attributes of AMPs have been correlated with macroscopic features, the 
physiological relevance of other properties has not yet been addressed. Pertinent 
and surprising conclusions have therefore been left unstated. strong 
membrane-binding and micromolar therapeutic concentrations of AMPs indicate 
that membrane-bound concentrations may be reached that are higher than 
intuitively expected, triggering disruptive effects on bacteria.
Antimicrobial peptides (AMPs) represent a 
wide range of short, cationic, gene‑encoded 
peptide antibiotics that can be found in 
virtually every organism1. Different AMPs 
display different properties, and many 
peptides in this class are being intensively 
researched not only as antibiotics, but also 
as antivirals2,3, templates for cell‑penetrating 
peptides4, immunomodulators5 and 
antitumoural drugs6.
Despite sharing a few common features 
(for example, cationicity, amphipathic‑
ity and short size), AMP sequences vary 
greatly, and at least four structural groups 
(α‑helical, β‑sheet, extended and looped) 
have been proposed to accommodate the 
diversity of the observed AMP conforma‑
tions7,8. likewise, several modes of action as 
antibiotics have been proposed, and there is 
debate about whether the primary target of 
many of these peptides is the cell membrane 
or whether the primary target is cytoplasmic 
invasion and disruption of core metabolic 
functions9.
Several bilayer interaction and disruption 
models have been proposed for those AMPs 
that depend on membrane interference 
for their antimicrobial activity10–12 (fIG. 1). 
however, it is now becoming obvious that 
such models might be too rigid to account 
fully for the many interactions that these 
small molecules can establish in a complex 
environment, such as the cell membrane. The 
limitations of the previously proposed mod‑
els have been exposed in molecular dynamics 
simulations of AMPs interacting with phos‑
pholipid bilayers. Observations from these 
studies included multiple coexistent struc‑
tures (frequently unrelated to clean α‑helices 
or β‑sheets), nonspecific peptide–peptide 
interactions and membrane perturbation 
dictated by stochastic events13–15 (fIG. 1). The 
advantage of this indefinite behaviour is that 
bacteria seem to find it hard to circumvent 
AMP action, which is certainly a reason 
behind the multistep mutations usually 
required for resistance to evolve16.
Independently of the chosen membrane 
perturbation model, an implicit concen‑
tration threshold is always required for 
disruption (fIG. 1). This is supported by 
several observations, in model systems, 
of phenomena related to such threshold 
crossings13,17–19. Nevertheless, AMP con‑
centrations that are close to full membrane 
coverage, which are often considered 
unphysiological conditions, are a frequent 
requisite for such observations (TABLe 1).
In this Opinion, we survey reports of 
threshold events of AMPs and propose 
a correlation between these events and 
properties such as bactericidal concentra‑
tion and membrane binding. we use this 
relationship to support our view, which 
reconciles existing interaction models with 
Independently of the chosen 
membrane perturbation model, 
an implicit concentration 
threshold is always required  
for disruption.
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requirements of high membrane‑bound 
peptide concentrations.
Microscopic and macroscopic studies
Since their discovery, AMPs have been the 
subject of both biological and biophysical 
studies. Biological studies are required to 
characterize the activity of the peptides at 
a macroscopic level; for example, by profil‑
ing efficiency against a number of relevant 
strains20 or toxicity towards mammalian 
cells21. Biophysical studies attempt to find 
the molecular bases for macroscopic char‑
acteristics, usually with the ultimate goal of 
rational improvement of AMPs or design  
of related drugs4. however, integration of 
data from these two fields has not been 
straightforward. For example, molecular‑
level information on the membrane interac‑
tion and activity of AMPs obtained in vitro 
or in silico using model phospholipid bilay‑
ers has not been clearly correlated with 
observations of cell death22.
AMps as antibiotics: the threshold
As for all antibiotics, AMPs require a 
minimum concentration to be effective 
against a particular strain of bacteria. 
This concentration, often expressed as 
the minimum inhibitory concentration 
(MIC), is used as a parameter to compare 
antibiotic efficiencies and as a guideline 
for antibiotic dosage. Although the mac‑
roscopic effects of crossing the MIC are 
easily observed (for example, lysis, loss of 
viability or bacteriostasis20), identification 
of the molecular events that cause inhibi‑
tion to occur only after this threshold is 
another area where the macroscopic and 
microscopic characterizations of AMPs 
still do not overlap.
At the molecular level, the threshold 
that divides a thriving bacterium from 
a dying one can have several causes. 
Antibiotic‑induced cell death may occur, 
for example, owing to inhibition of an 
enzyme, leading to a block in bacterial 
metabolism. Alternatively, antibiotic mol‑
ecules may become concentrated enough 
to exhibit cooperative activity despite the 
absence of specific target binding; for 
example, by forming a pore in the mem‑
brane, as is the case for most AMPs13,17. 
Indeed, several independent studies have 
described the changes in the membrane 
interactions of different AMPs when cer‑
tain threshold concentrations were reached 
(for an overview of this behaviour in the 
widely studied AMPs alamethicin, melittin, 
magainin and protegrin, see Ref. 17).  
These changes include alterations in con‑
formation17, in‑depth membrane localiza‑
tion18,19 or association state13, as well as 
indirect changes in bilayer topology, such 
as pore formation or disintegration11,23–27. 
As these are all potentially disruptive 
events, such transitions have been sug‑
gested to be the molecular processes that 
trigger antibiotic activity and lead to cell 
death. however, these phenomena have 
only been observed in model phospholipid 
bilayers, and in some cases, AMP concen‑
trations in the membrane that were as high 
as one peptide molecule per six phospholi‑
pid molecules18 were required for these 
events to occur. These concentrations are 
close to, if not at, full membrane satura‑
tion (see TABLe 1 for a list of peptides that 
display transitions at high concentrations 
in the membrane). As the MICs for AMPs 
are typically in the low micromolar range, 
scepticism has understandably arisen 
regarding the relevance of these thresholds 
and their importance in vivo28,29.
How much peptide in a membrane?
Because important aspects of peptide–mem‑
brane interactions are neglected, the general 
notion that close‑to‑saturation peptide con‑
centrations in the membrane are impossible 
in vivo could stem more from intuition than 
accurate interpretation of facts.
Setting the rules: partitioning to the mem-
brane. A common biophysical approach 
for the study of AMP–membrane interac‑
tions involves determination of the extent 
of peptide partitioning or binding to model 
membranes, which is commonly translated 
into partition constants (BOX 1). The fact 
that these partition constants are usually 
significantly higher for bacterial model 
membranes than mammalian ones explains, 
in part, AMP selectivity and safety, and is 
considered when rationally designing new 
Table 1 | Antimicrobial peptides that display interaction thresholds at high membrane-bound concentrations*
peptide sequence‡ threshold 
l:p §
phospholipid system observed effect || refs
Omiganan ILRWPWWPWRRK-NH
2
6:1 POPc:POPG = 1:4 Internalization; bilayer saturation¶ 18
cecropin– 
melittin 
hybrids
KWKLFKKIGAvLKvL-NH
2
; 
KKLFKKILKYL-NH
2
8.4:1; 13:1; 
25:1
POPe:POPG: cardiolipin 
(–2 charge) = 14:5:1; 
DMPc:DMPG = 3:1
Internalization; pore formation; 
membrane charge neutralization; 
bilayer saturation and aggregation
19,26, 
38
Melittin GIGAvLKvLTTGLPALIsWIKRKRQQ-NH
2
12:1; 20:1; 
23:1
sphingomyelin; DPPc Membrane solubilization 23
Tritrpticin (and 
analogues)
vRRFPWWWPFLRR 25:1 POPe:POPG = 7:3; 
Escherichia coli polar lipids
Increase of membrane leakage¶ 33
PGLa GMAsKAGAIAGKIAKvALKAL-NH
2
18:1 DMPc complete peptide realignment 39
Tachyplesin I KWcFRvcYRGLcYRRcR-NH
2
7:1 egg yolk 
phosphatidylglycerol
Membrane charge neutralization; 
vesicle micellization
34
Aurein 2.2 GLFDIvKKvvGALGsL-NH
2
15:1 DMPc Internalization 40
*In the context of this article, high membrane coverage is used to describe bound antimicrobial peptide (AMP) concentrations that yield 25 phospholipid 
molecules, or less, per peptide. As a guideline, if it is assumed that an α-helical structure is adsorbed parallel to the bilayer (using 12 Å as the average helix diameter, 
including side chains, and 0.7 nm2 as the area per phospholipid41), the upper bound 25:1 value results in a relative membrane coverage of between one-fifth and 
one-third for a peptide that is 20– 30 amino acids long. ‡NH
2
 denotes carboxy-terminal amidation. §If information was unavailable, it was assumed that either the 
reported ratio at the thresholds was relative to the membrane-bound peptide concentration or that the lipid concentration allowed the global L:P to be 
approximately the same as the local ratio. ||Only the most structurally relevant effects, which occur at an L:P below 25:1, are listed. ¶Membrane charge 
neutralization can also be expected at the reported threshold ratios by taking into account the peptide charge and lipid composition of the system. DMPc, dimyris-
toylphosphatidylcholine; DMPG, dimyristoylphosphatidylglycerol; DPPc, dipalmitoylphosphatidylcholine; POPc, palmitoyloleoylphosphatidylcholine; POPe, 
palmitoyloleoylphosphatidylethanolamine; POPG, palmitoyloleoylphosphatidylglycerol.  
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peptides8 (BOX 2). Although this is a good 
example of correlation between molecular‑
level information and macroscopic AMP 
characteristics, the analysis of partition 
constants has typically been restricted to this 
biophysical approach. Partition constants are 
seldom considered in an absolute sense, but 
rather they are normally used to compare 
different systems. For example, partition 
constants in the order of 104 are common 
for the interaction of AMPs with bacterial 
membrane models (TABLe 2). This value does 
not only indicate that there is a stronger 
interaction with bacterial membranes than 
mammalian ones8,18,30, but also means that 
the local peptide concentration in a model 
bacterial membrane is approximately 10,000 
times higher than its concentration in the 
aqueous phase.
By taking into consideration absolute val‑
ues of partition constants and their physical 
indications, it can be shown that AMPs with 
MIC values that are usually in the micro‑
molar range can reach millimolar concen‑
trations in a membrane environment. For 
a typical MIC of 2 μM and a partition con‑
stant of 40 × 103, a high membrane‑bound 
peptide concentration of 80 mM would be 
expected, which corresponds to approxi‑
mately 16 phospholipid molecules per 
bound peptide (assuming typical values for 
the phospholipidic molar volume31). Actual 
values have been used to estimate the con‑
centration of the peptide omiganan, also 
resulting in a high concentration18. TABLe 2 
provides this result, as well as predictions 
for widely studied AMPs, using a similar 
approach. The fact that all these peptides are 
expected to have a low lipid to peptide ratio 
(l:P) in the membrane at the MIC shows 
that high levels of membrane coverage are, 
indeed, plausible.
The work described above focuses on 
peptides that exert their action primarily 
at the membrane level; only at this level 
is there a strong link between cell death 
and threshold concentrations in the 
Figure 1 | proposed mechanisms of antimicrobial peptide‑mediated 
membrane disruption. Antimicrobial peptides (AMPs) have been pro-
posed to disrupt the membrane bilayer during binding by different proc-
esses. All these models require, either explicitly or implicitly, that a 
threshold concentration in the membrane be crossed for disruption to 
occur. a | Barrel-stave pore10. Peptides insert perpendicularly in the bilayer, 
associate and form a pore. The peptides line the pore lumen in a parallel 
direction relative to the phospholipid chains, which remain perpendicular 
to the bilayer plane. b | carpet mechanism11. Peptides adsorb parallel to the 
bilayer and, after reaching sufficient coverage, produce a detergent-like 
effect that disintegrates the membrane. specific peptide–peptide inter-
actions are not required. c | Toroidal pore12. As for the barrel-stave pore, 
peptides insert perpendicularly in the bilayer, but instead of packing par-
allel to the phospholipid chains, induce a local membrane curvature in 
such a way that the pore lumen is lined partly by peptides and partly by 
phospholipid head groups. A continuity between inner and outer leaflets 
is established. d | Disordered toroidal pore13. A recent modification to 
the toroidal pore proposes that less-rigid peptide conformations and 
orientations are formed; the pore lumen is lined by the phospholipid 
head groups.
…the local peptide 
concentration in a model 
bacterial membrane is 
approximately 10,000 times 
higher than its concentration in 
the aqueous phase.
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Kp= 
[P]L
[P]W
membrane. In the case of peptides that 
target intracellular components4, the rela‑
tionship between the partition constant, 
aqueous phase and membrane‑bound pep‑
tide concentrations is still valid. however, 
these parameters do not directly correlate 
with the disruptive threshold events that 
take place in the cytoplasm. Adaptations 
of the previous assumptions must also be 
made if the antibiotic is immobilized in a 
solid matrix or linked to a larger carrier32.
Saturation: unlikely, possible or essential? 
The values for l:P from the estimates in 
TABLe 2 correspond clearly to situations of 
high membrane coverage, showing that high 
peptide concentrations in the membrane 
can be expected. It should also be noted that 
these estimates took into account published 
Box 1 | The partition constant
The extent of the solute–membrane interaction is usually expressed, in thermodynamic terms, by 
means of binding or partition constants. Antimicrobial peptides (AMPs) have been observed to 
partition strongly towards anionic bacterial membrane models and such constants have been 
determined for many bacterial systems (for examples, see TABLe 2).
Under a commonly accepted framework — fully developed elsewhere26,35,36 — the partition 
constant (denoted K
p
) is defined as the concentration ratio of the peptide in the lipidic and aqueous 
phases ([P]
L
 and [P]
W
, respectively), in which the lipidic phase corresponds to the membrane volume 
(Equation 1).
(1)
Although K
p
 is constant, the values of [P]
L
 and [P]
W
 depend on the relative amounts of lipidic and 
aqueous phases available for peptide interaction. However, when the amount of membrane is small 
— as estimated to be the case for bacterial membranes under physiological conditions, in which 
only nanomolar phospholipidic concentrations are expected18,37 — both [P]
W
 and [P]
L
 approach their 
respective maximal values of [P]
TOTAL
 and K
p
 ∙ [P]
TOTAL
; [P]
TOTAL
 being the total peptide concentration36. 
This means that, for the small quantities of phospholipid at physiological bacterial densities18,37, the 
membrane-bound concentration of an AMP can be calculated by multiplying the global AMP 
concentration by the partition constant.
A related and also commonly used binding constant, usually denoted K
b
 and expressed in 
reciprocal molar units per mole, can be converted into K
p
 after division by the lipidic molar 
volume26,31 (0.763 litres per mole for fluid phase systems).
parameters that mimicked an in vivo envi‑
ronment, rather than unphysiologically high 
peptide concentrations that are achievable 
only in the laboratory.
Therefore, available data on the interac‑
tion properties of AMPs with membranes, 
as well as their efficiency profiles against 
bacteria, validate the plausibility of the 
occurrence in vivo of membrane‑bound 
AMP concentrations at, or close to, bilayer 
saturation. In addition, another important 
aspect must be pointed out: the high pre‑
dicted membrane conentrations were cal‑
culated using peptide concentrations that 
were equal to the MIC and not any other 
concentration. Because the MIC represents 
the macroscopically observable threshold 
for the onset of AMP activity, the obtained 
relationship between a low l:P and the 
MIC strongly suggests that high membrane 
coverage may be an actual requirement for 
AMP activity. This is supported by the bio‑
physical observations discussed above of 
membrane‑disrupting events that occur at 
such low l:P values (TABLe 1).
It should be noted that this hypothesis 
accommodates observations of low l:P dis‑
ruptive thresholds from current membrane‑
perturbation models (fIG. 1), and as such, 
does not encompass AMPs, such as alam‑
ethicin, that display activity thresholds at 
higher l:P values17. 
Saturation and surface charge neutraliza-
tion. Because AMPs are highly cationic and 
bind strongly to the membrane, neutraliza‑
tion of bacterial surface charge would be 
likely for l:P ratios that are similar to those 
in TABLe 2. This phenomenon would be 
expected to severely affect membrane func‑
tion as well as integrity. For example, the 
intrinsic surface potential generated by the 
asymmetry of charged membrane phos‑
pholipids would be perturbed and, if not 
a lethal event as such, would be likely to 
stimulate the onset of antibacterial action8. 
Indeed, taking into account the peptide 
and membrane charges, an analysis of pub‑
lished data reveals that neutralization does 
occur along threshold events displayed 
by several AMPs18,26,33,34 (TABLe 1). As such, 
membrane charge neutralization coupled 
to saturation of the bacterial membrane 
is a likely killing mechanism, at least for 
some peptides.
Reasoning or intuition
Because of the different magnitudes of AMP 
partition constants, MICs and physiologi‑
cal phospholipid concentrations, it is hard 
to assess the actual amount of interacting 
peptide without resorting to calculation. 
This may be the reason behind the intuitive 
idea that it is impossible for a peptide that 
is present only in micromolar concentra‑
tions in the aqueous phase to saturate the 
cell membranes of bacteria in suspension. 
we have reviewed and presented published 
observations that support our view that high 
peptide concentrations can be expected 
in vivo.
In addition, the reviewed literature 
clearly suggests that there is a simple cor‑
relation between AMP MICs, partition con‑
stants and threshold concentrations in the 
membrane, which can ultimately be used to 
predict activity ranges in vivo from simple 
biophysical parameters (see the relationship 
in the footnote of TABLe 2) and thus better 
design new antibiotics.
Table 2 | MiC ranges, partition constants and predicted L:p values for AMps 
peptide Mic range (μM)* Kp/103 ‡ expected l:p in the membrane§ refs
Melittin 9–18 60 2.5:1 42,43
Magainin-2-amide 40–50 7 5:1 25,44,45
Omiganan 4–8 23 14:1 18,46
Indolicidin 2–16 39 17:1 20,47
Dermaseptin s1 1.4–25 37 26:1 11,48
cecropin P1 0.3–17 157 28:1 20,30
*Average minimum inhibitory concentration (MIc) range against susceptible Escherichia coli and 
Staphylococcus aureus strains. ‡The published partition constant from the system that best mimicked 
bacterial membranes was chosen for each peptide. §The lipid to peptide ratio (L:P) = 1/
(K
p
 ∙ MIC ∙ 0.763); 0.763 being the phospholipidic molar volume, in litres per mole31. The L:P provided is 
the largest obtained from the range of MIcs, thus reflecting the lowest expected membrane 
concentration. AMP, antimicrobial peptide.
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Prediction of antibacterial activity from biophysical properties of 
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Consensus is gathering that antimicrobial peptides 
(AMPs) that exert their antibacterial action at the 
membrane level must reach a local concentration 
threshold to become active. Studies of peptide inter-
action with model membranes do identify such dis-
ruptive thresholds but demonstrations of the possible 
correlation of these with the in vivo onset of activity 
have only recently been proposed. Here we fully de-
velop an interaction model of AMPs with mem-
branes, and explore the consequences of the under-
lying partition formalism. Disruptive thresholds in 
model membranes and the onset of antibacterial 
peptide activity are shown to occur over the same 
range of locally bound peptide concentrations (10 to 
100 mM), supporting a correlation between the two 
types of observations. The interaction model further 
yields a relationship that provides AMP activity pre-
diction from simple biophysical parameters. A 
straightforward and robust method to implement 
this relationship is presented, with potential applica-
tion to high-throughput screening approaches. 
Antimicrobial peptides (AMPs) are a broadly defined 
class of gene-encoded peptides produced by virtually 
all organisms. Members of this class are usually short, 
cationic, and able to adopt amphipathic structures, es-
pecially when in interaction with membranes. The most 
studied feature of AMPs, as the name indicates, has 
been their antibiotic potential, and since their discov-
ery several microbiology methodologies have been de-
veloped and employed to characterize the in vivo ac-
tion against their targets, usually prokaryotes.1,2 
In turn, the relative simplicity in sequence and second-
ary structure of AMPs, together with mechanisms that 
depend largely on membrane interaction,3 prompted 
the use of biophysical tools as the methodologies of 
choice for identifying the molecular level modes of ac-
tion of AMPs. The distinct microbiological and biophysi-
cal approaches have, however, opened a gap in the in-
formation on AMPs: the macroscopic information on 
AMP activity from biological studies is seldom corre-
lated to the findings on peptide behavior at the mo-
lecular level. This is not to say that the bases of all 
macroscopic phenomena displayed by AMPs are poorly 
understood – for instance, AMP selectivity has been 
successfully modeled and described by a preferred par-
titioning of the peptides towards bacterial versus 
mammalian membrane models.3 Nonetheless, some 
very detailed molecular descriptions from biophysical 
models, such as pore formation in phospholipid bilayers, 
need to be more clearly connected to the events that, 
in vivo, lead to AMP-mediated bacterial death. 
There is one point where observations from biological 
studies overlap with molecular models of AMP action: 
a given peptide concentration must be overcome to 
trigger peptide activity. From a biological, macroscopic 
perspective this threshold is expressed as the minimum 
inhibitory concentration (MIC); the molecular level pa-
rallel of this threshold is the membrane-bound peptide 
concentration above which a disrupting process (disin-
tegration, pore formation, translocation, etc.) is initi-
ated – in fact, several cases have been reported 
where peptides become disruptive against membrane 
models above a certain threshold.4 It is tempting to as-
sume a correlation between the macroscopic MICs 
and the molecular level disruptions, but the fact is that 
it is not yet known if the topology of membrane per-
turbation in vivo is at all related to what is observed in 
artificial phospholipid membranes. 
Quantification of binding to model  phospholipid mem-
branes has been an important aspect of studies on 
drug interactions.3,5,6 In the case of AMPs, information 
on the membrane-bound peptide concentration in 
bacterial and model membranes may explain more 
than just selectivity. It may corroborate the connection 
between the MIC and the molecular level observations 
of disruption in model membranes if both thresholds 
are shown to occur at the same local concentrations 
in the membrane. Indeed that correlation was recently 
shown to be expected for typical AMPs, even at seem-
ingly high bound concentrations.4,7,8 
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Concentrations corresponding to disruption thresholds 
in model membranes can be directly extracted from 
published data as these are usually expressed as the 
peptide-to-lipid ratio (P/L) at which the threshold oc-
curs – commonly falling in the 1:10 to 1:100 range4,9 (see 
the Supplementary Material for possible approxima-
tions in the values taken from published data). Division 
by the phospholipid molar volume (γL) readily trans-
lates P/L values into concentrations, which range, in 
this case, from 13 to 130 mM. 
A peptide-lipid interaction model was constructed to 
calculate the extent of AMP binding to real bacterial 
membranes (all equations derived in the Methods sec-
tion). This model was based on a set of parameters 
that reflect a relevant scenario of peptide-bacteria in-
teraction – a MIC assay – involving a generic AMP 
with typical characteristics. We then explored the 
consequences of the underlying chemical biology to ar-
rive at theoretical and practical conclusions on the 
parallelism of peptide activity against model and bac-
terial membranes. 
The peptide fraction bound to bacterial membranes at 
activity thresholds was calculated using Equation 2, 
which requires knowledge of the amount of membrane 
lipid available for peptide binding under MIC assay 
conditions. An estimate based on reported values for 
the dry weight per bacterium and phospholipid mass 
percentage of dry bacteria (for E. coli) yielded, under 
MIC assay conditions, a total membrane phospholipid 
concentration ([L]MIC assay) of 58 nM. This value is in 
good agreement with, and corroborates, published re-
sults from distinct calculations based on bacterial sur-
face area10,11 (66 and 25 nM, respectively); the impact 
of the accuracy of the estimates on the results is dis-
cussed in the Supplementary Material. Application of 
Equation 2 also requires knowledge of the partition 
constant (Kp) of the peptide towards bacterial mem-
branes. It was assumed that an AMP interacts with 
such membranes and their model counterparts with 
similar affinity and, so, that binding or partition con-
stants determined for the latter are valid to predict 
behavior in real membranes. Equation 2 was solved us-
ing a typical4 AMP-membrane partition constant of 
5 x 10.4 With the given parameters only 0.22% of the 
total peptide was predicted to bind bacterial mem-
branes in a MIC assay. 
The very low fraction obtained indicates that almost 
all peptide remains in the aqueous phase but it does 
not mean that the local concentration in the mem-
brane is low: indeed, for a typical MIC value of 2 μM a 
bound concentration of 100 mM is expected (see Equa-
tion 3). This is a high concentration – about 13 phos-
pholipids per bound peptide – which matches some of 
the highest reported bound threshold concentrations 
in model membranes. Such a high bound concentration 
predicted from physiological parameters supports the 
notion that, as recently remarked,4 high membrane-
bound AMP concentrations, rather than unphysiologi-
cal, are expectable events in vivo. 
The observed agreement between concentrations at 
microscopic and macroscopic threshold events sup-
ports assumptions that phenomena that take place in 
the simpler membrane models parallel those occurring 
in vivo. The usefulness of the same relationship was ex-
tended, in a more quantitative sense, to predict antim-
icrobial activities from known threshold occurrences in 
model membranes (denoted here as a critical peptide-
to-lipid ratio P/L*). Equation 6 explicitly relates simple 
physical-chemical parameters of peptide-membrane in-
teractions (Kp and P/L*) with antibacterial activity. 
Prediction was tested with the published parameters 
and activities of the peptides omiganan8,12 and 
BP100.7,13,14 A remarkable agreement of the predicted 
activities with the observed antibacterial performance 
was obtained for both peptides, summarized in Table 1. 
A linear relationship can be established (Equation 7) 
relating the global peptide and lipid concentrations 
when threshold events occur in the membrane. The 
remarkable feature of this linear correlation is that its 
intercept is the global peptide concentration required 
to reach P/L* in the membrane when [L]→0, which is a 
condition that parallels the very low [L]MIC assay. Indeed, 
the MIC estimate defined in Equation 6 is equivalent to 
the intercept of the straight line defined by Equation 7 
(see equation 8). Thus, upon identification of the criti-
cal threshold event in model membranes, MIC values 
can be estimated from a single experiment consisting 
in the determination of peptide vs. lipid threshold 
curves. This method does not require explicit calcula-
tion of Kp or P/L* values – although these can be re-
covered if needed.8,15 
Table 1 – Estimated and observed activities for the AMPs 
BP100 and omiganan against Gram-negatives. 
Peptide 
Membrane interaction 
parameters 
MIC estimate 
(μM) Observed MIC (μM) 
 Kp/103 P/L*   
BP1007,13 17.8 – 90.1 1 : 8.4 1.7 – 8.8 2.5 – 7.5 
Omiganan8,12 23.5 – 43.5 1 : 5.9 5.2 – 9.8 4.5 – 9.0 
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Furthermore, because the MIC estimate only depends 
on the intercept of the curve, the prediction is relative-
ly independent of the actual stock lipid concentrations 
that are used, as long as the relative dilutions between 
data points are kept. Inaccurate concentrations of lipid 
stocks will generate incorrect P/L* and Kp values, but 
the intercept – and thus the MIC estimate – will not 
be affected. This robustness not only avoids the need 
for accurate lipid quantification but also introduces the 
possibility of using liposomes that have not been sub-
jected to any process to induce unilamellarity16,17 (such 
as freeze-thaw, extrusion, or sonication), obviating a 
time- and resource-consuming step usually associated 
to the use of model membranes. 
Application of the approach to published threshold da-
ta for the peptides omiganan and BP100 was successful, 
with good approximations of the actual MICs (Figure 1). 
The method was further tested using threshold points 
of BP100 interaction with multilamellar vesicles, deter-
mined from the optical density of the system. The re-
sults are in good agreement with the other predictions 
and with the actual MICs (Figure 2). In this case two 
threshold points were detected, only one of which cor-
responds to the P/L* determined elsewhere.7 The pre-
diction is consistent with that from Figure 1 and the 
observed range of activities of the peptide, not being 
affected by the use of multilamellar vesicles. 
The relevant biophysical parameters for MIC estima-
tion can be alternatively obtained by methods8 that 
involve the explicit calculation of P/L* and Kp. Some of 
these approaches may have the advantage of provid-
ing parameter estimation from a single data curve, un-
like the application of Equation 8 (see Figure 2). How-
ever, these methods require complex and time-
consuming analyses of peptide binding, not suitable for 
routine implementation. 
The method based on Equations 6 – 8 may also be 
used to estimate other relevant thresholds, such as the 
minimum hemolytic concentration (MHC) of a peptide. 
The concentration of erythrocyte membrane phospho-
lipid in an MHC assay ([L]MHC assay) was estimated to be 
of 89 μM (see Methods). This is a much higher concen-
tration than that in MIC assays, and of the same order 
of magnitude, or higher, as MHC values of hemolytic 
peptides.18,19 This is a borderline situation regarding the 
validity of Equation 6, and the method is more likely to 
estimate a lower bound of an MHC than a central val-
ue. Published threshold data on the interaction of the 
AMP melittin with different erythrocyte membrane 
models is available.15,20 These verify the linearity ex-
pected from Equation 7 and predict MHC values from 
0.02 to 15.3 μM. Notwithstanding the high [L]MHC assay 
and the wide prediction interval, the values do over-
lap with the observed MHC range,18,21 between 0.9 
and 2.5 μM. 
It can be seen that, within a simple binding formalism, 
the average local peptide concentrations predicted at 
the MIC and those observed for thresholds in model 
membranes occur over the same magnitude of con-
centrations. This concurrence strongly supports a cor-
relation between both observations and validates the 
use of model systems to study these phenomena. In-
deed, a recent study has shown that the energetics of 
membrane disruption become largely favorable when 
surface-wide coverage is attained,22 this being a possi-
ble origin of threshold behavior. 
In addition to its simplicity and robustness, the predic-
tion method is relatively independent of the chosen 
technique to detect threshold points: data in Figure 1 
were obtained from the peptides’ fluorescence, those 
in Figure 2 and reference 15 from the turbidity of lipo-
some suspensions, and those from reference 20 by de-
tection of liposomal leakage. It should be noted that, 
because biophysical parameters are usually obtained 
from model systems, only an approximate rendition of 
a biological behavior can be expected from our inter-
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Figure 1 – Application of the MIC prediction method to pub-
lished threshold data on the interaction of the AMPs BP100 
and omiganan with model membranes. Data adapted from 
refs. 7,8 for the interaction of BP100 (circles) and omiganan 
(Omg, triangles) with POPC:POPG 1:2 unilamellar vesicles. 
Data were fit with Equation 8, yielding intercepts of 
1.8 ± 0.5 μM and 6.8 ± 0.3 μM, respectively. Intervals drawn 
next to the [P]threshold axis indicate the range of MIC values de-
termined in vivo against different Gram negatives, for each 
peptide12,13 (Table 1); the regression intercepts, predictive of 
the MIC (see text), lie within, or very close to, these ranges. 
Article vi 127
4 
action model; furthermore, the offset of some of the 
predictions relative to observed values stresses the 
importance of using relevant model membrane sys-
tems. However, since MICs and MHCs are seldom de-
termined in vivo with great precision, Equation 6 still 
allows for useful, educated guesses of activity ranges 
to be made relying solely on biophysical data. 
This work demonstrates that it is possible to use a 
purely physical-chemical reasoning to understand, 
model, and predict the mechanisms of complex biologi-
cal interactions such as AMP-mediated bacterial death. 
The resulting methodology is a fast, cost-effective way 
to screen libraries of AMP drug leads by means of high 
throughput techniques. Moreover, the predictive rela-
tionships can be coupled with drug design algorithms, 
further improving the process. More than bridging the 
fields of chemistry and biology, these findings have im-
portant practical applications that may ultimately lead 
to a faster, more efficient antibiotic drug development. 
METHODS 
Peptide partition to the membrane 
The developed interaction model follows a commonly 
used simplification in which the membrane is consid-
ered a lipidic phase in coexistence with the bulk aque-
ous phase; the distribution of the peptide in both 
phases then obeys a simple Nernst equilibrium.23 Under 
this framework, fully developed elsewhere,5 the parti-
tion constant Kp is defined as the concentration ratio 
of the peptide in the lipidic and aqueous phases: 
 [ ]
[ ]
L
p
W
P
K
P
 Eq. 1 
where [P]L and [P]W are the peptide concentration in 
the lipidic and aqueous phases, respectively – the Sup-
plementary Material details some simplifications im-
plicit in this definition, as well as the conversion from 
other types of binding constants.6 
From Equation 1, the fraction of peptide molecules in 
the lipidic phase (XL) can be obtained as 
 
[ ]
1 [ ]
p L
L
p L
K L
X
K L
γ
γ  Eq. 2 
where [L] is the total lipid concentration and γL is the 
molar volume of the lipid phase. 
Finally, the local peptide concentration in a membrane 
at a lipid concentration [L] will be given by 
 
TOTAL[ ][ ]
[ ]
L
L
L
X P
P
L γ  Eq. 3 
where [P]TOTAL is the peptide concentration over the 
global volume. 
In addition to this process, if the bound peptide-to-lipid 
ratio (P/L) is known, [P]L can be obtained easily after 
division of P/L by γL. 
Membrane-bound concentrations 
Membrane-bound peptide concentrations were calcu-
lated according to Equation 3. A Kp value of 5  104 
was used together with a global peptide concentration, 
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Figure 2 – Application of the MIC prediction method to thre-
sholds in BP100 interaction with multilamellar vesicles. (a) Op-
tical density of a suspension of multilamellar vesicles (60 μM 
POPC:POPG 1:2) at different concentrations of added BP100. 
Critical threshold points are indicated by arrows. (b) Plot and 
linear fit, according to Equation 8, of critical points in a) and in 
similar curves obtained with different lipid concentrations; 
empty and full symbols denote the first and second critical 
points, respectively, of each curve. The intercept of the line 
fitted to the second critical points yields a MIC estimate of 
2.1 ± 0.9 μM, according to Equations 6 – 8. The value is both 
close to the estimate in Figure 1 and to the observed activity 
range of BP100, indicated next to the [BP100]threshold axis. 
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[P]TOTAL, of 2 μM. A γL value of 0.76 M,-1 reported for 
fluid phospholipid systems,24 was used. Lastly, the 
amount of membrane lipid available for interaction 
was calculated at the bacterial densities of a MIC as-
say (thus termed [L]MIC assay): a bacterium dry mass of 
489 fg was assumed,25 8.2% of which are 
phospholipids26 (data for E. coli); admitting a maximum 
bacterial titre27 of 106 cfu/mL this yields an [L]MIC assay of 
4 μg/L. A molar value can be obtained by approximat-
ing all phospholipids to have the molecular weight of 
dipalmitoylphosphatidylethanolamine (691.96 g.mol-1). 
A surface area approach was taken to estimate the 
concentration of membrane phospholipid in an MHC 
assay ([L]MHC assay). The [L]MHC assay was obtained from 
the concentration of erythrocytes in the human 
blood28 (5  106 cells/μL) their average surface area29 
(150 μm2), the area per phospholipid headgroup30 
(0.7 nm2), and a commonly used dilution in MHC de-
termination14,18 (final 5% vol/vol of blood). 
MIC prediction 
Equations 2 and 3 were combined to define P/L as a 
function of [P]TOTAL, Kp and [L] (because thresholds are 
often reported as the bound P/L ratio rather than a 
local concentration the former was preferred): 
     
1
TOTAL TOTAL
1 [ ]
/
[ ] [ ]p L
L
P L
P K Pγ  Eq. 4 
Under the conditions where activity is triggered in vivo 
[P]TOTAL is the MIC, P/L is the disruption threshold in 
the membrane (here termed P/L*) and [L] is of the 
magnitude of [L]MIC assay. Equation 4 can be rewritten as 
       
1
MIC assay* [ ]1/ MIC
MIC MIC p Lp L
L
P L K
K
γγ  Eq. 5 
The approximation in the expression is possible be-
cause the nanomolar values of [L]MIC assay are two to 
three orders of magnitude smaller than the typical mi-
cromolar MICs,1 and, given average values for AMP 
partition constants,4 [L]MIC assay/MIC becomes negligible 
for the result. Finally, a clear relationship between the 
activity (MIC) of an AMP and its disruptive behavior on 
a model membrane (P/L*) can be obtained from a sim-
ple rearrangement of Equation 5: 

*/
MIC
p L
P L
K γ  Eq. 6 
A method to apply Equation 6 values from biophysical 
data implements a relationship, deduced elsewhere,8,15 
between the global peptide and lipid concentrations at 
a critical threshold: 
  
*
*
threshold threshold
/
[ ] / [ ]
p L
P L
P P L L
K γ  Eq. 7 
According to Equation 6 the MIC is given by the inter-
cept of this straight line: 
  *threshold threshold[ ] MIC / [ ]P P L L  Eq. 8 
Method implementation 
The prediction method was implemented using the 
AMP BP100 (H-KKLFKKILKYL-NH2; synthesized as de-
scribed elsewhere7) and multilamellar vesicles of a 1:2 
proportion of the phospholipids POPC and POPG 
(1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine and 
1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-rac-1-
glycerol, from Avanti Polar Lipids, Inc., Alabaster, Ala-
bama). Multilamellar vesicles were prepared as de-
scribed elsewhere.7 Optical densities of the vesicle sus-
pension were measured for several lipid-peptide con-
centration pairs; breaking points putatively corre-
sponding to disruption were fittted according to Equa-
tion 7. An MTX Labsystems, Inc. (Vienna, Virginia) Mul-
tiskan EX plate reader and BD Falcon (San Jose, Cali-
fornia) UV-transparent 96-well plates were used for 
measurement. 
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Supplementary Discussion 1 – Analyzing published data 
Published data regarding thresholds in the membrane is not always clearly pre-
sented as the bound P/L ratio. Instead, the global P/L ratio is often found. This ratio 
is not as accurate as the local ratio as no information is provided on the amount of 
peptide that is actually bound to the membrane. If Kp and the sample volume are 
known, a global ratio can be corrected, but if no binding information is available 
approximations must be made: a shortcut to obtaining the local ratio without ex-
act knowledge of Kp is to consider XL very close to 1, in which case the global P/L 
ratio will tend to the value of the local ratio. From Equation 2 in the main article it 
can be seen that this is valid if [L] is large enough so that Kp·γL·[L] is much greater 
than 1. For a Kp of 5 x 105 more than 90% of bound peptide will be attained for [L] 
greater than 0.3 mM. Because many studies with AMPs are in such conditions, one 
can usually approximate the global P/L ratio as the local one, if no better alterna-
tives are available. 
Supplementary Discussion 2 – Robustness of the in vivo binding model 
In the calculations carried out in this work an in vivo scenario was severely simpli-
fied in several aspects. It is thus important to assess the extent to which approxi-
mations affect the obtained practical and theoretical conclusions. 
– Estimation of [L]MIC assay 
The estimation of [L]MIC assay from a bacterium’s weight is prone to error and implic-
itly assumes an average value. Likewise, the geometric estimates approximate the 
bacterium membrane as a spherical shell, which may not be entirely accurate, es-
pecially if rod- or spiral-shaped bacteria are considered; the same stands for the 
number of leaflets – which may double if a Gram-negative outer membrane is add-
ed – and for the area per phospholipid – which will surely vary under physiological 
conditions. However, the precise value of  [L]MIC assay is unimportant because the 
term containing [L]MIC assay in Equation 5 (in the main article) is negligible when 
[L]MIC assay << MIC, and, since (MIC·Kp·γL)-1 is in the order of 1 x 10,1 even [L]MIC assay 
equal to the MIC will only add around 10% error to the result. As such, any errors 
in the approximation of [L]MIC assay will only be of significance if they impose a correc-
tion larger than the two to three orders of magnitude by which typical MICs are 
greater than the estimated nanomolar lipidic concentrations. 
– Presence of other system components 
This model does not take into account possible interactions of the peptide with 
other system components besides the cell membrane. However, for such interac-
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tions to influence the bound concentrations – namely by significantly reducing the 
unbound amount of peptide – they would have to be extremely strong or the in-
teracting components would have to be in a very high concentration. The only 
other cellular constituent present in enough quantity to potentially sequester a sig-
nificant amount of peptide is the anionic Gram-positive peptidoglycan wall. Even so, 
this structure has at most only 20 times the volume of the membrane1 and, despite 
not being the subject of many studies, a proportionally lower affinity towards it was 
reported for the peptide omiganan,2 meaning that the presence of peptidoglycan is 
roughly equivalent to having a second membrane for the peptide to interact with. 
Likewise, bacterial DNA and RNA molecules, being markedly anionic, could bind a 
significant portion of the peptide and render the above conclusions invalid (irre-
spectively of the physiological relevance of such interactions3). This, however, should 
have little impact on the results: a total of about 3 x 107 nucleotide-associated ani-
onic charges per bacterium can be obtained taking into account average amounts 
of DNA, mRNA and tRNA in an E. coli cell.4,5 Under MIC assay conditions that num-
ber of anionic charges would bind 8 nM of a 6+ charged peptide, assuming a one-
to-one charge interaction. This is 0.4% of a 2 μM MIC – low enough not to signifi-
cantly affect the estimations. 
However, while cellular components seem to be unable to prevent high peptide ac-
cumulation in the membrane, the same might not be true for bulk phase constitu-
ents,6,7 which are often present in milimolar concentrations: one can expect high io-
nic strengths to reduce the degree of peptide interaction with the membrane by 
neutralizing the effective charge of both the peptide and the membrane surface, 
especially if the involved counterions are not easily displaced. This effect can be 
compensated for by using physiological ionic strengths when measuring partition 
constants. 
Supplementary Discussion 3 - Approximations in the partition model 
There are two simplifications implicit in the definition of the partition constant and 
partitioned peptide fraction (Equations 1 and 2 in the main article) where it is as-
sumed that the amounts of peptide in the membrane (np,L) and in the aqueous 
phase (np,W) are small compared to the total amount of lipid (nL) and water (nW) 
molecules, respectively.8 While np,W << nW is valid for practical peptide concentra-
tions, np,L << nL may not always be true for some of the high concentrations con-
sidered. The bound peptide concentration can be corrected by using the full Kp defi-
nition,8 as per Supplementary Equation 1: 
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where γL and γW are, respectively, the molar volumes of the lipid and water mole-
cules; the approximation can made assuming np,W << nW. Using Equations 1 and SE.1, 
the relative change in the [P]L value upon correction can be obtained (the ‘c’ sub-
script stands for corrected parameters): 
 γ
, ,
, ,,
[ ]
1 [ ][ ]
[ ] [ ]
p c W c
L p c W cL c
L p W
K P
K PP
P K P
 SE.2 
One can assume that Kp values, being calculated away from excessively high pep-
tide densities in the membrane, are equivalent to Kp,c. In addition, admitting that 
[P]W will not change significantly in vivo (see text), [P]W,c can be made approxi-
mately equal to [P]W. Thus, 
    γ γ
,[ ] 1 1 1
[ ] 1 [ ] 1 [ ] 1 /
L c
L L p W L L
P
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 SE.3 
This correction, even at [P]L = 130 mM (P/L = 1:10), amounts to a difference of only 
11% in the corrected concentration.  Furthermore, it is a correction in the direction 
of higher bound concentrations. Rather than invalidating any of the conclusions in 
the analysis this further approximates the results to membrane saturation. 
It should be borne in mind that, besides the above correction, the entire partition 
formalism as presented here is based on the assumption of the two phases being 
ideally diluted solutions (i.e. the peptide molecules are dilute enough not to signifi-
cantly interact with each other). As one approaches high extents of membrane 
coverage this assumption is inevitably invalidated. However, the fact that peptide vs. 
lipid fluorescence curves for BP100 and omiganan are essentially linear almost up to 
membrane saturation2,9 suggests that there is little error introduced by having high 
bound concentrations, in that range of conditions. 
Supplementary Discussion 4 – Conversion from other constants 
A different binding constant, Kb (M
-1) – or its inverse, the dissociation constant Kd 
(M) – is also commonly used, where it is assumed that the peptide interacts with 
the membrane phospholipids to form a 1:1 complex10 with reaction equilibrium con-
stant Kb; the validity of this approach to interpret membrane partitioning is dis-
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cussed elsewhere.8,11 Because published data are sometimes analyzed in this alterna-
tive framework, a conversion between both Kp and Kb is presented. Kb is defined as: 
   
 
       
complex
free free
[ ]
(1 ) (1 )
L L
b
L L
PL X P X
K
P L X P L X L
 SE.4 
where [PLcomplex] is the concentration of the 1:1 peptide:lipid complex, [P]free, [P], [L]free 
and [L] are the unbound and the total concentrations of peptide and phospholipid, 
respectively, and XL is the mole fraction of the bound peptide. The approximation 
of [L]free to [L] significantly simplifies the calculations, but, in the case of high extents 
of binding, an error will be introduced. Because this approximation is roughly 
equivalent to the assumption of np,L << nL in Supplementary Discussion 3, the result-
ing correction of the bound concentrations will be subject to an error of similar 
magnitude. 
Supplementary Equation 4 can be solved for XL: 
 
  1
b
b
L
K L
K L
X  SE.5 
It then becomes obvious, by comparison with Equation 2 in the main article, that in 
the limit of weak interactions: 
 γp b LK K  SE.6 
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This concludes my account of the methodological side of my research —
although the interested reader can find in the Appendix further experi-
mental processes I developed during my PhD.
Looking back, I am amazed at the time it took to make all the relatively
simple connections described in this part. The theoretical notions derived
in this section can be explained to any biophysicist in less than an hour.
Still, they took five years to mature! It is somewhat scary, and challenging,
that a trivial breakthrough can be as elusive as a complex find. In the end
I am glad that with this PhD I also got to learn such peculiarities of the
construction of scientific knowledge.
End of Part II

Unfinished business
During this project there were, inevitably, several avenues of investigation
that were only partly undertaken at one time or another, or that are still
open at the time of writing. The reasons for not having carried them out
to completion range from lack of motivation to lack of time. Nevertheless,
I find it positive that my work consisted not only in addressing scientific
questions but also in generating them – even if these remain unanswered
for the time being.
The toxicity of BP100 to mammalian cells
The move to the Institute of Molecular Medicine drove my research
towards more biological goals. Namely, the inclusion ofAnaCorreia in the
group prompted us to try and tackle questions that could be addressed by
her technical expertise in cell biology. In this section, all the experimental
aspects of cell preparation were carried out by Ana, whereas I was
mainly involved in fluorescence microscopy and data analysis (although
I had little prior experience in fluorescence microscopy, by being familiar
with its spectroscopic counterpart as well as having attended an IMM
shortcourse on bioimaging, I was able to learn the basic practical aspects
and become independent pretty quickly).
Ana started out by subjecting three types of cultured mammalian
cells (V79 Chinese hamster lung fibroblast, Huh-7 human hepato cellular
carcinoma, and HeLa — henceforward collectively abbreviated “cultured
cells”) to BP100, and the first observation was that these cells were about
five-fold more susceptible to the peptide than what had been reported for
erythrocytes42 (the initial set of these results, with hamster fibroblasts,
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was included in Article iv). Three different viability assays testing for
membrane integrity, mitochondrial function, and adhesion, closely agreed
on the IC50 value, the drug concentration required to kill half of the
cells. In spite of this susceptibility, BP100 is still a good 10- to 20-fold
more active against the Gram-negatives tested in Gerona42 and by us (see
Section 3.5) than against the cultured cells.
This observation indicated that the erythrocyte may be an overly simple
model, at least concerning this peptide’s toxicity, and the possibility that
the same might be true for other AMPs is very interesting: the erythro-
cyte is a prevalent model in AMP toxicity assessment; if discredited, the
safety of many AMPs would have to be reevaluated. Once again, we
were aiming at hypotheses with far more impact than just the peptide at
hand.
Differences in the composition of the plasma membranes of the erythro-
cyte and the cultured cells could account for a distinct lytic behavior but
we preferred to focus on a much more interesting hypothesis based on the
difference in organelles between the two cell types: admitting that BP100
is able to translocate across the plasma membrane, a very likely inner tar-
get in the cultured cells, given the peptide’s affinity for bacteria, would be
the mitochondria. And these happen to be conveniently absent from the
mature erythrocyte.70 Equipped with this hypothesis I started envisioning
toxicity processes by which mitochondria would burst, leaving the cell to
die of ATP deprivation, or, alternatively and more spectacularly, releasing
mitochondrial effectors71 that would trigger cascades ultimately culminat-
ing in apoptosis! This last hypothesis-from-a-hypothesis was particularly
appealing, as there is something about “apoptosis-mediated toxicity” that
distinctly sounds like “cancer therapy”. 72
At this point we had two hypotheses to test: are the mitochondria the
primary targets in BP100 toxicity? And could other AMPs act similarly?
We put our efforts into following, in real time under the microscope, the
fate of the mitochondria in the hamster fibroblasts upon addition of BP100.
To this end we relied on JC–1, a two-in-one fluorescent mitochondrial
probe that fluoresces red if there is a transmembrane potential (i.e. mito-
chondrial respiration is active) and green if not. While JC–1 fluorescence
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was observed, the shape of the cells was monitored, using transmitted
light, to detect occurrence of lysis.
The first images we took, in the absence of peptide, were great. Bunches
of green mitochondria filaments, not unlike noodles, spotted bright red
here and there, could be clearly seen within the cells: it was very inter-
esting to observe, though expected from other reports on mitochondrial
staining,73 that only a small segment of the mitochondrion is normally po-
larized while the rest sits idle, perhaps awaiting a sudden increase in the
demand for ATP. The recorded images, captured in a confocal microscope,
were not as cool as observed through the eyepiece in widefield mode* but
were good enough to attempt quantification of the increase/decrease of
either color upon addition of BP100 and, indeed, a clear reduction of the
red fluorescence intensity was visible in the first fewminutes after peptide
addition. Because mitochondrial depolarization would strongly support
our hypothesis we were very excited about this, only to learn shortly
afterwards that the controls displayed the same intensity decrease due to
a very fast and red-selective photobleaching. Disappointed, we carried on,
trying to adjust observation parameters to get rid of the dreaded bleach-
ing, hoping that some peptide effect would be visible underneath. These
hopes were not completely unfounded: in the same experiment where
the fast decrease of the JC–1 red fluorescence intensity was observed, a
small increase of the green fluorescence, indicative of depolarization, was
also detected; and this increase was visible even before any correction for
photobleaching. In another occasion I made an interesting observation,
albeit anecdotal like most in these experiments: we had left for a couple of
hours a fibroblast culture incubating, under the microscope, with a BP100
concentration equal to its IC50. When I returned I found that apart from
the imaged region, which had become inevitably bleached, most adherent
cells were bright red — quite unlike the situation at rest — but several
others had detached (and presumably died), and these were mostly green.
*At the time we were using a confocal microscope not because we needed confocality —which
actually was not ideal for whole cell observation — but because it was the microscope most
accessible to us with temperature and CO2 control, required to keep the cells alive during the
observation time.
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Many possible direct and indirect effects of BP100 may have elicited that
cellular response in the survivors; in any case, had we been able to repro-
duce the observation, this would be a clear link between the mitochondria
and the toxicity process.
To deal with the photobleaching issue, we started using a widefield
microscope, but the change in system entailedfurther steps of optimization.
Even after those, no matter what we tried, the probe seemed to be getting
more and more susceptible to photobleaching. At this point, things took
another turn for the worst: our cells started to mysteriously lose viability
and JC–1 seemed to be the culprit — although it had behaved perfectly
well in the initial runs! I was quickly losing motivation: what had begun
as a challenging biophysics-meets-biology experiment had by then become
a problem of optimization of several parameters, most of them related
to cell culture techniques. Not only did I find this very unappealing, I
also felt impotent to provide valuable input and, eventually, I stopped
dedicating effort to this project. We never got to testing other AMPs.
Testing saturation in bacteria
After having found evidence linking the in vivo charge neutralization
of E. coli with the MIC Carla Alves and I looked for a way to verify
the MIC-saturation correlation hypothesis. The co-occurrence of satura-
tion and neutralization in model membranes had been observed, which
indirectly supported the hypothesis, but we needed stronger evidence.
We decided to employ with BP100 a method similar to the approach I
describe in Section 4.3 to measure the magnitude of omiganan interaction
with peptidoglycan: BP100 was incubated with bacteria, the suspension
was then centrifuged and the fluorescence emission of the unbound peptide
measure from the supernatant. As we were looking for saturation, and
contrary to theworkwith peptidoglycan, it was the peptide concentration
to be scanned instead of the amount of bacteria. Carla carried out the
majority of the practical part of the work and I did most of the data
analysis.
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I was aware that the main obstacle to this, and probably most ap-
proaches, is that the recommended bacterial densities for MIC assays74
(between 2 and 7× 105 cfu/mL — ‘cfu’ standing for ‘colony-forming unit’)
are likely to be too low for even a strong binding to be detected, much less
for a distinction between saturation and non-saturation to be observed —
recall the conclusion from the application of Equation 4.2 to an in vivo
setting, in Section 6.1. Our workaround was to use higher bacterial densi-
ties: at 109 cfu/mL Equation 4.2 predicts 43% of bound peptide (under the
assumptions detailed in Section 6.1), which should already be measurable.
In practice, we took a bacterial suspension in exponential growth phase,
washed it thrice in buffer (in the process concentrating it to the target
109 cfu/mL), incubated with different amounts of peptide (10 minutes),
centrifuged one last time, discarded the pellet and collected the supernatant
for measuring. Using such high densities, however, departed from ideal
conditions and if saturation was observed any relation to the MIC would
have to be extrapolated. Furthermore, the E. coli strain we were using
reached at most 108 cfu/mL on its stationary phase: forcing a density
ten times higher than that value, even for the short preparation period,
could have unexpected results. I hoped, nevertheless, that the putative
saturationwould be observed and that, consistently, the saturating peptide
concentration would be proportional to the bacterial density — in that
case the extrapolation back to MIC assay bacterial concentrations would
be straightforward.
I expected saturation points to be identifiable from a curve of bound
fraction vs BP100 concentration: if anything similar to a Kp or a Dv
partition was valid then the bound fraction should be constant before
saturation, whereas afterwards it should decrease with every addition of
the peptide. However, when we tried to obtain those points Carla and
I came across a serious obstacle: strong contaminating fluorescence was
visible in the samples’ emissions. The responsible compounds were either
being released by bacteria into the supernatant (as the peptidoglycan had
in the omiganan–cell wall interaction studies) or they were unwashed
growth medium leftovers. These contaminants had a high protein content,
judging by the characteristic tryptophan and tyrosine emission spectrum,
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and their fluorescence overwhelmed the peptide’s tyrosine emission at all
but the highest BP100 concentrations. Correction using controls without
peptide was error-prone because of a high variability in the degree of
contamination and of the difference in magnitudes between the peptide
and contaminant fluorescent intensities — not to mention the possibility
that release of cellular contents depended on peptide concentration.
Instead of attempting the subtraction of a given control I tried instead
to fit the observed emission spectra with a linear combination of the
spectra of BP100 and of the contaminants (obtained from a control). I
hoped to reach good fits because the contaminants’ spectrum was domi-
nated by tryptophan emission, with only a small relative contribution of
tyrosine (as expected for any biological sample with average amounts of
tryptophan and tyrosine, given the latter’s lower absorptivity and quan-
tum yield). Any tryptophan-like emission in our samples could then be
used to gauge the relative contribution of the contaminants’ spectrum;
the remaining fluorescence would be due to BP100 emission. At this
point we became aware of an additional, and significant, fluorescence
contamination that prevented the spectral decomposition of the emission
spectra of our samples. This time the offending compound was polypropy-
lene. Polypropylene is a ubiquitous material in sample preparation and
has an emission spectrum that significantly overlaps with tryptophan. We
were able to narrow down the main source of polypropylene to the filters
we were using to sterilize the stock peptide solutions; by skipping this
step, which was unnecessary since we were not interesting in observ-
ing bacterial growth, we were able to drastically reduce contamination.
Still, centrifugation in plastic tubes and the use of plastic pipette tips
was enough to introduce some polypropylene into the samples. To be
able to achieve good spectral decompositions despite of this fluorescence
background I opted to take excitation–emission maps of samples and con-
trols (Figure a.1). The three-dimensional fluorescence spectra did allow a
better separation of the emissions of BP100 and contaminants but spectral
decompositions was not of good quality (Figure a.1f). I suspect that
the spectrum of the biological contamination was not constant, probably
due to variable contributions of tyrosine and tryptophan emission. The
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Figure a.1 –Excitation–emission maps (unpublished) of (A) buffer, (B) polypropylene, (C)
proteic contaminant from bacteria or growth medium, and (D) 50 µm BP100; intensities in
arbitrary units (a.u.). Map A was previously subtracted from maps B through D. These
four spectra were used to decompose the excitation–emission map of the supernatants from
peptide-bacteria incubations. Spectrum E is one such map, at 10 µm BP100; residuals from
the best decomposition fit are plotted in F (lighter traces indicating negative values) and are
clearly not random, especially in the 340 nm, 290 nm region; combination factors were 1.86,
1.16, and 0.14 for maps B, C, and D, respectively; the factor of map A was always 1.
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results obtained this way did not exhibit any sign of saturation. On the
contrary, the more peptide was added to bacteria the more it seemed to
bind. Many inferences would be possible from this observation, such as
cooperative peptide-bacterium interaction, or permeabilization of bacteria
followed by binding to internal components. I preferred, however, not
to waste clean thoughts on dirty data, especially since the error in the
decomposition (expressed as the sum-of-squares of the residual spectra)
increased with peptide concentration.
Carla’s departure and my starting to write this book put an end to
our efforts to observe saturation in vivo. Alternatives to our method
may include peptide labeling with a fluorophore, although I always feel
uncomfortable at the idea of appending anything to such a short sequence.
Another option may be to synthesize 13C or 15N labeled BP100 and
proceed to its detection by liquid NMR (or even to use the already
synthesized fluorinated analogs). This approach would, in principle, allow
the detection of binding without the need for phase separation: the
molecules that are bound to bacteria will have a very slow correlation
time, which causes their signal to vanish (very slow correlation times
entail very fast spin-spin relaxations and a consequent broadening and
flattening of the corresponding peaks); the measured signal would then
be proportional to the unbound peptide fraction.
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The work I carried out during my PhD was mainly related to AMPs.
There were, however, some exceptions that fell outside the scope defined
by the title of this thesis — sometimes even unrelated to the field of peptide
studies altogether. For that reason publications resulting from this work
were not included in this book and are only referred to instead.
Work with non-AMPs stemmed mostly from a partnership Miguel
established with the group of Andrea da Poian at the Federal University
of Rio de Janeiro. This collaboration focused on the study of dengue virus
and, as usual, we provided biophysical expertise on the characterization
of peptide-membrane interactions. The Rio group expressed and purified
relevant peptides (from the capsid and envelope proteins), and performed
a wide range of biochemical and biological studies with both peptides and
whole viruses. Fausto Stauffer, then finishing his PhD under Andrea’s
supervision, was the first exchange student under this collaboration. He
visited our group to apply our methodologies to study segments of the
dengue virus envelope protein, namely, peptides putatively responsible
for fusion of the viral envelope with the host’s membrane.
At the time Miguel and I were reaching the first conclusions on
saturation and it was interesting to observe that Fausto’s peptides also
displayed changes in interaction behavior upon the crossing of some
sort of bound concentration threshold. I helped Fausto apply my recent
conclusions to his case and design some relevant experiments. I also
analyzed data he had obtained on the in-depth bilayer localization of
the peptide, using the algorithm I had been working on (see Section
‘Differential quenching’ in the Appendix). Lastly, I wrote a small part of
the resulting paper,75 of which I am co-author.
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* * *
Shortly after I began my studies with BP100 I was given the opportunity
to go to Rio for a six months’ stay to learn NMR techniques. Work was
carried out in the groups of Ronaldo Borges and FábioAlmeida, both close
collaborators of Andrea’s. The objective was to better understand the
fusion process of the dengue virus, usingNMRto structurally characterize
the binding to membranes of the viral fusion peptide.
While in Rio, I learnt the basics of NMR spectroscopy, from spectro-
meter operation to data analysis. I also became familiar with some of the
technique’s idiosyncrasies, namely, the complex and lengthy data acquisi-
tion process and the highly disputed operation time. Indeed, during those
six months I only used an NMR spectrometer in about ten occasions —
too little equipment time for me to become an independent user. Also be-
cause of the limitations on equipment time measurements were restricted
to the fusion peptide, although I had initially hoped to also be able to
study my AMPs by NMR. I did, however, get a first-author publication
on the findings with that peptide.76 In addition, after I learned the basics
of spectral analysis, and also as part of my training, I collaborated with
the group of José and Lúcia Previato in a study on glycolipids, which also
resulted in a publication.77
Besides NMR, I also did some molecular biology work while in Brazil:
the cloning of E. coli bacteria with a gene encoding for the fusion peptide.
The objective was to mass express the peptide while being able to incor-
porate 13C or 15N isotopes into it, thus widening the range of applicable
NMR methodologies. Although the peptide expression would turn out
to be too low for purification, practice in the handling of bacteria came
in very handy later, when Carla and I were planning and carrying out in
vivo validation of hypotheses.
My training in Rio was not sufficient for me to be able to independently
perform NMR measurements upon returning to Lisbon, especially since
no high-field spectrometers were readily available to our group. To use
NMR we would have to either buy equipment time or partner with an
NMR group, which was what we later did with the Ulrich lab.
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NMR is a very powerful technique and my training made me aware of
its possibilities — namely, those of liquid NMR, the variety I worked with
in Rio. As the reader will have noticed, I always seek to expand upon
the methods I use and there are many ways NMR can be customized and
potentially improved. I was a bit disappointed, though, that given the
scarcity and cost of equipment time there is usually little chance for trial-
and-error experiments with measurement conditions. Still, and despite
being mostly unrelated to AMP studies, my trip to Brazil was of great
importance to the construction of my scientific background.
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Postface
In this book I frequently departed quite a lot from a formal scientific
writing. More than a matter of style this was a way to convey the true
dimension of my first years as a researcher and the contribution of each
advance and failure to my learning.
I also wanted to transmit my view on the different facets of research,
which is something I found very important to become aware of. I
now have a much better idea of which kind of work I prefer and am
more productive at. Taking that into account, I recently chose to di-
rect my future training and research towards computational simulation
techniques, namely those involving molecular dynamic simulations of
peptide-membrane interactions. Working in this field will allow me to
test some of the hypotheses raised during my PhD, and, very importantly,
to do so using methodologies where experiments and mathematical models
come together. In addition, I will very likely be addressing some of the
ends that were currently left loose.
Future directions are, by no means, restricted to the incomplete work
described in the ‘Unfinished business’ chapter: in this book many con-
clusions were taken on the mechanism of “typical” AMPs and on the
applicability of methods to peptides in a general sense. While the perfor-
mance of some of the predictions against peptides other than omiganan
and BP100 was assessed in Articles v and vi, most other hypotheses
and methods remain only weakly tested. There is plenty of room for
improving upon the research presented here.
Lastly, I must say I have looked upon the writing of this book hardly as
an obligation but as an opportunity to use my creativity to honor my many
collaborators and the good scientific work they helped me achieve. And,
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irrespectively of the actual impact (if any) on the field of peptide studies,
it seems — judging from the selected news clippings in the opposite page —
that I am already leaving a legacy!
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View from the FEBS Booth
By Louise
This year I have decided to give out two special FEBS News awards.  The winners are:
Bravery Award
Last year FEBS News reported that fearless Secretary-General 
Israel Pecht, was the only man to attend the Women in Science 
Career lunch. This year the honour went to this chap, whose 
name I don’t know, but I do know he was from Portugal.  The 
WISE lunch is open to all, yet this fool hardy man was the only 
one strong enough to take on the might of 76 women partici-
pants.  I hear on the rumour mill that he enjoyed it and found it 
interesting.  So hats off to you!  
The thing I want to know is why more men don’t attend.  Come 
on chaps! 75 intelligent, articulate, scientists with varied and 
interesting opinions from all over the world all together in one 
room!!  Yes dreams can come true!
For our 2008 Bravery Award winner, If you are reading get in touch, we would really like to hear your opinions.

in FEBS News, Sep 2008
FEBS NEWS 
View from the FEBS Booth 
  
By Louise McSeveny 
 
I also have to make a special mention to participant Henri 
Franquelim from Portugal.  Last year I reported that only 
one brave Portuguese man had what it took to attend the 
Women in Science lunch and enjoy the company of room 
full of intelligent women. Well this unnamed chap went 
back home told Henri he should attend, which he did and 
here he is: 
I should point out that the WISE career lunch is about 
discussing careers of women, but can the careers of 
women be discussed in a vacuum without the participa-
tion of men?  Shouldn’t we work together to resolve is-
sues of family, glass ceilings and career development? I 
lay down the challenge to all young men reading this for 
more active participation in the WISE event in Gothen-
burg next year.  You too can have your photo on these 
pages! 
Prague Congress News 
in FEBS News, Sep/Oct 2009
Obviously Portuguese men are made of sterner stuff. 
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Appendix — Other methods
Article vii How to address CPP andAMP translocation?Methods to detect
and quantify peptide internalization in vitro and in vivo
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The methods I have developed, though always involving peptide-mem-
brane interaction, are not limited to the scope of partition and saturation.
In this chapter I present other contributes I made: on the assessment
of peptide translocation across membranes, on the detection of peptide-
induced vesicle leakage, and on the measurement of in-depth peptide
positioning in a bilayer.
I sought a method to detect translocation for about three years; in
the meantime Miguel, Sónia (who had also carried out work involving
translocation) and I even got to write a review on available alternatives,
classifying them and detailing their pros and cons. I start out by presenting
this review, the writing of which inspired subsequent ideas.
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How to address CPP and AMP translocation? Methods to detect and
quantify peptide internalization in vitro and in vivo (Review)
SO´NIA TROEIRA HENRIQUES, MANUEL NUNO MELO, &
MIGUEL A. R. B. CASTANHO
Centro de Quı´mica e Bioquı´mica, Faculdade de Cieˆncias da Universidade de Lisboa, Lisbon, Portugal
(Received 22 June 2006 and in revised form 13 October 2006)
Abstract
Membrane translocation is a crucial issue when addressing the activity of both cell-penetrating and antimicrobial peptides.
Translocation is responsible for the therapeutic potential of cell-penetrating peptides as drug carriers and can dictate the
killing mechanisms, selectivity and efficiency of antimicrobial peptides. It is essential to evaluate if the internalization of cell-
penetrating peptides is mediated by endocytosis and if it is able to internalize attached cargoes. The mode of action of an
antimicrobial peptide cannot be fully understood if it is not known whether the peptide acts exclusively at the membrane
level or also at the cytoplasm. Therefore, experimental methods to evaluate and quantify translocation processes are of first
importance. In this work, over 20 methods described in the literature for the assessment of peptide translocation in vivo and
in vitro , with and without attached macromolecular cargoes, are discussed and their applicability, advantages and
disadvantages reviewed. In addition, a classification of these methods is proposed, based on common approaches to detect
translocation.
Keywords: Cell-penetrating peptides, antimicrobial peptides, membrane translocation, peptide uptake, evaluation of peptide
internalization
Introduction
The introduction of hydrophilic molecules into
mammalian cells has become a key strategy for the
investigation of intracellular processes and drug
therapy. Several methods have been devised to
achieve this goal, but they all have limitations [1].
Some peptides are able to translocate across cell
membranes with low toxicity [25] and to mediate
cellular uptake of proteins [3] and other macromo-
lecules [6,7]. These peptides are known as cell-
penetrating peptides (CPPs) but the CPP designa-
tion is now generalized for all the peptides with the
ability to translocate across membranes even when
cargo uptake properties are unknown. They include
natural, newly synthesized and chimeric peptides
[8]. Beside the ability to translocate through cell
membrane, these peptides are normally character-
ized as short, cationic, water-soluble peptides with
high efficiency and low cytotoxicity [9]. The me-
chanism used by CPPs to pass the membrane is not
well understood and is a controversial topic in the
literature. At the beginning the internalization me-
chanism of CPPs was generalized and considered to
be endocytosis-independent [2,5]. Nowadays there
is experimental evidence for both endocytic and
non-endocytic routes (for further information see
[9,10]). Considering the information available in the
literature a unique mechanism for all the peptides
does not seem reasonable and more than one
mechanism can operate for a single peptide [10].
Ribosomal antimicrobial peptides, or AMPs, are
efficient antibiotics against a variety of microbial
pathogens [1114]. These peptides are usually short
and cationic [15] such as CPPs, but they are also
characterized by a strong interaction with cellular
membranes, and by the ability to selectively attack
pathogens without disturbing host cell integrity
[16,17]. AMPs are potential candidates of a new
antibiotic generation against multiresistant bacterial
strains [16].
Despite the fact that most AMPs exert their
principal activity at the membrane level [15,17],
translocation processes have been shown to occur for
many of them [18,19]. Considering this, AMPs are
natural templates for designing cell-penetrating
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molecules, which can be developed into carriers
[9,20]. AMPs and their derivatives are thus very
promising molecules to use both as antibiotics and as
drug transporters.
To guarantee that a specific peptide works as a
CPP, its ability to cross the membrane and the
capacity to transport attached cargoes is of first
importance. Regarding AMPs, internalization is not
a prerequisite and the biological efficiency of AMPs
can be evaluated without translocation assessment.
However the characterization of such membrane
processes is of great value both in the development
of new antibiotics and in the design of templates for
CPPs [10].
In this paper we will review methods that are
available to evaluate peptide uptake into cells or
vesicular model membranes.
Methods used to evaluate peptide uptake
Assessment of peptide translocation without attached
cargo or labelled with a fluorescent probe
In vivo methods. The CPPs internalization mechan-
ism is a matter of vibrant discussion in the literature.
To evaluate if CPPs are internalized by endocytosis
the dependence of translocation on temperature, or
in the presence of specific endocytic inhibitors must
be assessed in vivo. The intrinsic fluorescence of Trp
or Tyr residues cannot be used to investigate peptide
internalization in vivo, due to the relatively large
cellular background fluorescence in the near-UV.
Therefore, CPPs are normally derivatized with
fluorophores such as Rhodamine B (Rh) [2124],
Fluorescein [5,2532] and Nitrobenzoxadiazole
(NBD) [24,33]. Alternatively, the properties of
macromolecular cargoes can be used. In most of
the methods described in this section, peptide
fluorescence is the experimentally measured signal.
However the need to derivatize a peptide can be a
limitation not only due to experimental and costly
requirements but also because the presence of a dye
may alter its properties [34].
Available methods for the in vivo detection of
peptide internalization can be divided into three
categories: quantification of cytosolic concentration,
direct visualization of internalization and peptide
activity analysis.
Quantification of cytoplasmic concentration. Quantifi-
cation of cytoplasmic concentration is usually car-
ried out by means of direct measurement of
fluorescence emission of peptides. In these methods,
elimination of the non-internalized and cell-
adsorbed peptide fractions is required to avoid an
overestimation of peptide internalization; conse-
quently, extensive washing procedures, including
trypsinization and centrifugation, are required
[21,22,29,30,35,36]. Quenching of peptide fluores-
cence is an alternative to annihilate non-internalized
peptide signal [24,33,37].
A cell lysate should be prepared and the fluores-
cence intensity of labelled-CPP in supernatant
measured [29,32]. The washing procedures can be
responsible for a signal reduction, due to sample loss
and fluorescence bleaching. An additional limitation
is the necessity to distinguish the peptide fluores-
cence from the cell background fluorescence; to
assure a good signal/noise ratio the fluorophore
should be chosen carefully to avoid overlap with
intrinsic cellular fluorescence emissions and to
circumvent a fast fading of fluorescence. For in-
stance, Trp fluorescence of peptide can hardly be
used due to the intrinsic fluorescence of cellular
proteins. The fluorescence of cellular NAD(P)H
(/460 nm) and FAD (/530 nm) is an additional
concern. A high amount of cellular sample should be
used to provide a good emission signal and controls
without fluorophore in the same conditions (e.g.,
cell number and washing procedures) must also be
used; a calibration curve should be prepared to allow
quantification of internalization. In this case, abso-
lute quantification of the internal peptide concentra-
tion may also require information on the total
cellular volume.
Oehlke et al. developed a method to discriminate
membrane surface-bound, membrane-inserted and
internalized peptide fractions [38]. To obtain quan-
titative information on the peptide fraction asso-
ciated with plasma membrane and the peptide
fraction actually internalized, the exposed peptide
was treated with diazotized 2-nitroaniline. This
procedure modifies the peptide fraction bounded
to the surface, without damaging the cell [39].
Bound and internalized fractions were detected by
HPLC analysis of cell lysates and quantified by
spectrofluorimetry (5(6)-carboxyfluorescein-N-hy-
droxysuccinilmide esterlabelled peptide detected
with excitation at 445 nm and emission at 520 nm).
The fraction of surface bound peptide is strongly
modified by the diazo reagent which renders the
peptide completely undetectable in HPLC chroma-
togram (there is a strong retention of highly hydro-
phobic modified products on the stationary phase of
the HPLC column). The fraction of peptide inserted
into plasma membrane is slightly protected from
the attack of the diazo reagent, so this fraction is
only partially modified. The fraction of peptide
inaccessible to the diazo reagent is the internalized
fraction [38].
Flow cytometry analysis by fluorescence activated
Cell Sorter (FACS) is a tool to quantify cellular
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association of a fluorophore-labelled peptide. A large
number of cells are analysed and dead cells are
identified by propidium iodide staining [21,22,30,
32,33,35,40]. The cell subpopulation displaying
significant fluorescence emission is identified and
quantified, and the CPP uptake is measured as the
cell-associated fluorescence intensity. An absolute
quantification of the internalized amount of peptide
requires either a comparison with a standard [41] or
the use of additional methods, such as the ones
described above. The need to wash/quench the
membrane-bound peptide fraction, also applies for
flow cytometry analysis.
A kinetic evaluation of the translocation process
has been obtained by testing the inaccessibility of
externally added trypan blue to fluorescein-labelled
peptides [42]; the rationale behind this approach is
shared by many methods described for in vitro
translocation studies (see below).
Matrix-assisted laser desorption ionization-time-
of-flight mass spectroscopy (MALDI-TOF MS) has
been used to evaluate the exit of internalized
peptides from cells into the culture medium
[32,43], to detect peptide internalization and to
investigate intracellular degradation [32,36,4345].
This method allows the direct detection of the
peptide and uptake quantification [44]. The sample
(extracellular or intracellular supernatant) has to be
concentrated to improve the signal. Elmquist and
Langel proposed a procedure where samples are zip-
tipped, analysed by MALDI-TOF MS and com-
pared with synthetic peptides for a quantitative
analysis [32,43]. Instead of synthetic peptides the
quantification of the internalized CPP can be
achieved with an internal standard with the same
sequence but labelled with deuterium. Peptides are
biotinylated and, after cell lysis, they are captured by
streptavidin-coated magnetic beads. Finally, beads
are washed and analyzed by MALDI-TOF MS and
the absolute amount of internalized peptide is
determined. This procedure is also adequate to
know if the peptide has been degraded during
sample preparation or inside the cell [44]. Inherent
disadvantages in this method are the necessity for
specialized and expensive procedures, and equip-
ment to obtain peptide quantification. Moreover, it
is rather time-consuming.
Direct visualization of internalization. In early studies,
CPP internalization into cells was studied by fluo-
rescence microscopy or in fixed cells where the
fluorescence emission of a peptide-derivatized probe
was directly visualized [5,26,33,46]. Internalization
of some AMPs has also been identified by a
fluorescent label and visualized under the confocal
microscope. For instance, biotin-labelled polyphe-
musin I [47] and FITC-labelled buforin II [48] were
detected in the cytoplasm of E. coli without dama-
ging the membrane; FITC-labelled magainin 2 was
detected on the E. coli cell wall [48]. Internalization
in mammalian cells was also observed with biotin-
labelled LL-37 and localization in the perinuclear
region was detected [49]. Alternatively, the presence
of peptides in cells can be detected by immuno-
fluorescence; for example, the localization of LL-37
was visualized with a specific antibody [49].
Fixation procedures can bias the location of
peptides in cells as the illusionary presence of
peptides inside cells can arise from the high affinity
of cationic peptides to cell surface [50]. Therefore,
peptide internalization in cells has to be compared in
fixed and non-fixed conditions [27,30]. Cell treat-
ment with trypsin to digest the peptide at cell surface
[27,30,32], or quenching of peptide fluorescence has
to be performed to remove the interference of the
membrane-bound fraction. In these conditions it is
possible to distinguish a deep localization inside the
cell from membrane adsorption [24]. With confocal
microscopy different cellular plans can be used to
confirm, or refute, peptide internalization.
Peptide activity analysis. In this class of methodolo-
gies, the effect of the peptides in the cytosol or in the
membrane is evaluated. AMP translocation in vivo
has been inferred from observations of intracellular
damage (e.g., [51]) or morphological alterations of
bacteria [5254].
In other reports, the peptide interaction with
membranes was evaluated by electrophysiological
transmembrane current measurements in oocytes
[55,56]. With this setup it is possible to have access
to both sides of lipidic membranes and it is not
necessary to derivatize the peptide with a fluoro-
phore. However, this detection can be ambiguous
because transbilayer current can arise from the
activation of endogenous channels in oocyte mem-
branes. In order to rule out this possibility these
experiments should be repeated on artificial lipid
membranes [57]. In addition, only qualitative
information about translocation can be obtained
unless a quantitative relationship between trans-
membrane current and internalization is assumed.
Lastly, the occurrence of membrane destabilizations
induced by peptides is not a proof of their ability to
translocate across the membrane and reach the
cytoplasm.
In vitro methods. Various biophysical approaches
have been used to study peptide-lipid interaction in
model bilayers. When CPPs are internalized by a
physically-driven translocation mechanism, peptide-
lipid interactions are truly important. Application of
CPP and AMP translocation 175
Article vii 157
in vitro methods to evaluate the internalization of
CPP is, however, scarce; on the other hand, AMP
translocation has been essentially studied using
model membranes. Nevertheless, in vitro studies
face some difficulties and limitations. Large unila-
mellar vesicles (LUV), or small unilamellar vesicles
(SUV), are the most used membrane models for the
in vitro study of peptide-bilayer interactions. But,
detection of peptide entry into the vesicular lumen is
not easy. Theoretically, in a simple setup, it is
possible to encapsulate an aqueous phase entity
that could report peptide proximity or interaction
(a quencher, or a fluorescence resonance energy
transfer (FRET) acceptor for Trp fluorescence for
example) and use it to probe the translocation event.
However, the feasibility of this task can be hampered
by several factors (see worked examples in part 1 of
the Supplementary material in the online version).
Several methods have been proposed to overcome
these limitations, for instance peptide-lipid FRET
(e.g., between Trp-labelled peptide and Dansyl-
PE-labelled lipidic vesicles) and/or permanent
alteration of the peptide either in or out of the
vesicles (e.g., peptide digestion by trypsin) [18,19].
A classification of methods can be devised regarding
the peptide location with respect to the bilayer:
(i) detection of entrapped peptide lack of accessi-
bility from the outer phase, (ii) detection of inward
peptide positioning within the membrane, (iii) direct
detection of peptide in the inner phase, and
(iv) detection of encapsulated peptide escape. Be-
cause of the many possible combinations of techni-
ques and experimental setups some reported
methods do not fall within the given categories,
therefore, a fifth group of ‘unclassified methods’ is
also presented. This classification differs from the
one used for the in vivo methods mostly because for
in vitro a wider range of approaches to the assess-
ment of translocation have been described.
A schematic representation of in vitro methods
from all the classes, with focus on the fluorescence
methodologies, is depicted in Figure 1.
Detection of entrapped peptide lack of accessibility from
the outer phase. A semi-quantitative determination of
translocation can be performed by detection of
peptide inaccessibility to a non-translocating entity
[19,24,5860] after incubation with the model
membranes (see Figure 1, panel A). For example,
translocation of AMP magainin 2 was identified by
the observation that the percentage of inaccessible
peptide increases with peptide-lipid incubation
time [19]. To perform this experiment trypsin was
used to digest peptide after interaction with accep-
tor-labelled lipid vesicles. It was shown that proteo-
lysis-dependent FRET reduction decreases with
incubation time before trypsin addition. It was thus
concluded that the peptide becomes inaccessible to
trypsin with time. This is consistent with peptide
translocation.
This concept can be used with different external
components, for instance non-labelled vesicles to
desorb the peptide from the labelled vesicles [19,60].
An inverted setup has also been reported where the
peptide (in this case, labelled with NBD or bimane
fluorophores) was incubated with the non-labelled
vesicles and desorption was induced by addition of
acceptor-labelled anionic vesicles [59] (a FRET
increase, rather than a decrease, was detected in
this case). The use of NBD-labelled peptides and
addition of dithionite ion as the non-translocating
entity is another possibility; in this case, the NBD
fluorescence intensity was measured without the
need to label the vesicles [24,59]; dithionite acts in
a way similar to digestion by trypsin in that the NBD
reduction/quenching is permanent. In all these
approaches, an estimation of the translocation
kinetics can be obtained by adding the non-translo-
cating component at different incubation times
[24,59].
It should be noted that in all these methods a
time-dependent measurement is required to deter-
mine the degree of peptide inaccessibility (as ex-
plained in detail in section 2 in the Supplementary
material online).
These methods have a number of disadvantages:
first, they are unable to discriminate membrane-
bound and internalized peptide; second, in the case
of lysis, which can occur for AMPs, peptide popula-
tions in inner and outer layers could be accounted as
accessible, resulting in a low extent of apparent
translocation; finally, not all of these methods are
compatible with all peptides: for instance some
AMPs are resistant to trypsin proteolysis (e.g.,
Polymixin B and Gramicidin S) [18]. In addition,
when using trypsin, extents of translocation may be
overestimated if the peptide fragments also interact
with the membrane.
Detection of inward peptide positioning within the
membrane. In this category, the passage of the
peptide to the inner leaflet of the bilayer is mon-
itored. In all the reports where this method is used
[19,61,62], internalization is evaluated by the use of
vesicles with asymmetric labelling. The fluorophore
in membranes is a FRET acceptor for Trp-contain-
ing peptides (see Figure 1, panel B).
Wimley and White developed a methylcoumarin
derivatized lysophospholipid (LysoMC). This lipid
is easily incorporated into bilayers (into both bilayers
or only into the outer one) and is able to act as an
efficient Trp-fluorescence acceptor/quencher [63].
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This probe was initially used to characterize the in-
depth membrane distribution of Trp-containing
peptides [63], but more recently, Norden and co-
workers have developed a method in which LysoMC
is used to specifically test translocation; in addition,
they described a procedure where is possible to use
LysoMC to selectively label the inner layers [61,62].
Experimentally, translocation information is ob-
tained by comparison of emission spectra of inner
leaflet LysoMC-labelled vesicles in the presence and
absence of the peptide. The Trp residues are donors
for FRET. An increase in FRET efficiency in the
presence of the peptide means internalization; how-
ever, because some outer-to-inner bilayer FRET
may occur, it becomes necessary to compare the
obtained results with controls where translocating
(tryptophan octyl esther [63]) or non-translocating
(Ac-18A-NH2: Ac-DWLKAFYDKVAEKLKEAF-
NH2 [63]) Trp-containing molecules are used
[61,62].
Matsuzaki and co-workers had already described a
similar method to assess peptide translocation in
which vesicles are labelled only on the outer leaflet,
with the tryptophan FRET acceptor DNS-PE [19].
With this method it is possible to follow the FRET
change during time with a single sample and an end-
point approach for each incubation time is not
required. Experimentally, after peptide addition,
there is an initial increase in FRET efficiency (this
corresponds to a peptide partitioning to the outer
Figure 1. In vitro methods for translocation assessment, using FRET and quenching methodologies. Peptide molecules are represented by
empty rectangles and additional non-translocating compounds by circles; peptide molecules that have interacted with those compounds are
dashed; phospholipids labelled with an acceptor for the peptide’s fluorescence are indicated by light grey headgroups. (A) Measurement of
the inaccessibility of the peptide to a non-translocating entity with the ability to digest, sequester or permanently quench it; the interaction
between the two prevents the peptide from acting as a FRET donor to the labelled phospholipids; small FRET reductions will indicate that
the peptide was protected from that interaction; this indicates that the peptide is buried in the membrane or is located in lumen.
(B) Detection of inward peptide movement; after the initial adsorption interaction of the peptide with asymmetrically acceptor-labelled
vesicles (despite the representation, both inner-leaflet and outer-leaflet labelling can be used), translocation or membrane penetration
processes causes the mean distance between peptide and labelled phospholipids to increase (assuming an outer-leaflet labelling) and a
concomitant reduction of FRET. If the peptide has quenching capabilities, a quenchable probe can be used to symmetrically label the
vesicles; translocation can then be identified by full probe quenching, which is only possible if the peptide reaches the inner bilayer surface.
(C) Detection of peptide in the inner phase; in the case of translocation, digestion by encapsulated trypsin (solid circles) reduces the overall
amount of peptide available for membrane interaction and, consequently, FRET between peptide and labelled-membrane; trypsin
inhibition (dashed circles) is required in the outer phase, prior to peptide addition. (D) Detection of encapsulated peptide escape; in the
event of translocation, the peptide fluorescence decreases as it becomes accessible to an externally added, non-translocating quencher; the
quencher can, alternatively, be co-encapsulated with the peptide, and the quenching reduction monitored instead. The figure is reproduced
in colour in Molecular Membrane Biology online.
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leaflet); with time, a decrease in FRET efficiency is
observed (which corresponds to translocation where
peptide is no longer close to the FRET acceptor in
the outer leaflet). With this method, a kinetic
analysis of the translocation event can be carried
out. Quantitative information may be obtained if
additional methods are used to quantitatively relate
FRET intensity to luminal peptide concentration.
With these methodologies, peptides do not need
to be derivatized and small peptide and lipid con-
centrations can be used (0.7mM and 100mM respec-
tively [61]). With these methods, in-depth location
of peptide can be erroneously measured as translo-
cation; inaddition, they cannot be used with peptides
that induce lipid flip flop (FRET acceptor bilayer
asymmetry is lost). So far this methodology has been
applied only to Trp-containing peptides, although
the use of others donor/acceptor pairs is also
possible.
Direct detection of peptide in the inner aqueous phase.
Methods based on this principle are able to detect
the presence of peptides in the inner luminal
aqueous phase. With this approach actual transloca-
tion, rather than just membrane internalization, is
measured (see Figure 1, panel C).
Three different approaches fit in this class of
methods. In the first, described by Matsuzaki and
co-workers [19], encapsulated trypsin and a peptide-
lipid FRET system (Trp-containing peptide and
Dansyl chromophore incorporated in vesicles) is
used: trypsin is added at the hydration stage of the
preparation of symmetrically labelled vesicles; after
extrusion, non-encapsulated trypsin is inhibited by a
trypsin inhibitor. Upon addition of the peptide to
this system, an increase in acceptor fluorescence
through FRET is expected as the peptide enters the
bilayer; if the peptide is not internalized afterwards,
the fluorescence intensity is expected to remain
constant after the initial increase. However, if the
peptide translocates into the vesicle lumen, it be-
comes accessible to the uninhibited trypsin and is
digested; assuming that the resulting fragments
do not interact with the membrane, this degradation
of the peptide will lead to a decrease of the amount
of peptide in the bilayer and consequent reduction of
FRET. A quantitative analysis of the extent of
translocation can be easily carried out considering
that 100% translocation implies the digestion of all
the peptide molecules and absence of FRET; the
fluorescence intensity of the system should be the
same as in the absence of the peptide. Conversely,
0% translocation will correspond to the maximum
fluorescence intensity right after the peptide addition
[18,19]. This method cannot be applied to proteo-
lysis-resistent peptide and/or without Trp residues
(e.g., Polymixin B and Gramicidin S) [18]. At high
translocation efficiency, membrane perturbation
caused by peptide fragment accumulation inside
vesicles can cause difficulties in internalization
quantification. In addition, there is the possibility
of digested fragments re-entering the membrane,
which can lead to a translocation underestimation.
A second method that detects the presence of the
peptide in the inner aqueous phase was recently
developed by Ba´ra´ny-Wallje et al. In this method the
experiment is performed with planar lipid mem-
branes (PLMs) and the distribution of fluorescently-
labelled peptides, between the two compartments
and partitioned in PLM, is followed by confocal
fluorescence spectroscopy [64]. This powerful
method allows the direct scanning of fluorescence
intensity and quantification of peptide in each
compartment. Another advantage is the possibility
to easily generate asymmetric aqueous phase condi-
tions: a transmembrane potential can be set without
the need for ionophores [64]. Besides the need to
label the studied peptides (and care must be taken to
choose a photostable label), this method has the
disadvantage of requiring an uncommon setup with
a custom PLM trough.
Another possible method to evaluate peptide
translocation with model membranes is to follow
peptide interaction with giant vesicles (GVs). With
this method direct visualization of peptide interac-
tion with membranes is possible by confocal micro-
scopy. The translocation of peptide across these
vesicles can be confirmed by the presence of the
fluorophore inside the vesicles [64,65]; in this case,
just as with the methodology described for fluores-
cence imaging of in vivo internalization, the use of
confocal analysis is crucial to distinguish whether the
peptide is inside the vesicle or only adsorbed at the
membrane surface. As with the PLM method
described above, the peptide has to be derivatized
with a fluorophore, which should be carefully chosen
to avoid photobleaching.
With GVs it is possible not only to directly
visualize the peptide inside the vesicles but also to
evaluate its effect on membrane properties: mem-
brane integrity can be followed with a labelled lipid
such as N-Rh-PE (the fluorochrome has to be
different from the one used to label the peptide),
and the possibility of pore formation can be eval-
uated in GVs loaded with two similar dyes attached
to other molecules of very different sizes (for
instance Alexa488-Dextran (MW 10000) and
Alexa546-maleimide (MW/1300)). This experi-
mental setup enables direct observation of changes
in the membrane permeability during the course of
observations and in the case of pore formation to
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have information on pore size due to sequential
escape of the dyes from the GVs [66,67].
Detection of encapsulated peptide escape. Using a
fluorescence quenching assay, Magzoub et al. had
developed methodologies in which the escape of a
CPP from liposomes is determined in the presence
and absence of a pH gradient [68] (see Figure 1,
Panel D). To track the peptide escape two assays
based on encapsulation were carried out: (i) vesicles
were prepared with the peptide inside and the Trp
quencher acrylamide was added to the outer phase
(the escape of peptide from liposomes was followed
by fluorescence quenching of peptide Trp residues
caused by acrylamide); (ii) fluorescein-labelled pep-
tides were encapsulated with a quencher (iodide)
and, in the case of translocation, a de-quenching of
the fluorescein label was observed. The fluorescence
intensity corresponding to 100% peptide escape was
determined by vesicle lyses with Triton X-100 and
the fraction of peptide escape was calculated at
different incubation times [68].
Both these approaches allow the quantification of
translocation as well as the determination of mem-
brane crossing kinetics. Under certain situations,
however, both methods can lead to misleading
conclusions: in method (i) acrylamide is excluded
from membranes, so only the fraction of peptide that
reaches the outer aqueous environment is accounted
for (if the peptide remains essentially partitioned in
the outer leaflet after crossing the membrane, a
lower translocation extent is measured); in method
(ii) if the peptide does not translocate but has a deep
location in the bilayer, it becomes inaccessible to the
encapsulated quencher and is counted as having
crossed the membrane.
In these methods if the peptide translocates very
efficiently a significant amount of peptide can escape
from the liposome during the gel filtration step (used
to remove non-encapsulated peptide); therefore,
these methods are only applicable to peptides that
require special conditions to translocate (such as pH
or potential membrane gradients), so that mem-
brane crossing can be triggered only after the
separation procedure.
Another peptide escape assay was described by
Ba´ra´ny-Wallje et al. in which vesicles uniformly
preloaded with peptide both in the lumen and outer
medium are dialysed so that any peptide outside of
the liposomes is washed away [64]. If any peptide
absorption/fluorescence remains after the dialysis,
it can be concluded that translocation from the
lumen/inner leaflet to the outer side did not occur;
conversely, the occurrence of translocation can
be inferred from the absence of any peptide signal.
Due to the very simple setup and instrumentation
requirements, this seems a good option to begin a
translocation study with; however, there are a
number of disadvantages that are addressed in
section 3 of the Supplementary material online.
Other methods. A methodology based on a particular
peptide property was developed in reference [69].
For this purpose, the specific fluorescence quench-
ing of Rh by the CPP pep-1 was taken advantage of.
Vesicles labelled symmetrically with N-Rh-PE were
used to evaluate fluorescence emission quenching of
Rh by pep-1 in the presence and absence of a
transmembrane potential. After the peptide is added
to LUVs, Rh fluorescence in the outer layer is
quenched. If translocation occurs, it can be identi-
fied by a further reduction in Rh fluorescence due to
contact of the peptide with Rh in the inner leaflet.
The effect can be improved by using labelled multi-
lamellas vesicles (MLVs): the fraction of Rh-PE
available for peptide access is smaller than if LUVs
are used, therefore a much larger relative increase in
quenching is expected if the peptide translocates and
accesses all the phospholipids [69]. Alternatively,
soluble Rh can be encapsulated in vesicles and its
fluorescence followed after peptide addition [69].
This method allows measurements to be taken
during a time course, enabling the kinetic evaluation
of the translocation process. Its main disadvantage is
that it is only applicable to peptides that are able to
quench a given fluorophore.
Another method using MLVs has been reported
[60,70]: dithionite ion was externally added to
NBD-PE-doped MLVs, resulting in quenching of
the fluorophores in the outermost leaflet; upon the
addition of a pore-forming peptide the dithionite ion
will have access to the first intramembranar space of
the MLVs, resulting in an increase in quenching; full
NBD quenching, however, will only be attained if
the peptide can translocate and form pores in the
inner bilayers because only then will all the fluor-
ophore become accessible to the dithionite ion.
This method does not require any peptide label-
ling or intrinsic fluorescence but, on the other hand,
this can only be applied to peptides that perturb the
membrane to an extent where dithionite can cross it
(by a pore or otherwise). Kinetic information can be
extracted but it is necessary to take into considera-
tion the multiple membrane crossing steps.
Assessment of peptide translocation with attached cargo
The translocation process of CPPs may vary if the
peptide is in free form or attached to a cargo.
Differences in peptide kinetics and cell localiza-
tion can occur [7173]. In the above described
methodologies the only attached ‘cargoes’ were
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fluorophores. The nature and size of the cargoes and
the nature of attachment to the peptide (whether
covalent [3,74] or weaker [7,75]) can also be a
determinant for the translocation mechanism. Given
these differences, development of consistent meth-
ods to evaluate the capacity to translocate/deliver
proteins across artificial/natural membranes would
be fruitful to systematically confirm (or refute)
vector properties of CPPs. Practically all methods
described above for in vivo or in vitro testing can, in
principle, be extended to assess the translocation of
CPP-cargo complexes, although no reports on such
usage were found; however, some properties of the
macromolecule attached to the peptide are addi-
tional advantages to detect and quantify transloca-
tion, opening the possibility for more sensitive
methodologies. Three methods that have been
reported for the in vivo studies and one for the in
vitro studies of the internalization of CPP-cargo
complexes are discussed here; while these can easily
fit into the above classification, they are presented
separately to underscore their importance in con-
firming the vector properties of a CPP.
Morris et al. had observed the efficiency of pep-1
to deliver GFP [75] and a similar approach demon-
strated the ability of the AMP buforin 2 to translo-
cate across bilayers with a macromolecular cargo
[76]. Recombinant proteins with CPP and GFP
domains have also been produced [7779]. Instead
of GFP, Wadia et al. labelled TAT-Cre recombinase
by coupling it to Alexa 488 or Alexa 546 fluoro-
phores [80]. GFP or Cre recombinase translocation
is followed by its intrinsic fluorescence; this is in all
aspects identical to what was previously described
for the in vivo direct visualization of internalization.
Another possibility to measure Cre recombinase
translocation mediated by TAT is by recombination
reporter assay, where the expression of enhanced
GFP (EGFP) is dependent on TAT-Cre transduc-
tion into cells, followed by nuclear import. The
signal of EGFP is followed and measured as a
consequence of TAT-Cre import [80].
Detection of b-Gal delivery into cells was also
reported. Translocation was assessed by monitoring
the X-Gal staining enzymatic activity of b-Gal
[75]. The detection of the enzymatic activity of the
cargo not only allows a sensitive detection of the
Figure 2. To evaluate the translocation of b-Gal/pep-1 (hexagons/rectangles) complexes across model membranes the following steps were
reported [81]: (1) valinomycin was added to K-loaded vesicles in Na-buffer to create a negative transmembrane potential; the complex
was added to the solution and translocated across bilayer; (2) trypsin (circles) was added to digest non-incorporated complex and free pep-1
or b-Gal (dashed hexagons/rectangles); (3) after digestion, trypsin was inhibited (dashed circles) with phenylmethylsulfonyl fluoride and
TX-100 was then added to facilitate the release of internalized b-Gal and allow its quantification (digestion debris were excluded from the
last two panels, and inhibited trypsin from the last, to avoid image crowding); (4) b-Gal activity was assayed by MUG (black triangles)
hydrolysis to a fluorescent product, 4-MU (lighter triangles). The figure is reproduced in colour in Molecular Membrane Biology online.
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internalized CPP-cargo complex, but also tests
whether CPP-mediated translocation can occur
without cargo damage/denaturation. A quantifica-
tion of b-Gal internalization was developed by
means of its enzymatic activity on the substrate 4-
methylumbelliferone b-D-galactopyranoside (MUG),
a non fluorescent substrate that is converted to 4-
methylumbelliferone (4-MU), which is a fluorescent
product. 4-MU production enables quantification of
protein internalization from its activity [37,81].
Another possibility to evaluate protein delivery
efficiency is by immunofluorescence, using a pri-
mary antibody raised against the carried protein and
a fluorescently labelled secondary antibody, as was
preformed with b-Gal [81]. This method is inde-
pendent of particular cargo properties; therefore, it
is suited to study the transport of cargoes that do not
have intrinsic fluorescence or detectable enzymatic
activity. With these methodologies it is possible to
obtain cell transfection efficiency, but not the
quantification of peptide/protein internalization.
Protein uptake was also evaluated in vitro with
pep-1/b-Gal, by taking advantage of the b-Gal
enzymatic activity and 4-MU fluorescent properties
(see Figure 2). Briefly, after peptide/protein incuba-
tion with LUVs, trypsin was added externally to
digest the non-incorporated peptide and b-Gal;
afterwards, phenylmethanesulfonyl fluoride (PMSF)
was added to inhibit trypsin. To induce LUV
permeabilization and leakage of the incorporated
b-Gal, Triton X-100 was added, and enzymatic
activity of b-Gal was determined by MUG hydrolysis
[81]. Intrinsic cargo fluorescence and/or enzymatic
activity are specific properties that can be used
for application of a similar methodology to other
peptides/proteins complexes.
The classification and the general advantages and
disadvantages of the application of each reviewed
method are summarized in Table I.
For all the methods presented here, it is possible
to conclude about the ability of peptides to translo-
cate. When further information is sought, quantita-
tive analysis should always be carefully carried out;
for this, several different complementing methodol-
ogies should be conjugated, regarding not only the
actual evaluation of translocation but also to quan-
tify the peptide distribution between the membrane
and aqueous environments and to characterize the
membrane topology upon peptide interaction (oc-
currence of membrane thinning, pore formation,
lysis, etc.).
Concluding remarks
Because most methods for the assessment of mem-
brane translocation have only been reported during
the last decade, it is understandable that this field is
regarded as being underdeveloped, methodology-
wise [18]. In addition, the description of new
methods has not always been given the due emphasis
by their authors, which further contributed to the
lack of visibility of these procedures. Yet, over 20
methods that address the assessment of membrane
translocation have been found. The authors of this
work hope that the gathering of this knowledge will
help others find and use the most appropriate
methods for their studies. On the other hand, this
compilation should by no means be regarded as an
ultimate source for information on translocation
assessment methodologies in a way that the devel-
opment of new methods, or the improvement of
already described ones, is discouraged. Rather, by
exposing the strengths and weaknesses of several
methodologies, it is hoped that the development of
newer and better methods is encouraged and facili-
tated.
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Problems associated with the detection of entry
of peptide into vesicles
At usual lipid concentrations, used to perform in vitro
studies, the volume occupied by the vesicles is very
small when compared to the bulk aqueous phase: for
100 nm diameter LUVs, produced at a total lipid
concentration of 1 mM, and assuming a mean
membrane surface area of 0.7 nm2 per phospholipid
[1], the ratio of luminal volume over the total volume
will be about r/0.003 v/v. Another problem arises
from the fact that these peptides usually have large
molar ratio partition constants towards lipidic mem-
branes (about 103 to 104, e.g., [2,3]). This means
that only a small concentration of peptide will be in
the aqueous phase unless relatively low lipid con-
centrations are used. Given the above-mentioned
obstacles, it is clear that methods based on the
detection of the concentration of internalized peptide
will have to deal with very low signal intensities that
will likely lie below instrumental detection limit.
Comments on time-dependent measurements
It should be noted that in all the methods presented
in the section Measurement of peptide inaccessibility
from the outer phase a time-dependent measurement
is required to determine the degree of peptide
inaccessibility: because the amount of free peptide
in the outer phase will decrease  as it is digested,
sequestered or permanently quenched  the inter-
nalized peptide will equilibrate back to the outer
phase. Consequently, two stages are expected: in the
first, signal magnitude increases (here ‘signal’, in a
very broad sense, can be FRET reduction, FRET
increase or fluorescence reduction, depending on the
particular method used), detecting the adsorbed/
non-internalized peptide fraction; then a second
stage ensues with a usually slower signal increase
[4,5], which corresponds to the detection of the
internalized peptide molecules that are returning to
the outer phase. At equilibrium, the signal magni-
tude should be approximately the same whether
translocation has occurred or not. The percentage of
accessible peptide is usually obtained by comparing
the end of the first stage with a control where
peptide, membrane and the non-translocating entity
are added simultaneously [4, 5]. From this, it can be
seen that, in a hypothetical situation where the
translocation kinetics were of the same magnitude
of the desorption kinetics, this method would be very
difficult to apply as both stages would have the same
approximate slopes and the end of the first stage
would be hard to detect. On the other hand,
information about translocation kinetics could, in
principle, be obtained from the rate at which the
peptide molecules return to the outer phase, in the
second stage.
Advantages and disadvantages associated with
the dialysis method
Due to the very simple setup and instrumentation
requirements for this experiment (see the section
Detection of encapsulated peptide escape) this seems a
good option to begin a translocation study with,
because membrane crossing may be ruled out
immediately avoiding the need to use more complex
and costly methodologies. However, in order for this
method to provide a measurable absorbance/fluores-
cence peptide signal in the absence of translocation
it is required that the amount of internalized peptide
be relatively large, to compensate for the effect of the
small encapsulation volume. This is only possible to
attain if the peptide partitions strongly towards the
bilayer and the lipid concentration is high enough:
under these conditions, upon vesicle preparation,
the peptide molecules can be expected to be equally
distributed by the inner and outer leaflets and very
few to be left in the aqueous phase; in the absence of
translocation, roughly one half of the peptide signal
will remain, correspondent to the peptide molecules
partitioned in the inner leaflet. Should the peptide
partition weakly to the membrane or there be a small
lipid concentration, the inner leaflet peptide fraction
could be undetected in the absence of translocation,
which would generate a false positive. This limita-
tion has to be accounted for by quantifying the
extent of membrane interaction. Other disadvan-
tages include the lengthy dialysis process and the
lack of any kind of translocation characterization,
which makes this method more suited to rule out,
rather than ascertain, peptide translocation.
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Translocation
The concept of peptide translocation detection seems, at first, to be easy
to implement. When using vesicles, the membranes effectively divide the
aqueous phase into two compartments and it would suffice to detect the
peptide in the lumen to ascertain translocation. As noted in Article vii,
however, practical aspects prevent such a straightforward approach: at
millimolar lipidic concentrations the fraction of luminal over the total
volume is very small, which means that only a negligible fraction of the
peptide will actually enter the lumina; this is worsened by the fact that,
given typical AMP partition constants, most of the peptide will leave the
aqueous phase and bind the membranes at typical 0.1 to 1 millimolar lipid
concentrations. Indeed, most of the methods described in Article vii
indirectly detect translocation into vesicles from its consequences to the
peptide-membrane interaction.
Sónia had had the fortune of working with a peptide that was able
to quench rhodamine: she would measure the quenching of rhodamine-
labeled phospholipid vesicles and determine if the quencher (peptide) had
access to all of the fluorophore — translocation — or only to the outer
fraction — no translocation.78 I was not so lucky as to have a quenching
peptide and had to work out another solution. I did so mostly because
I found the methods in Article vii unsatisfactory: either they were too
complex, involving techniques we didn’t have ready access to, or required
the labeling of the peptide,* or didn’t unequivocally identify translocation.
Miguel and I tried to find some compound that we could encapsulate,
that would bind the few peptide molecules that reached the lumen, and
that would then produce a strong signal in such a way that the above-
mentioned limitations were overcome. I spent quite a lot of time trying
to measure fluorescence transfer in the lumen between omiganan and
ANTS, a fluorophore with suitable spectral properties to accept trypto-
*Peptide labeling was something I really wanted to avoid. For such short sequences as the
AMPs’, addition of fluorophores — usually hydrophobic in nature —may cause drastic changes
in membrane interaction behavior. Sónia observed precisely that with her carboxyfluorescein-
labeled cell-penetrating peptide.79
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phan emission. I did not succeed: fluorescence transfer strongly depends
on acceptor concentration and millimolars of ANTS would have to be
encapsulated in order for a signal to be measured. Even if such high
concentrations of ANTS would be used and if the vesicles did not burst
because of the resulting osmotic difference, there would be too little signal
and too much excitation light sharing* for any conclusion to be drawn.
After writing Article vii, and inspired by the methods that involved
MLVs,80, 81 it dawned on me and Miguel that the reporter entity that
we were looking for could be the very phospholipid bilayer: peptides
that translocate have access to all the lipid in MLVs, whereas peptides
that don’t can only bind the outer fraction. And this was something very
simple to test by a simple adaptation of the fluorescence methodologies
we already used for measuring peptide-membrane binding. I implemented
the approach by following the binding of peptide, using fluorescence, with
time: AMP interactions with LUVs— at least of the peptides I studied —
reached equilibrium very quickly (far more quickly than the time it took
me to pipette the sample and place the cuvette in the fluorometer). When
MLVs were used, however, the membrane crossing steps took extra time.
Fluorescence intensity now took minutes instead of milliseconds to reach
equilibrium. Using this time-based measurement I was able to extract
two parameters to relate with translocation: the overall binding of the
peptide and the time to reach equilibrium. Figure 1 in Article iv outlines
the expected behavior of translocating and non-translocating peptides.
Some further steps were needed for a consistent application of the
method. The first was the realization that the overall lipid concentration
strongly influences how different the interaction kinetics with LUVs and
MLVs will be. If too much lipid is used it may happen that the exposed
lipid of MLVs is enough for almost total peptide binding. In this case
the binding kinetics should be fast in both cases. If too little lipid is used
there may not be a measurable binding. Of course, ‘too much’ and ‘too
*Excitation light sharing refers to the process of acceptor fluorescence by direct absorption
of excitation light — thus ‘sharing’ it with the donor. Fluorescence transfer pairs are usually
chosen so that the acceptor absorbs very little light at the wavelength of donor excitation;
however, high concentrations of acceptor may still significantly fluoresce due to this effect.
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little’ depend on how strongly the peptide binds the membrane (Kp) and
how brighter it fluoresces when bound (IL/IW ): it is thus very useful to
obtain a partition curve prior to the application of the method. Another
modification that enhanced the time-based detection of peptide binding
was the use of acrylamide. By quenching the water fraction of the peptide
I was able to increase IL/IW from 3.6 to close to 20, which gave me a
wider range of useful lipid concentrations to work with.
I successfully applied the method to BP100 (Article iv) and omiganan
and both did translocate across bacterial membrane models. By the time of
publication of Article iv, however, I had not yet tested the protocol with
a negative control. This gap would be bridged a few months later when
Joana Matos, a postgraduate researcher at the group, applied my method
to two of her peptides (segments of the dengue virus capsid protein).
One of them clearly translocated, the other clearly did not.
The method is very simple in concept and in experimental setup — it
may even be applied to molecules other than peptides. But it does have its
shortcomings. According to the advantage/disadvantage list we used in
Articlevii to qualify other methods, this one has the pro of being able to
use intrinsic peptide fluorescence but the con of being limited to peptides
with appropriate partition and kinetic properties. It is also unable to
quantify translocation rates or the amount of internalized peptide.
Margarida Rodrigues contributed to the extension of the method to
microscopy: her peptide did not have a suitable IL/IW — even after
addition of acrylamide — but it was rhodamine-labeled and its binding
to giant unilamellar vesicles (GUVs) could be observed by fluorescence
microscopy. We came up with the idea of trying to confocally image
multilamellar GUVs (they sometimes show up in GUV suspensions) to
see if the peptide also bound the inner membranes. Indeed, that was
precisely what was observed. Whether this is another method altogether
or just a variation on the same theme is left up to the reader. In the
end I am very glad I was able to tackle several theoretical and practical
problems of the detection of translocation. The fact that the method has
been successfully applied by others, and to peptides that are not necessarily
AMPs, is rewarding in itself.
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Leakage
Detection of peptide-induced leakage is a frequent way to assess mem-
brane perturbation. The standard, widespread method to this end con-
sists in encapsulating very high concentrations of the fluorescent probe
carboxyfluorescein — so high that it quenches itself. After the washing
of the leftover fluorophore on the outside of vesicles, and the addition
of the agent of interest, leakage can be monitored as an increase in car-
boxyfluorescein emission; this occurs as a consequence of probe molecules
escaping the self-quenching environment of the lumen. 100% leakage can
be obtained by lysing the vesicles, usually with a detergent.
A major disadvantage of this method is that the separation of vesicles
from unencapsulated probe molecules requires a filtration step (in other
methodologies where encapsulation is needed it is sometimes sufficient
to dilute the vesicle-probe suspension several-fold; in this case, however,
that shortcut is not possible as it would lead to the de-quenching of the
outer phase molecules). Besides time-consuming, the filtration process
produces a vesicle suspension of unknown lipid concentration. This may
be acceptable in some situations, but I wanted to test pre- and post-
saturation conditions (Article iv), and thus needed to accurately know
lipid concentration.
To overcome the limitation of the carboxyfluorescein method I tried
to use ANTS (described in the previous section) as the encapsulated
probe, and externally added iodide ions as a quencher. Upon membrane
leakage the quencher would come into contact with the probe and an
overall reduction in emitted intensity would be observed. Using this
method I could prepare a concentrated suspension (about one-hundred-
fold) of vesicles with ANTS and then dilute it to the required — and
relatively accurate — lipid concentration. The outer fraction of ANTS
would then become equally diluted while the inner fraction was kept at
the initial concentration. External addition of iodide further reduced the
contribution of the external ANTS molecules to global fluorescence.
I successfully applied the method to omiganan (Article iii) but was
not satisfied with its low sensitivity (again, the issue of there being too
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little luminal volume in a vesicle suspension). I then decided to adopt
a method used by Sónia,78, 82 which involves the preparation of vesicles
doped with a fluorescently labeled phospholipid — in this case, phos-
phatidylethanolamine labeled in its headgroup with a nitrobenzoxadiazole
moiety. Similarly to the ANTS-iodide procedure, a quencher (Co2+) is
externally added to the suspension. If the membrane is intact the quencher
will only affect the fluorophores labeling the outer headgroups, whereas
if it leaks all the headgroups become accessible.
My small contribution to the method consisted in deducing a relation-
ship between total fluorescence and percent leakage (incidentally, after
a referee prompted us to correct an overly simple initial approach). The
relationship was necessary in order to properly plot time-dependent leak-
age observations. Both the deduced equation and the application of the
method can be found in Article iv. In the article a correlation between a
change in leakage-inducing behavior and saturation is identified; this was
only possible by knowing the correct lipid concentration in the leakage
assays.
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Differential quenching
One of the biophysical methods routinely carried out at the lab is the al-
ready frequently mentioned measurement of in-depth peptide insertion in
membranes. This is a type of information not usually sought in studies of
peptide-membrane interaction but one that is valuable to the understand-
ing of peptide action. Regarding the studies with omiganan, for example,
the peptide was shown to move within the bilayer upon saturation, which
is important evidence supporting a saturation-triggered mechanism.
Methods to obtaining depth information from fluorescence measure-
ments usually involve doping membranes with at least two quencher-
labeled lipids.83, 84 In one of those the quencher is usually placed near the
carboxyl group while in the other it is closer to the end of the acyl chain.
The depth of the peptide (more accurately, of the reporting fluorophore
moiety within the peptide) is then inferred from the quenching perfor-
mances of each quencher: the peptide is closer to the one which quenches
it the most — hence the term ‘differential quenching’.
A quantitative measurement of the depth of peptide insertion can
be obtained if some assumptions are made on the quencher-fluorophore
interaction. A model of static83, 84 or collisional85 quenching* (or even a
mixed one) can be used to analyze each of the quenching profiles and
calculate the difference in depth between fluorophore and quencher. This
is where the use of a pair of quenchers comes in: a given fluorophore-
quencher distance translates into two possible depths in the membrane,
with the quencher position midway between the two; by using two
quenchers at different depths four possible locations are calculated, two
of which should overlap and correspond to the actual peptide position.
The general method has been appropriately termed parallax measurement.
*Static quenching is characterized by the fluorophore being in contact with the quencher at
the moment light is absorbed; there is a resonant fluorophore-quencher effect that prevents
the fluorophore from reaching the excited state; fluorescence emission lifetime is maintained,
but the number of emitting molecules decreases. In collisional quenching the fluorophores are
free to reach the excited state upon absorption but decay without emission if then hit by a
quencher molecule; this leads to a decrease in emission lifetime.
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Earlier work byMiguel involved the adaptation of the parallax method
to deal with fluorophore and quencher distributions. Previous implemen-
tations considered that fluorophore and quencher molecules lie exactly at
a given depth,83 or at least that the quencher molecules do.84 This is an
unrealistic approach as fluctuations in the depth of the system constituents
are very likely to occur, especially so in the case of the quenchers — usually
charged or very polar and not expected to sit unperturbed amidst the
apolar acyl chains. Miguel’s (and his coworkers’) approach was to find
the in-depth distributions of the quencher molecules and then to infer the
fluorophore’s from quenching information.
Quencher distributions were obtained by simulations of Brownian
motion within the bilayer — see the full work in reference 85. The
quenchers in question were stearic acid molecules labeled with nitroxide
doxyl groups, which are free radicals, at the fifth and sixteenth carbons
(5NS and 16NS; Figure a.2). The distributions were unimodal and could
be fit by Lorentzian curves (similar to Gaussians but with slower descents
to zero away from the mean).
Under a typical experimental setup the fluorescence lifetime of the
peptide in a peptide-vesicle system is measured as quencher is gradually
added; only one of the quenchers is used at a time. In measurements of
fluorescence lifetimes instead of steady-state emission only the dynamic
component of quenching is detected, which simplifies the quenching
model. Bruno Castro, a PhD student working with Manuel Prieto and a
long-time friend of mine, provided valuable input on the acquisition and
analysis of lifetime data, especially on ways to circumvent the artifacts
introduced by the intense light scattering of vesicle suspensions.
The fluorophore distribution is that which, under the assumptions
of collisional quenching and given the quenchers’ distributions, predicts
an emitted intensity as close as possible to the observed. The algorithm
developed byMiguel and coworkers for finding the best fitting fluorophore
curve involves the generation of a large number of possible distributions.
The central value of these distributions is swept along the depth of one
bilayer leaflet and their width is scanned from very narrow curves to
almost flat ones (for simplicity, the fluorophore distributionwas assumed to
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also be a Lorentzian). For each of the generated distributions an expected
quenching behavior is computed (a numerical approach that integrates
the expected fluorescence over small steps in the membrane85) and the
difference relative to the observed value is calculated. A solution surface
is thus generated for each quencher, corresponding to the difference to
the observed data as a function of the mean and width of the fluorophore
distribution; the fluorophore distribution will be that at which both
surfaces and the plane z = 0 intersect. The method was nicknamed
SIMEXDA, for SImulated EXperimental Data Analysis.
It was from this point that I contributed to the analysis process of dif-
ferential quenching. I first translated into Visual Basic the FORTRAN
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Figure a.2 – Chemical formulas of 5NS and 16NS and the in-depth
distribution of the free-radical doxyl moiety in bilayers (from reference 85);
a POPC phospholipid is included for comparison. It can be seen that the
distributions are shifted towards the bilayer surface relative to the doxyl
position in the acyl chain. This is likely due to the instability of the radical
moiety in the apolar region of the bilayer and to the short size of the stearic
acid next to neighboring phospholipids.
175
Appendix — Other methods
code used to generate the solution surfaces. Visual Basic code can be read-
ily integrated into Microsoft Excel or OpenOffice.org Calc spreadsheets,
which simplifies data analysis by not requiring an external program to
be run. I would later retranslate the code to C++ and compile it into
a shared library loadable from Visual Basic (the commented source code
files, as well as a working implementation in an Excel spreadsheet can
be found in the digital supporting material of this thesis); this afforded a
five-fold increase in computation speed — important since the algorithm
may take several seconds to complete and is often invoked several times
in a spreadsheet. Further gains in speed are achievable by creating an
Excel specific library (termed XLL) in C++; this approach obviates the
intervention of the slower Visual Basic code and allows a spreadsheet
to make use of multiple processors by running several instances of the
algorithm in parallel (useful when more than one cell uses the code). Not
being a critical upgrade, I have not yet endeavored to create an XLL.
My second contribution was to modify the algorithm into a least-
squares approach. As it stood, the method only used one data point per
quencher. This did not include any tolerance for error, which, besides
being a severe limitation by itself, often prevented the determination of the
fluorophore’s distribution because solution surfaces would not intersect in
the z = 0 plane. Under the least-squares approach each of the generated
fluorophore distributions is assigned a set of three scores: one sub-score
for each quencher — the sum of the square of the differences between
the predicted and the observed relative decrease in emission at each data
point; and a global score — the sum of the two sub-scores. The selected
distribution will be that which generates the smallest global score.
Users of this method — which so far have been most of the people
that have arrived at the lab after me — must always carefully analyze
the results for inconsistencies. The code also outputs the distribution
parameters that generated the minimum for each sub-score; it is unlikely
that the global solution lies very far from those. There is, however,
an exception to this: when dealing with relatively narrow fluorophore
distributions each sub-score will usually have two minima, corresponding
to central values on each side of the quencher distribution. This results
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from the approximately symmetric shape of the quenchers’ profiles, which
makes it hard to distinguish which side the fluorophore lies on — it is
basically the same problem that has prompted the use of two quenchers in
the parallax method: it may happen that the minimum that generates the
least sub-score of a quencher points to the “wrong” side of its distribution.
In this case the user should check if that sub-score is not much lower than
the one that generated the minimal global score (all values are output by
the code).
So far the score values and the above consistency checks are the only
indicators of fit quality. The analysis would greatly benefit from the
computation of confidence intervals of the returned parameters as well as
of the dependence between them. In addition, the quality of results could
be further improved by coupling one of several available minimum-finding
algorithms to the code, which should also become much faster.
Imade somefurther additions to the algorithm: I included the possibility
to generatemultimodal fluorophore distributions and to account for a static
quenching contribution (for the caseswhere only steady-state fluorescence
data is available). None of the approaches, however, is reliable. The
consistency of multimodal distributions with the data is hard to verify
and I suspect that the returned parameters are heavily dependent on each
other. The inclusion of static quenching would considerably simplify data
collection as steady-state fluorescence measurements are much easier to
acquire and analyze than time-resolved ones. Unfortunately I came to
the conclusion that most of the static quenching under this experimental
setups is generated by peptide-quencher binding outside of the membrane
(the 5NS and 16NS also partition between the aqueous phase and the
bilayer —Kp values in the order of 104—, meaning that there will always
be some unbound quencher molecules). This fact, together with the
addition of another parameter (the quencher-fluorophore distance under
which static quenching occurs) prevents proper data analysis. The code
in the digital supporting material does not contain these features.
Good fits have been obtained by employing the unimodal, least-squares,
collisional-quenching SIMEXDA to fluorescence lifetime data. In-depth
measurement of BP100 results was very reproducible and consistent with
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a parallel burying of the helix as Rafael had predicted. Unfortunately —
from a methodological perspective — the method was not duly emphasized
in Article iv because the peptide depth was little affected by saturation.
The differential quenching data of omiganan interacting with vesicles was
presented in raw form in Article iii: at the time I had not yet added the
least-squares analysis to SIMEXDA and as it stood the method would
return extreme results (very narrow distributions centered either at the
surface or the middle of the bilayer). Inward movement upon saturation
may still be qualitatively deduced from the data that were published.
In Miguel’s work it was mentioned that the results would be fairly
independent of the Stern-Volmer quenching constant (KSV , inm-1 — the
product of the bimolecular quenching kinetic constant and the fluorescence
lifetime of the unquenched fluorophore). I found however, that results
were sensitive to KSV changes in the order of 0.1m-1, which possibly
results from the adaptation of the method to a least-squares approach. In
any case, that parameter is now also scanned when looking for the best
fitting fluorophore distribution. The tyrosine-containing peptides with
which the method has been applied consistently returnKSV values in the
1 – 2m-1 range.
There are some pitfalls in the interpretation of results from SIMEXDA.
As the method returns a unimodal distribution one cannot expect to
detect peptide insertion if most molecules remain adsorbed. Such may be
the case of peptides that form disordered toroidal pores (recall Figure 1.1).
Also regarding toroidal pores, if the quencher lipid is bent or rotated at
the pore site the reported depth will be skewed. Lastly, peptides bearing
more than one fluorophore will have a broadened distribution and may
be poorly fit by a unimodal curve.
Overall, this is a method that is not straightforward to apply andwhose
solutions need careful user inspection. Still, it is a method able to produce
good results if fed good data. And, besides the application aspect, I had
a great time putting my amateur programming skills into practice while
programming it.
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